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An important hallmark of cancer is the inactivation of tumor suppressor genes.  
The most common genetic alteration in cancer is the mutation of the TP53 gene occurring 
in about half of all cancers, but very little progress has been made on how to 
therapeutically target the signaling defects in these cancers. Additionally, the PTEN 
tumor suppressor is mutated in a wide variety of cancer types, and its expression is often 
lost in the absence of mutation.  PTEN is a haploinsufficient tumor suppressor that 
exhibits dose-dependent effects in cells.  In the context where PTEN is lost or 
downregulated, PI3K signaling and downstream signaling through AKT is overactive, 
leading to an increase in cell growth and proliferation, among other effects. Acting as 
both a protein and lipid phosphatase, loss of PTEN also affects the PI3K-independent 
signaling of PTEN, and results in an increase of migration and invasion phenotypes. 
Importantly, PTEN transcript level is the key determinant for PTEN protein expression, 
and downregulation of PTEN is part of a poor-prognosis gene expression signature in 
breast cancer. Downregulation of tumor suppressor gene expression represents a 
reversible change that is often sufficient to drive tumorigenesis. However, our 
understanding of the broad molecular mechanisms by which the expression of these 
tumor suppressors is lost remains limited, but is required to develop effective therapeutic 
strategies to target malignancies driven by tumor suppressor loss.  
 In Chapter 2, we characterize the problem of transcriptional downregulation of 
PTEN in breast cancer. We investigate the expression of PTEN in various normal and 
	
tumor cells at both the transcript and protein level. We identify various model systems 
that we believe are suitable to model normal PTEN expression and the PTEN 
downregulation that mimics what is observed in tumors. We employ a sophisticated 
approach that couples RNA-sequencing with Nanostring nCounter analysis in order to 
obtain a detailed and thorough transcriptional profile of the PTEN and pseudogene 
PTENP1 genomic loci, as well as expression of the poor-prognosis gene signature 
associated with PTEN downregulation. In this study, we obtained an understanding of the 
changes in the PTEN transcriptional profile that occur in the progression from normal to 
cancer, and we believe this approach could be applied to other key tumor suppressor 
genes.  
 In Chapter 3, we discovered that basally expressed p53 maintains expression of 
thirteen well-validated tumor suppressors. p53 is expressed at low levels under normal, 
low-stress conditions, and is expressed at much higher levels under enhanced stress, 
leading to the activation of stress-response genes. We begin the study by highlighting an 
association between TP53 mutation and downregulation of PTEN expression. Upon 
performing chromatin immunoprecipitation coupled with next generation sequencing for 
p53 under normal, low-stress conditions, we found that p53 binds in the vicinity of 
thirteen tumor suppressor genes, including PTEN. Basally expressed p53 binds to classic 
consensus binding sites in enhancers and promoters of target tumor suppressors to 
maintain their expression at baseline. CRISPR/Cas9-mediated knockout of the 
endogenous basal p53 binding site upstream of PTEN led to a decrease in PTEN 
expression and an increase in tumorigenic phenotypes. Given that mutation of TP53 leads 
to tumorigenesis in mice, but loss of p53 stress-response targets or loss of the ability of 
	
p53 to activate these stress-response targets does not lead to spontaneous tumorigenesis, 
it is likely that these tumor suppressor targets of basal p53 contribute to p53-mediated 
tumor suppression.  
 In Chapter 4, we identified yet another mechanism by which transcriptional 
repression of PTEN occurs in triple-negative breast cancer (TNBC) through polycomb 
repressive complex 2 (PRC2)-mediated repression of the PTEN promoter and upstream 
regulatory region. Previous research has shown that mutated NOTCH1 represses PTEN 
through the HES-1 transcription factor in acute myeloid leukemia (AML), and that 
NOTCH translocations are frequent in TNBC and are sufficient for transformation in 
vitro. We discovered that NOTCH1 and NOTCH2 mutations and translocations correlate 
with PTEN downregulation by immunohistochemistry in a cohort of TNBC cases. The 
TNBC cell line exhibiting PRC2-mediated repression of PTEN also harbors a SEC22B-
NOTCH2 translocation that creates a gene product resembling the NOTCH2 intracellular 
domain. The NOTCH target HES-1 co-localizes on the PTEN promoter with EZH2 (the 
lysine methyltransferase involved in PRC2-mediated transcriptional repression), and 
knockdown of NOTCH2 in this cell line led to decreased expression of EZH2, and 
restoration of PTEN expression at the transcript and protein level. We also demonstrated 
that EZH2 inhibitors, HDAC inhibitors, and DNA hypomethylating agents robustly 
restore PTEN transcript levels. Taken together, these results elucidate another mechanism 
by which PTEN is transcriptionally repressed in the highly aggressive and poor-prognosis 
TNBC subtype of breast cancer that may be applicable to other cancer types. The results 
also suggest that this repression is reversible by pharmacological approaches, 
highlighting a promising therapeutic avenue.  
	
 Taken together, the studies presented in this thesis begin to unravel the complex 
mechanisms of transcriptional repression of tumor suppressor genes in cancer. As is the 
case with PTEN and p53, multiple regulatory mechanisms can influence expression in 
combination or in a context-dependent manner. The loss of expression of tumor 
suppressor genes is one of the key hallmarks of cancer, yet very few of the therapeutic 
approaches used in the clinic today aim to restore tumor suppressor expression. Our 
results demonstrate proof of concept that restoration of tumor suppressor expression is a 
plausible and promising therapeutic approach for many different types of cancer, but 
requires a detailed understanding of the underlying molecular mechanisms of 
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ENDOGENOUS TUMOR SUPPRESSION 
	
The discovery of tumor suppressors  
	
 Healthy cells maintain a delicate balance between activating and inhibitory 
signals and have natural mechanisms to protect the body from tumorigenic growth. 
Molecular signaling pathways in cells often have components of negative feedback to 
ensure that signaling is well regulated and in homeostasis. Abnormal signaling in the cell 
is often driven by genetic mutation 
or changes in gene expression that 
can lead to neoplasia and eventually 
cancer, characterized by cell growth 
that is not under physiologic 
control. An extensive body of 
research has aimed to understand 
the progression from normal cells to 
cancer, and has identified multiple 
‘hallmarks’ or traits that the cells can acquire that allow them to progress to a 
tumorigenic state. These hallmarks can help to explain the wide diversity of malignant 
phenotypes observed (Figure 1.1) (Hanahan and Weinberg, 2011). The first oncogenes, 
genes whose functions cause or drive cancer, were discovered using RNA tumor viruses 
(also known as oncogenic retroviruses) as tools to capture or modify genes.  These 
viruses, such as the Rous sarcoma virus (RSV) first discovered by Peyton Rous in 1911, 
are a subset of viruses that have acquired host oncogenes, as evidenced by highly 
conserved versions of these viral genes in the genome of the host.   
Figure 1.1: Hallmarks of cancer (Hanahan and 
Weinberg, 2011). 
	 3	
It is thought that 
a previous non-
transforming ancestor of 
RNA tumor viruses 
acquired and modified 
this genetic material 
from the host and now 
carries it with its 
replication genes, thus creating a transforming form of the virus (Figure 1.2) (Weinberg, 
2007). RNA tumor viruses, such as RSV, have RNA genomes that contain these 
oncogenes that are reverse transcribed into DNA, and then integrated into the host 
genome [process reviewed in (Pierotti et al., 2003)]. In the case of RSV, the virus carries 
a modified version of the cellular-src (c-src) proto-oncogene called viral-src (v-src), and 
integrates v-src into the host genome. Infection with these viruses leads to 
transformation, characterized by tumorigenic phenotypes such as altered cell morphology 
and increased proliferation (Stehelin et al., 1976). These cancer-associated genes were 
termed ‘oncogenes’ as they were able to drive carcinogenesis, and many of these have 
been discovered since the initial c-src discovery. Scientists hypothesized the existence of 
genes that oppose oncogenes, now known as ‘tumor suppressors’, long before 
experimental evidence was obtained.  
 Initial evidence suggested that tumor suppressor genes are recessive; meaning that 
gene function on both alleles of the gene has to be lost in order to cause malignancy.  The 
first experiment suggesting the existence of endogenous tumor suppressor agents was 
Figure 1.2: Creation of RSV RNA tumor virus from 
ancestral non-transforming avian leukosis virus (ALV) 
(Weinberg, 2007). 
	 4	
performed in 1969 using somatic cell hybridization (the fusion of normal and tumor 
cells), and showed that A9 murine fibroblast cells can inhibit the tumorigenicity of 
various types of malignant cells (Harris et al., 1969). This result suggested that an 
endogenous tumor suppressive agent was present in the A9 cells that acted on the 
malignant cells to reduce their tumorigenicity. In the few years following this discovery, 
the existence of tumor suppressor genes in humans was predicted, and the ‘two-hit’ 
model of tumorigenesis was formed that would remain a predominant paradigm for 
decades to come (Knudson, 1971; Tewari et al., 1973).  
 Knudson both predicted the existence of a retinoblastoma tumor suppressor gene 
and proposed the two hit model of carcinogenesis through statistical examination of the 
inherited and the nonhereditary forms of retinoblastoma cancer of the retina (Figure 1.3) 
(Knudson, 1971). He proposed that while both forms of retinoblastoma arise from a 
similar mechanism, inherited retinoblastoma is typically earlier onset and occurs when a 
germline mutation is passed from parent to offspring, and the second mutation occurs 
sporadically. Bilateral retinoblastoma is almost always inherited because there is a greater 
Figure 1.3: Inactivation of tumor suppressor genes (Payne and Kemp, 2005). 
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probability of developing the cancer in two distinct sites when a germline mutation 
already exists. In nonhereditary retinoblastoma, both mutations are gained sporadically, 
which typically produces unilateral disease. Knudson’s prediction was proven to be true 
in 1986, when the Retinoblastoma (RB1) tumor suppressor gene was successfully cloned 
(Friend et al., 1986). Bi-allelic mutations of the RB1 gene occur not only in 
retinoblastoma (both inherited and nonhereditary), but also in other tumor types (Cerami 
et al., 2012; Godbout et al., 1983).  
 The ‘two-hit’ model of carcinogenesis was challenged when the concept of 
haploinsufficiency was discovered. For certain tumor suppressors, two hits are not 
required, and loss of one copy is sufficient to cause malignancy (Figure 1.3). In the case 
of these haploinsufficient tumor suppressor genes, one copy of the gene does not produce 
a high enough dose to satisfy the normal tumor suppressive function of the gene product 
in the cell (Figure 1.4). Loss of haploinsufficient tumor suppressor genes also reduces the 
latency of tumors because only one genetic hit is required. Although the concept of 
haploinsufficiency has long been known in Drosophila genetics, the concept was not 
applied to tumor suppressor genes until 1998 when Fero et al. discovered that the cell 
cycle inhibitor gene p27kip1 (also known as CDKN1B) is a haploinsufficient tumor 
Figure 1.4: The activity of tumor suppressor proteins versus gene dosage 
(Payne and Kemp, 2005). 
	 6	
suppressor in mice (Fero et al., 1998). In the same year, two other tumor suppressors 
were identified as haploinsufficient, p53 and transforming growth factor beta 1 (Tgf-β1) 
(Tang et al., 1998a; Venkatachalam et al., 1998).  Since then, quite a large number of 
tumor suppressors have exhibited evidence of haploinsufficiency [reviewed in (Payne and 
Kemp, 2005)]. There have also been examples of dominant negative tumor suppressor 
alleles that mask or prevent the function of the wild-type allele, as is the case for 
particular WT1 mutations (Englert et al., 1995; Haber et al., 1992; Moffett et al., 1995; 
Reddy et al., 1995).   
 Haploinsufficiency and dominant-negative alleles of tumor suppressor genes 
created exceptions to the ‘two-hit’ paradigm of carcinogenesis. Another level of 
complexity that can be added to this model is that many tumor suppressors are 
pleiotropic; they don’t have a single role or function in tumor suppression, but function in 
multiple cellular processes.  Notably, a pleiotropic tumor suppressor may not show a 
consistent effect of single allele loss across each of its cellular functions, and some 
functions may be more dose-dependent. This is the case for the tumor suppressor p53 
which is haploinsufficient for functions involved in apoptosis and the maintenance of 
genomic integrity, but recessive for its transcriptional regulation of specific targets 
(Bouffler et al., 1995; Haber et al., 1992). There are many examples of how the 
penetrance of a particular mutation can be inconsistent and/or context-dependent. 
Modifier genes exist that can either enhance or suppress the phenotype of a particular 
mutation, and these modifiers are often tissue specific, helping to explain the spectrum of 
tumors when a particular tumor suppressor is lost. For example, the haploinsufficiency of 
the p27 tumor suppressor is tissue-specific (Muraoka et al., 2002; Philipp et al., 1999) 
	 7	
and the genes Dnmt1 and Mdr1 are tumor suppressive modifiers of Apcmin-driven 
intestinal tumorigenesis in mice (Eads et al., 2002; Yamada et al., 2003).  
 The Knudson ‘two-hit’ model of oncogenesis has been a useful framework to 
understand tumor suppressor genetics. Over the years, additional levels of complexity 
have been layered onto this model. Although it was initially assumed that tumor 
suppressor genes had simple on/off switches, it has become clear that recessivity and 
haploinsufficiency are often context- and tissue-dependent, allowing the body to develop 
a wide and diverse set of signaling contexts and outputs. Since the Retinoblastoma (RB1) 
tumor suppressor was discovered more than four decades ago, a wide variety of tumor 
suppressor genes have been discovered that play important and unique roles in mediating 
tumor suppression.  
 
THE P53 TUMOR SUPPRESSOR 
	
Discovery of p53 
 
The first evidence of another highly important tumor suppressor gene appeared in 
1969, when the scientists Li and Fraumeni described a dominantly inherited tumor 
susceptibility syndrome characterized by increased incidence of osteosarcoma, breast 
cancer, and rhabdomyosarcoma in female carriers (Li and Fraumeni, 1969).  It was later 
discovered that this syndrome, termed Li-Fraumeni, is caused by germline mutations of 
the p53 tumor suppressor gene (TP53) (Malkin et al., 1990; Srivastava et al., 1990). 
Interestingly, the mutant p53 gene was first classified as an oncogene in transformation 
experiments using the simian virus 40 (SV40) DNA tumor virus. The gene product of 
p53, a 53 kilodalton (kDa) protein, was observed by multiple groups to be associated with 
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the SV40 viral-encoded large tumor antigen (large T-antigen) in SV40 transformed cells 
(Kress et al., 1979; Lane and Crawford, 1979; Linzer and Levine, 1979; Melero et al., 
1979; Smith et al., 1979). p53 was expressed at high levels not only in SV40-transformed 
cells, but also in other types of cancer cells (Linzer and Levine, 1979) and in cells 
transformed by the Abelson murine leukemia virus (Smith et al., 1979), but was 
expressed at much lower levels in non-transformed cells. 
 Given the observation that SV40 infection leads to increased expression of p53 
and transformation, it was assumed that p53 was an oncogene that drives carcinogenesis, 
and researchers continued to gather evidence that suggested this notion. In order to study 
the specific functions of p53 in the cell, the gene needed to be cloned. In short order, 
human and mouse cDNA and genomic clones had been created [reviewed in (Levine and 
Oren, 2009)]; however, molecular cloning methods were not efficient at the time, so 
cancer cell lines were selected for cloning that express increased amounts of p53. Many 
of these clones of p53 exhibited tumorigenic properties when overexpressed, but there 
were some clones that showed the opposite. It was ultimately discovered that many 
cancer cell lines harbor mutations in the TP53 gene that confer transforming properties, 
and that wild-type p53 does not, in fact, have these properties (Eliyahu et al., 1988; 
Finlay et al., 1988; Halevy et al., 1991).      
 The question became, if wild-type p53 cannot transform cells, then what is its 
function? An early hint towards the answer to this question was discovered when the 
TP53 gene was found to be extensively rearranged and the coding region was almost 
entirely deleted, preventing p53 from being expressed in the human leukemia cell line 
HL60. This suggested loss of p53 function in cancer, though this finding was initially 
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thought of as an exception (Wolf and Rotter, 1985).  The laboratory of Bert Vogelstein 
subsequently discovered that the wild-type TP53 gene is frequently deleted and/or 
mutated in colorectal cancer (Baker et al., 1989).  Around the same time, two laboratories 
also performed in vitro experiments that demonstrated that overexpression of wild-type 
p53 can inhibit transformation caused by the MYC and HRAS oncogenes (Eliyahu et al., 
1989; Finlay et al., 1989).  These observations, coupled with the finding of germline 
TP53 mutations in Li-Fraumeni syndrome and frequent somatic mutations of TP53 in 
many of the most common tumor types, helped to confirm p53 as a tumor suppressor.  It 
was later understood that the SV40 virus could transform cells by sequestering p53 
protein through binding to large T-antigen or E1B adenovirus proteins to prevent it from 
performing its tumor suppressor functions, thus replicating the p53-loss that frequently 
occurs in human cancer [virology reviewed in (Levine, 2009)].  
The impact of p53-loss or mutation in development and disease 
	
An extensive body of work spanning decades of research has revealed that the TP53 gene 
is the most commonly altered tumor suppressor in cancer and is mutated in about half of 
all human cancers. It is apparent now that both loss of wild-type p53 function and gain-
of-function in the TP53 mutants can contribute to tumorigenesis [gain-of-function 
mutants reviewed in (Brosh and Rotter, 2009)]. Germline mutation of the TP53 gene has 
also been established as the cause of the Li-Fraumeni cancer susceptibility syndrome in 
most families (Malkin et al., 1990; Srivastava et al., 1990), as previously mentioned, but 
it still remained to be explored whether loss of Trp53 (mouse homolog of human TP53) 
alone could cause spontaneous tumorigenesis in mice. In 1992, the first Trp53-knockout 
mouse was created, and these mice developed early spontaneous cancers (mostly 	
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 lymphomas) at high penetrance (Figure 1.5a) (Donehower et al., 1992). The p53-null 
(Trp53-/-) mice also developed soft-tissue sarcomas, testicular tumors, osteosarcomas, 
carcinomas, as well as other types of cancer (Figure 1.5b).  
Interestingly, the p53 heterozygous mice (Trp53+/-) developed tumors of 
intermediate latency (Fig. 1.5a) with a shifted tumor spectrum, including a greater 
proportion of osteosarcomas, soft-tissue sarcomas, carcinomas, and a smaller proportion 
of lymphomas; a finding that indicated that p53 is haploinsufficient for tumor suppression 
Figure	1.5:	Tumor	phenotypes	of	p53-deficient	mice	(Donehower	and	Lozano,	2009) 
Figure 1.5: Tumor phenotypes of p53-deficient mice. (A) Kaplan-Meier curves 
for Trp53+/+, Trp53+/-, and Trp53-/- mice. (B) Tumor spectrum for each genotype. 
(Donehower and Lozano, 2009). 
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(Figure 1.5b) (Suzuki et al., 2001). The first transgenic mouse overexpressing mutant p53 
was developed before the first p53-knockout mouse, and 20% of those mice developed 
tumors by 18 months, suggesting gain-of-function for the mutant p53 protein (Lavigueur 
et al., 1989). In addition to the above described seminal experiments, the specific 
consequences of p53-loss has been studied in great detail in transgenic mice [reviewed in 
(Donehower and Lozano, 2009)]. 	
 p53 is a pleiotropic protein that has important functions not only in tumor 
suppression, but in other areas of cell biology and signaling. In addition to the role of p53 
in tumor suppression, p53 also has a pivotal role in development. Most p53-deficient 
mice develop normally, but roughly 20-30% of female mice develop exencephaly, 
meaning that the brain is located outside of the skull, caused by failed neural tube closure 
in the growing fetus (Armstrong et al., 1995; Donehower et al., 1992; Sah et al., 1995). 
Furthermore, p53-mediated apoptotic response is essential to suppress teratogenesis in 
the developing fetus that may arise from oxidative stress, radiation, or DNA damaging 
chemicals (Nicol et al., 1995; Norimura et al., 1996; Wang, 2001). p53-deficient mice 
have an increased incidence of teratologic abnormalities resulting from these damaging 
agents, and have a decreased rate of cell death, suggesting that p53 plays a guardian role 
during embryonic development to remove teratogenically injured cells, ultimately 
reducing the rate of congenital defects. 
 It is also immediately evident that p53-/- female mice have fertility defects.  p53 
transcriptionally activates the leukemia inhibitory factor (LIF), where LIF aids in embryo 
implantation. Interestingly, p53-/- female mice have lower levels of LIF during the 
implantation period of pregnancy leading to increased implantation failure. This 
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relationship between p53 and fertility is preserved in humans, as particular 
polymorphisms in the TP53 gene cause apoptotic defects, and lead to reduced fertility 
from implantation failure (Hu et al., 2008; Hu et al., 2007; Kay et al., 2006).  
 Interestingly, loss of function of wild-type p53 is often accompanied by gain of 
function (GOF) of the mutant p53. Thousands of mutations of the TP53 gene have been 
cataloged, and there are key hotspot mutations that are much more recurrent in cancer. 
These hotspot mutations, such as p53-R172H (amino acid 175 in humans) and p53-
R270H (amino acid 273 in humans), disrupt the DNA binding domain and display gain-
of-function aggressive phenotypes, such as increased growth in soft agar, and increased 
tumorigenesis when xenografted into nude mice (Cho et al., 1994; Dittmer et al., 1993; 
Sigal and Rotter, 2000).  In fact, mice harboring these heterozygous knock-in mutations 
do not show a difference in survival from Trp53+/- mice, but display increased metastatic 
potential (Lang et al., 2004; Liu et al., 2000; Olive et al., 2004). The specific new 
functions of the different p53 GOF mutants are still being discovered in current research.  
The functions and regulation of the p53 tumor suppressor 
	
p53 is a transcription factor that binds DNA in a sequence-specific manner (Kern 
et al., 1991). About 80% of the missense mutations that inactivate p53 in cancer are 
concentrated within the DNA binding domain (Figure 1.6a), indicating that the tumor 
suppressive activity of p53 occurs primarily through transcriptional transactivation of its 
targets (Hollstein et al., 1991). p53 is expressed at low basal levels in the cell and is 
activated to much higher levels of expression in response to a variety of cell stressors 
including but not limited to DNA damage, radiation, hypoxia, nutrient deprivation, 
oxidative stress, hyperproliferative signals, telomere attrition, and replicative stress	
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 [reviewed in (Bieging et al., 2014)].  In response to these cell stressors, p53 activates 
numerous targets (Figure 1.6b) including p21, GADD45a, and PTEN, among many 
others to activate apoptosis, cell cycle arrest, DNA repair, and senescence pathways 	
(El-Deiry, 1998; El-Deiry et al., 1993; El-Deiry et al., 1995; Stambolic et al., 2001; Zhan 
et al., 1998) [functions reviewed in (Bieging et al., 2014)].  However, p53 is expressed at 
measureable levels baseline (also known as ‘basal p53’), and the levels of basal p53 
depend on the tissue type (Seim et al., 2016). The expression of basal p53 also depends 
on various physiologic stresses involved in normal cell maintenance such as oxidative 
stress, replicative stress, and immunogenic responses (Loewer et al., 2010; Lu et al., 
2012; Sablina et al., 2005). Additionally, p53 is known to activate the constitutive 
expression of several genes such as CDKN1A (p21), MDM2 (described below), and miR-
Figure	1.6:	Transactivation	of	target	genes	by	p53	(Bieging	et	al.,	2014) 
Figure 1.6: Transactivation of target genes by p53. (a) Hot-spot mutations in cancer 
localize to the DNA binding domain of the p53 protein, and (b) p53 targets involved in 
apoptosis, cell cycle arrest, senescence, and DNA repair (blue) or other cellular processes 
(beige) (Bieging et al., 2014).  
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34a, as well as several targets important for the antioxidant functions of p53 (Hamard et 
al., 2013; He et al., 2007; Tang et al., 1998b).  
 One of 
the key negative 
regulators of p53 






p53 to target p53 
for degradation 
(Fuchs et al., 
1998a; Honda et al., 1997). In many different types of cancer, MDM2 is overexpressed 
and/or amplified [reviewed in (Wade et al., 2013)], causing destabilization of p53 and a 
subsequent inability for p53 to respond to cell stressors, such as UV exposure (Knights et 
al., 2003).  Interestingly, the ARF tumor suppressor promotes stability of p53 by binding 
to MDM2, leading to the sumoylation of MDM2 and hindrance of the MDM2-p53 
interaction (Xirodimas et al., 2002).  Another member of the RING domain protein 
family called MDMX (also known as MDM4) is also a strong negative regulator of p53 
that is upregulated in many different types of cancer and forms an active heterodimer 
with MDM2 (Finch et al., 2002; Linke et al., 2008; Ramos et al., 2001). p53 can also be 
Figure 1.7: p53 responds to various cell stressors to activate 
numerous downstream pathways (Bieging et al., 2014) 
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negatively regulated by several other proteins independently of MDM2/MDMX 
including the c-JUN NH2-terminal kinase (JNK), TATA-box binding protein associated 
factor 1 (TAF1), aurora kinase A (AURKA), anterior gradient 2 (AG2), cyclin G 
(CCNG1), and nucleophosmin (NPM) among others (Fuchs et al., 1998b; Katayama et 
al., 2004; Li et al., 2004; Maiguel et al., 2004; Ohtsuka et al., 2004; Pohler et al., 2004).  
 In reference to its ability to activate numerous targets in response to cell stress, 
p53 was informally named ‘the guardian of the genome’, and it is classically believed 
that p53 suppresses tumors at least in part through this function. Aberrant activation of 
oncogenes in human cancer leads to increased proliferation and replicative stress, which 
activates p53; the end result being the activation of downstream apoptosis or senescence 
pathways (Bartkova et al., 2005b; Halazonetis et al., 2008; Wootton et al., 2005). p53 is 
highly sensitive to DNA damage in the cell, and the induction of p53 in response to DNA 
damage is initiated by the ataxia-telangiectasia mutated (ATM) and the ataxia-
telangiectasia and Rad3-related (ATR) protein kinases that promote the degradation of 
MDM2 and MDMX (Meulmeester et al., 2005a; Meulmeester et al., 2005b; Stommel and 
Wahl, 2004).  
Figure 1.8: DNA damage response pathways target p53 (Meek, 2009) 
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ATM and ATR are part of signaling complexes that respond to various forms of 
DNA damage (Figure 1.8)[reviewed in (Meek, 2009)], where ATM is involved mainly in 
the immediate response to double stranded DNA breaks, and ATR responds to other 
forms of DNA damage, such as replication stress or crosslinking. When the MRN 
complex (as depicted in Figure 1.8, named after its protein components) detects DNA 
damage, it activates ATM to phosphorylate various substrates including p53, MDM2, and 
the transducer kinase CHK2, which can also phosphorylate p53. Other types of DNA 
damage are coated by the replication protein A (RPA), which attracts ATR to the site of 
damage to then activate the 9-1-1 complex (depicted in Figure 1.8, also named after its 
components), resulting in further activation of ATR. ATR is also able to phosphorylate 
multiple substrates including p53, MDM2, and the transducer kinase CHK1, where 
CHK1 can also phosphorylate p53. p53 is phosphorylated at Serine 15, Threonine 18, and 
Serine 20 in response to DNA damage and the phosphorylation event prevents p53 from 
interacting with its negative regulator MDM2, but also allows p53 to interact with 
transcriptional machinery to perform transactivation of particular response genes[ 
reviewed in (Bode and Dong, 2004)]. Cells can enter cell cycle arrest downstream of this 
signaling cascade if DNA damage is not sufficiently repaired.  
Malignant cells often show signs of replicative stress due to aberrant proliferation, 
and it was generally thought that the p53-mediated DNA damage response is important 
for tumor suppression because it can play a role in the early detection and repair of cells 
harboring DNA lesions (Bartkova et al., 2005a). Interestingly, multiple studies have 
shown that the immediate p53-mediated acute DNA damage response (response to a high 
dose of an acute DNA damaging agent such as ionizing radiation or chemotherapeutic 
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drugs) is not required for tumor suppression (Christophorou et al., 2006; Efeyan et al., 
2006; Hinkal et al., 2009). One explanation for these results is that maintenance of 
genome integrity by p53 is ongoing in cells and that these tumor suppressive activities 
play a larger role than the temporal response to acute DNA damage or other cell stressors.  
The role of p53 in apoptosis was first discovered because loss of p53 accelerated 
tumorigenesis in a choroid plexus epithelial tumor model caused by loss of function of 
the Rb proteins. These tumors had a substantial apoptotic response that was eliminated by 
loss of the p53 (Symonds et al., 1994). Furthermore, in the same tumor model, deletion of 
the pro-apoptotic p53 target gene Bcl2-associated X gene (Bax) also accelerated 
tumorigenesis (Yin et al., 1997) (p53-mediated apoptotic response targets reviewed in 
Figure 1.6). Heterozygous loss of p53 significantly accelerated Eµ-Myc-driven 
lymphomagenesis, where the vast majority of these mice lost the remaining wild-type 
allele of p53, and these tumors also had attenuated apoptotic response (Schmitt et al., 
1999). The expression of dominant negative Caspase-9 (pro-apoptotic) or overexpression 
of B-cell/CLL lymphoma 2 (Bcl-2, anti-apoptotic) gene caused more aggressive tumors 
even while p53 was retained. This result suggests that the apoptotic response downstream 
of p53 is important for tumor suppression in this lymphoma model (Schmitt et al., 2002).  
Additional experiments with transgenic mice have helped to elucidate the role of 
the p53-mediated apoptotic pathway in tumorigenesis. Surprisingly, mice deficient in 
p53-upregulated modulator of apoptosis (Puma, also known as Bbc3), Noxa (also known 
as Pmaip1), Bax, or the p53 apoptosis effector (Perp) do not develop spontaneous tumors 
(Ihrie et al., 2006; Jeffers et al., 2003; Knudson et al., 2001; Villunger et al., 2003). 
However, in the Eµ-Myc mouse model of lymphoma, loss of Puma or Bax accelerated 
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tumorigenesis relative to Eµ-Myc alone (Dansen et al., 2006; Eischen et al., 2001; 
Hemann et al., 2004; Michalak et al., 2009). Loss of Perp can also accelerate UVB-
induced skin cancer in mice (Beaudry et al., 2010). These studies demonstrate a clear role 
for the p53-mediated apoptotic response in tumorigenesis. Loss of apoptotic response 
targets alone, however, does not lead to spontaneous tumor formation, which suggests 
that additional tenets of p53-mediated tumor suppression are likely also important.  
More recently, some of the non-canonical functions of p53 have been identified.  
For example, p53 can inhibit the transition of somatic differentiated cells to induced 
pluripotent stem cells (iPSCs), which is thought to be partially dependent on the ability of 
p53 to inhibit the cell cycle and induce apoptosis (Hanna et al., 2009; Hong et al., 2009; 
Kawamura et al., 2009; Li et al., 2009; Marion et al., 2009; Utikal et al., 2009; Yi et al., 
2012). It has also been suggested that p53-regulated microRNAs including mir-34 and 
mir-145 can also suppress the reprogramming of differentiated somatic cells by 
downregulating pluripotency factors (Choi et al., 2011; Lin et al., 2012).   In 
glioblastoma, p53 and PTEN cooperate to activate differentiation pathways, and inhibit 
neural stem cell renewal and tumorigenesis (Zheng et al., 2008).   Furthermore, p53 also 
inhibits the self-renewal of hematopoietic stem cells (Pant et al., 2012), and in a mouse 
model of acute myeloid leukemia (AML), p53 suppressed the self-renewal of leukemia 
stem cells (Zhao et al., 2010b). These findings complement the observation that tumors 
caused by p53-loss are undifferentiated and have gene expression signatures that 
resemble stem cells, and suggest that the ability of p53 to regulate stem cells may 
contribute to tumor suppression. 
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 Another non-canonical function of p53 that may play an important role in tumor 
suppression is its ability to regulate metabolic functions of the cell. In the same way that 
p53 can act as the ‘guardian of the genome’, it can also monitor cellular metabolism and 
counteract the metabolic reprogramming often observed in cancer cells. The ‘Warburg 
Effect’ is a well-known phenomenon where cancer cells shift from oxidative 
phosphorylation as a main energy source to glycolysis, even when oxygen is readily 
available. This shift to glycolysis observed in cancer cells is inhibited by the 
transcriptional activities of p53, where p53 activates cytochrome oxidase (Sco2) to induce 
oxidative phosphorylation to counteract the over-reliance on glycolysis (Matoba et al., 
2006). Additionally, p53 transcriptionally represses the glucose transporters GLUT1 and 
GLUT4 to inhibit glycolysis (Schwartzenberg-Bar-Yoseph et al., 2004). p53 can also  
activate the TP53-induced glycolysis and apoptosis regulator (TIGAR) gene, which de-
phosphorylates fructose-2,6-biphosphate into fructose-6-phosphate (Bensaad et al., 
2006). This causes a decreased rate of glycolysis and an increased rate of 
gluconeogenesis, as well as a conversion to glucose-6-phosphate. The excess glucose-6-
phosphate is shunted into the pentose phosphate pathway, leading to decreased levels of 
reactive oxygen species (ROS) and thus, decreased ROS-induced apoptosis (Bensaad et 
al., 2006). 
 p53 plays additional roles in reducing the levels of ROS in the cell. Trp53-/- mice 
have increased ROS levels, and treatment with a reducing agent such as N-acetylcysteine 
both reduces these ROS levels and delays the onset of T-cell lymphomas in these mice 
(Gottlieb and Vousden, 2010; Sablina et al., 2005). This protective function of p53 to 
reduce ROS is mainly due to its ability to transcriptionally activate glutaminase 2 (GLS2), 
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sestrin 1 (SESN1), and sestrin 2 (SESN2) (Budanov, 2011; Budanov et al., 2004; Hu et 
al., 2010; Sablina et al., 2005). Additionally, p53 is able to maintain energy homeostasis 
through the regulation of autophagy, a process of degradation that removes damaged 
cellular parts such as mitochondria that can be a source of ROS. Autophagy also 
functions to recycle cellular components and produce energy (Mathew and White, 2011; 
Yang and Klionsky, 2009). Although autophagy can inhibit or promote tumorigenesis 
depending on the context, p53 activates autophagy by inducing multiple genes involved 
in the process (Crighton et al., 2006; Gao et al., 2011; Kenzelmann Broz et al., 2013).  
Knockout of autophagy related 5 (Atg5) in mouse embryonic fibroblasts (MEFs) led to 
transformation and defects in p53-mediated apoptosis, which implicates autophagy not 
only in reducing ROS and in the apoptotic response by p53, but also in p53-mediated 
tumor suppression (Kenzelmann Broz et al., 2013).  
 Recent work has also identified a perhaps expected role for p53 in inhibiting 
invasion and metastasis. Interestingly, tumors that lack p53 have been shown to be both 
more aggressive and more vascularized (Lu et al., 2001). A signature associated with 
invasiveness in mouse small intestinal tumors deficient for both p53 and casein kinase 1α 
(CK1α), termed ‘p53-suppressed invasiveness signature (PSIS)’, has been identified, and 
is dependent on p21, independently of the known role for p21 in p53-mediated cell cycle 
control (Elyada et al., 2011). Along these lines, multiple sources have reported that p53-
loss leads to increased invasive behavior and motility in many cell types in vitro 
(Alexandrova et al., 2000; Gadea et al., 2007; Gadea et al., 2002; Guo et al., 2003; Guo 
and Zheng, 2004). Epithelial-mesenchymal transition (EMT), a process where epithelial 
cells acquire characteristics of mesenchymal cells, such as decreased focal adhesion and 
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increased motility, is frequently observed in the transition from normal cells to cancer 
cells and is highly associated with invasion and metastasis (Thiery et al., 2009).  p53 can 
inhibit EMT by targeting microRNAs that are involved in the process. p53 can activate 
mir-200c, which represses both ZEB1 and BMI1, where ZEB1 is a transcription factor 
known to promote EMT, and BMI1 is a polycomb group protein that maintains the self-
renewal property of stem cells and also promotes EMT (Chang et al., 2011; Kim et al., 
2011b). Furthermore, the SNAIL protein (also known as zinc finger protein SNAI1) 
promotes EMT by repressing E-cadherin, an adhesion molecule responsible for the tight 
interaction between epithelial cells, causing cells to migrate and become mesenchymal. 
p53 activates mir-34, which then represses SNAIL, allowing for the appropriate 
expression of E-cadherin in epithelial cells (Kim et al., 2011a). In mice, p53 deficiency 
correlates with EMT in colon, skin, and breast cancer (Bornachea et al., 2012; Jiang et 
al., 2010; Schwitalla et al., 2013). The mechanisms by which p53 functions to inhibit 
invasion and metastasis are still being uncovered, but may be an important facet of p53-
mediated tumor suppression.  
 Another emerging role of p53 involves its function in establishing a tumor 
suppressive microenvironment. The characteristics of the tumor microenvironment can 
strongly affect the ability of the tumor to grow, and the surrounding adipose tissue, 
fibroblasts, immune cells, blood vessels, and extracellular matrix have unique 
characteristics that influence this microenvironment.  One popular topic of research is the 
ability of immune cells to influence tumor growth, and p53 can activate many genes 
involved in immune response (Menendez et al., 2013b; Xue et al., 2007). For example, 
p53 activates immune cytokines, which create a hostile environment for the tumor due to 
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the recruitment of macrophages, natural killer cells, and neutrophils. This recruitment of 
immune cells by p53-induced cytokines can eventually cause senescence, apoptosis, and 
even tumor regression (Xue et al., 2007). In hepatic stellate cells (HSCs), the presence of 
p53 can promote the M1 anti-tumor macrophage phenotype over the M2 pro-tumorigenic 
macrophage phenotype, where p53-null cells display the M2 phenotype (Lujambio et al., 
2013). p53 can inhibit angiogenesis in the tumor microenvironment by activating 
thrombospondin 1 (TSP-1) (Dameron et al., 1994). Additionally, p53 function is often 
lost in the tumor stroma of multiple tissues types, which is thought to contribute to tumor 
formation (Guo et al., 2003; Matsumoto et al., 2003; Tuhkanen et al., 2004). In further 
support of a role for p53 in tumor stroma, prostate stromal fibroblasts undergo p53-
dependent cell cycle arrest upon inactivation of the Rb tumor suppressor in mouse 
prostate epithelium, demonstrating that p53 can activate a tumor suppressive program in 
the microenvironment in response to potentially tumorigenic changes in the epithelium 
(Hill et al., 2005). Immunotherapy is a rapidly emerging field that requires a detailed 
understanding of how the tumor stroma, often containing robust immune cell recruitment, 
can affect the growth of the tumor. Our understanding of the role for p53 in this process 
is not fully understood, but mounting evidence suggests that p53 can exert tumor 
suppressive functions through this mechanism.   
 p53 is also able to regulate the ageing process. Most studies have been performed 
in p53-deficient mice, but mice hypermorphic for p53 that were missing the amino 
terminal sequences display an increased resistance to cancer, as expected, but also harbor 
an accelerated ageing phenotype (Maier et al., 2004; Tyner et al., 2001).  However, mice 
harboring a complete additional copy of the Trp53 gene had increased expression of p53 
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and increased resistance to cancer, but did not display an early ageing phenotype 
(García‐Cao et al., 2002; Serrano and Blasco, 2007). It is thought that the difference in 
phenotypes between these two mice is due to the mechanisms by which the various forms 
of p53 are regulated, where the truncated form may be constitutively upregulated.  
Given the broad array of functions of the p53 protein, it is not surprising that 
TP53 is the most mutated tumor suppressor gene in cancer. As discussed in this chapter, 
p53 plays important roles in stress response, DNA repair, apoptosis, stem cell 
maintenance, metabolism, protection from ROS, prevention of invasion and metastases, 
establishment of a tumor suppressive tumor microenvironment, and ageing. It is likely 
through a complex combination of these functions that p53 mediates its role as a tumor 
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Figure 1.9: p53-mediated cell cycle arrest, senescence, and 
apoptosis are not required for suppression of early-onset 
tumorigenesis in mice. (A) Genetically engineered mouse 
models were created containing the three mutations K117R, 
K161R, and K162R that are deficient in p53-mediated cell cycle 
arrest, senescence, and apoptosis in response to acute stress. (B) 
Mice did not succumb to early-onset tumorigenesis in the manner 
that p53-/- mice do (Li et al., 2012). 
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2012). In this study, three lysine to arginine mutations (K®R) were made in the DNA 
binding domain of p53 that prevented the acetylation of these residues (Figure 1.9, A). 
These mice were deficient in p53-mediated cell cycle arrest, apoptosis, and senescence in 
response to acute stress, but did not succumb to early-onset tumorigenesis in the manner 
that p53-/- mice do, rather they more resembled the p53+/+ wild-type mice (Figure 1.9, B).  
Furthermore, two other studies have now supported the idea that these functions are not 
required for p53-mediated tumor suppression (Brady et al., 2011; Valente et al., 2013).  
The function of p53 as a transcription factor, however, is required for p53-mediated 
tumor suppression, though the transcriptional program required for tumor suppression is 
distinct from that required for the DNA-damage response (Brady et al., 2011). Taken 
together, these results indicate that the ability of p53 to mediate acute stress response in 
the cell is not synonymous with its ability to suppress tumorigenesis. This leads one to 
ask the question: by what mechanism does p53 mediate tumor suppression in the cell if 
not through acute stress response? In Chapter 3, the role of p53 in maintaining the 
expression of multiple other tumor suppressor genes will be explored in detail.  
  
THE PTEN TUMOR SUPPRESSOR 
	
Discovery of PTEN 
	
It was evident from early molecular and cytogenetic studies in the 1980s that 
partial or complete loss of chromosome 10 occurred in human gliomas (Bigner et al., 
1984). In 1997, mapping of homozygous mutations on chromosome 10 led to the 
discovery of phosphatase and tensin homolog, deleted on chromosome 10 (PTEN) as a 
putative tumor suppressor gene on the 10q23 locus. PTEN is a protein/lipid dual 
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specificity phosphatase tumor suppressor protein that is inactivated in multiple sporadic 
tumor types, and germline mutations of PTEN occur in patients with the Cowden’s 
hereditary cancer predisposition syndrome (Li et al., 1997; Liaw et al., 1997; Steck et al., 
1997). Following these initial discoveries, PTEN has been shown not only to be a 
ubiquitously expressed tumor suppressor whose loss leads to spontaneous tumorigenesis 
in several different tissues, but also to perform essential functions in normal physiology, 
signaling, and development.  
 
The functions of the PTEN tumor suppressor 
	
The most studied function of PTEN is its contribution to the PI3K/AKT signaling 
axis. Class I phosphatidylinositol-3-kinases (PI3Ks) are lipid kinases that can 
phosphorylate phosphatidylinositol-(4,5)-bisphosphate, PIP2, to phosphatidylinositol-
(3,4,5)-trisphosphate, PIP3 (Maehama and Dixon, 1998), and are activated downstream of 
receptor tyrosine kinase (RTK) or G protein-coupled receptor (GPCR) stimulation 
(Vanhaesebroeck and Waterfield, 1999). One of the key functions of PTEN is to act as a 
lipid phosphatase to antagonize PI3K through the hydrolysis of PIP3 to PIP2 (Maehama 
and Dixon, 1998). The lipid phosphatase action of PTEN reduces the amount of PIP3 on 
the plasma membrane of the cell. The presence of PIP3 leads to the recruitment of the 
serine/threonine kinase AKT to the membrane, which is then phosphorylated by 
mammalian target of rapamycin complex 2 (mTORC2) and then phosphoinositide-
dependent kinase 1 (PDK1) at Serine 473 and Threonine 308, respectively (Alessi et al., 
1997; Sarbassov et al., 2005). Active phosphorylated AKT then leaves the membrane to 
activate its downstream effectors involved in proliferation, cell growth, cell migration, 
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metabolism, survival, cell motility, cell polarity, stem cell renewal, and apoptosis 
(Chalhoub and Baker, 2009; Song et al., 2012). Thus, PTEN opposes the activation of 
these downstream effectors. The PI3K/AKT signaling axis is broadly important in 
virtually all cells; thus, as the key negative regulator of this pathway, PTEN occupies a 
ubiquitous inhibitory signaling niche. 
PTEN harbors functions independent of its lipid phosphatase activity, and also has 
functions independent of its phosphatase activity altogether. As previously mentioned, 
PTEN is dual-specificity phosphatase, meaning that it dephosphorylates both lipids and 
proteins (Myers et al., 1997). Protein substrates include focal adhesion kinase (FAK also 
known as PTK2), where dephosphorylation of FAK by PTEN inhibits migration, 
spreading, and adhesion (Tamura et al., 1998), and the nuclear target cAMP responsive 
element binding protein (CREB), where dephosphorylation by PTEN inhibits CREB-
mediated gene transcription and cell proliferation (Gu et al., 2011), among others. PTEN 
interacts with phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2 
(PREX2) to restrain invasion mediated by PREX2-catalyzed activation of RAC1, which 
can occur in the absence of the lipid phosphatase domain of PTEN (Mense et al., 2015). 
Also, the ability of PTEN to suppress JNK pathway activity is also independent of its role 
in AKT activation (Vivanco et al., 2007). The microspherule protein 1 (MSP58 also 
known as MCRS1)-mediated cellular transformation and the eukaryotic translation 
initiation factor 2α kinase 2 (eIF2α2 also known as PKR)-eIF2α phosphorylation cascade 
are regulated by PTEN independently of its phosphatase activity (Mounir et al., 2009; 
Okumura et al., 2005).  
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PTEN protein is also present and functional within the nucleus. It is thought that 
PTEN has both phosphatase-dependent and -independent functions in the nucleus. In fact, 
nuclear pools of PIP3 are not hydrolyzed by PTEN, indicating that the lipid phosphatase 
activity of PTEN does not play a role in its nuclear function (Lindsay et al., 2006). In 
addition to its nuclear lipid phosphatase-independent role in regulating CREB (mentioned 
above), nuclear PTEN has been shown to regulate cell cycle progression and genomic 
stability (Puc and Parsons, 2005; Shen et al., 2007; Sun et al., 2014). Two studies have 
reported the interaction of nuclear PTEN with acetyltransferases p300/CBP and PCAF to 
regulate both histone acetylation and protein acetylation, including the acetylation of p53 
in response to DNA damage (Li et al., 2006; Okumura et al., 2006). In addition, nuclear 
PTEN interacts with histone H1 to regulate chromosome condensation (Chen et al., 
2014). PTEN has also been implicated in DNA repair and damage response, and the 
SUMOylation of PTEN in its nuclear localization (Bassi et al., 2013). Nuclear PTEN 
controls the DNA replication process in response to replicative stress through its 
interaction with minichromosome maintenance complex component 2 (MCM2), where 
PTEN dephosphorylates MCM2 at Serine 41 to restrict replication fork progression (Feng 
et al., 2015). Nuclear PTEN is localized to the nucleus in primary, fully differentiated 
resting cells compared to rapidly dividing cancer cell lines, which have reduced amounts 
of nuclear PTEN (Gimm et al., 2000; Perren et al., 2000). The function of PTEN in the 
nucleus and the mechanisms of nuclear localization continue to be hotly debated, but 
converge on the idea that nuclear PTEN exerts tumor suppressive function in the nucleus 
by protecting genomic integrity.  
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The complex transcriptional regulation of PTEN 
	
The regulation of PTEN is complex, and occurs at the transcriptional, 
translational, and post-translational levels including through localization and binding 
partners [reviewed in (Salmena et al., 2008; Song et al., 2012)]. Although many 
mechanisms of PTEN regulation have been identified (Figure 1.10, A-C), broadly 
relevant mechanisms of PTEN downregulation have remained elusive.  
PTEN transcript level is the key determinant for PTEN protein expression, and 
PTEN immunohistochemical (IHC) status correlates with PTEN transcript level in breast 
cancer (Saal et al., 2007). PTEN can be upregulated by many transcription factors 
including peroxisome proliferation-activated receptor γ (PPARγ), early growth-regulated 
transcription factor-1 (EGR1) functioning downstream of insulin-like growth factor 2 
(IGF2), p53, and activating transcription factor 2 (ATF2) (Patel et al., 2001; Shen et al., 
2006; Stambolic et al., 2001; Virolle et al., 2001). Conversely, PTEN can also be 
Figure	1.10:	Mechanisms	of	PTEN	loss-of-function	(Song	et	al.,	2012) 
Figure 1.10: Mechanisms of PTEN loss-of-function by A) genetic alteration, B) 
transcriptional regulation, and C) regulation by microRNAs (Song et al., 2012).  
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downregulated by a number of known proteins. c-Jun can function through the RAS-
RAF-MEK-ERK pathway to downregulate PTEN (Chow et al., 2007; Hettinger et al., 
2007). PTEN can also be repressed by the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) transcription factor acting through the MEKK4 and JNK 
pathways to suppress apoptosis by direct binding to the PTEN promoter (Xia et al., 
2007). Two transcription factors, Snail and inhibitor of DNA binding (ID1), compete 
with p53 for binding on the PTEN promoter to repress PTEN (Escriva et al., 2008; Lee et 
al., 2009). Interestingly, some proteins have the ability to regulate PTEN in different 
ways depending on the context. One example of this is NOTCH, which can activate 
PTEN transcription through the MYC and CBF-1 transcription factors (Chappell et al., 
2005; Jarrett T. Whelan, 2007; Palomero et al., 2007), or repress PTEN through HES-1 
(Palomero et al., 2007).   
Recent studies have suggested that epigenetic mechanisms can mediate the 
transcriptional repression of PTEN (see Chapter 4 for background on the epigenetic 
regulation of transcription). For example, CpG dinucleotide-rich regions in the promoter 
of PTEN are methylated in over 50% of thyroid cancers, 48% of sporadic breast cancers, 
and 16% of hepatocellular carcinomas (Alvarez-Nunez et al., 2006; Garcia et al., 2004; 
Wang et al., 2007). In fact, promoter hypermethylation of PTEN among other cancer-
related genes is a prognostic factor in acute lymphoblastic leukemia (ALL) and confers 
resistance to therapy in both ALL and chronic myeloid leukemia (CML) (Montiel-Duarte 
et al., 2008; Nishioka et al., 2011; Roman-Gomez et al., 2004). Promoter methylation is 
generally accepted to be an event that causes gene silencing, though the direct role of 
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promoter methylation in the expression of PTEN remains controversial (Zysman et al., 
2002).  
In nasopharyngeal cancer, PTEN transcription is epigenetically repressed by 
polycomb group (PcG) proteins including the polycomb repressive complex 2 (PRC2) 
through direct binding to the PTEN promoter to cause EMT (Li-Bing Song et al., 2009). 
Additionally, ecotropic viral integration site 1 (EVI1), a protein involved in proliferation 
of hematopoietic stem cells that is upregulated in 10% of leukemias, binds to the PTEN 
promoter and other PcG proteins to repress PTEN in leukemia (Palomero et al., 2007). 
Histone deacetylases (HDACs) also control PTEN transcription. At the PTEN promoter, 
Sal-like protein 4 (SALL4) 
associates with the NuRD repressor 
complex (which possesses HDAC 
activity) to repress PTEN (Lu et al., 
2009). PTEN and its neighboring 
gene, ATPase family AAA-
containing protein (ATAD1 also 
known as THORASE), are oriented 
head-to-head and are separated by 
about 50 kilobases (kb) (Figure 1.11, 
A). Interestingly, PTEN and ATAD1 
transcript levels are highly 
correlated, and are coordinately 
downregulated in a signature of 
Figure	1.11:	PTEN	and	ATAD1	are	coordinately	
downregulated	in	breast	cancer	(Saal	et	al.,	2007) 
Figure 1.11: PTEN and ATAD1 are coordinately 
downregulated in breast cancer. (A) Map of 
PTEN/ATAD1 locus. (B) PTEN and ATAD1 
transcript levels coorelate with other members of 
the poor-prognosis signature. (C) PTEN and 
ATAD1 transcript levels are highly correlated (Saal 
et al., 2007). 
	 31	
poor-prognosis breast cancer (Figure 1.11, B-C) (Saal et al., 2007), suggesting epigenetic 
downregulation of the neighborhood of chromatin through a shared regulatory region. It 
is likely that regions of chromatin upstream of the PTEN promoter can also modulate 
PTEN transcription. Taken together, these data suggest complex epigenetic regulation of 
PTEN transcription that is tissue- and context-dependent.  
Multiple studies show that PTEN can be repressed by the binding of microRNAs 
(miRNAs) to the 3’ untranslated region (3’UTR) of the PTEN transcript to prevent 
translation and cause transcript degradation. The sequence of the 3’UTR is conserved 
across metazoan eukaryotes and contains several seed matches for known microRNAs 
that could downregulate PTEN in various contexts. For example, miR-21 is upregulated 
in many different types of cancer, and represses PTEN in hepatocellular carcinoma 
(Meng et al., 2007).   miR-26a is also a direct regulator of PTEN expression, and is 
frequently amplified in glioma (Huse et al., 2009). In prostate cancer, miR-22, miR-25, 
and miR-302 also directly regulate PTEN expression (Nadav Bar, 2010; Poliseno et al., 
2010a). PTEN has a transcriptionally active pseudogene called PTENP1 that is located on 
chromosome 9q21 and is not translated. In fact, PTENP1 transcripts can regulate PTEN 
by acting as a decoy for PTEN-targeting miRNAs or by acting as a guide for the 
recruitment of the PRC2 complex to the PTEN locus, depending on the transcript splice 
form and strand of origin (Johnsson et al., 2013; Poliseno et al., 2010b). 
 
The impact of PTEN-loss in development and disease  
	
Given the many functions of PTEN in normal physiology and signaling, it is not 
surprising that PTEN has important roles in development, tumor susceptibility, and other 
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diseases. The regulation of PTEN is highly important in cancer because PTEN is a 
haploinsufficient tumor suppressor, and it exhibits dose-dependent effects in cancer that 
are most extreme when another oncogenic hit is present. Notably, only a 20% reduction 
in expression can result in spontaneous tumor formation in mice (Alimonti et al., 2010; 
Trotman et al., 2003; Vasudevan et al., 2007). Due to the strong dose-dependency of 
PTEN, subtle downregulation of the PTEN gene can be of similar detriment to the cell as 
mutation or deletion of the gene altogether. In tumors where PTEN is lost or 
downregulated, PI3K lacks opposition, causing increased accumulation of PIP3 on the 
membrane and increased activation of downstream effectors, such as AKT. Activation of 
the PI3K pathway is correlated with increased metastatic potential and poor prognosis in 
breast cancer (Saal et al., 2007). Loss or downregulation of PTEN has been implicated 
not only in cancer, but also in neurological disorders (Goffin et al., 2001; Griffin et al., 
2005; Varga et al., 2009). 
Germline PTEN-loss plays a pivotal role in the development of a spectrum of 
inherited tumor predisposition syndromes. 70-80% of the patients harboring germline 
mutations in PTEN develop hamartoma tumor syndromes (PHTS) including Cowden 
syndrome, Lhermitte-Duclos disease, and Bannayan-Riley-Ruvalcaba syndrome 
(Blumenthal and Dennis, 2008). PTEN-null mice are embryonic lethal before embryonic 
day 10 (Di Cristofano et al., 1998; Suzuki et al., 1998). Mice that are heterozygous for 
PTEN develop hyperplastic-dysplastic phenotypes in the skin, colon, and prostate that are 
characteristic of PHTS, and develop spontaneous colon, thyroid, germ cell, prostate, and 
gonadostromal tumors as well as T-cell lymphomas/leukemias (Cristofano et al., 1998; 
Suzuki et al., 1998). Since homozygous full-body loss of PTEN is embryonic lethal, 
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tissue-specific knockout mice have been used to study the effect of complete PTEN-loss 
in tissues of interest. For example, tissue-specific deletion of Pten in mice led to rapid-
onset tumor formation in the endometrium, mammary gland, prostate, and T-cells 
(Daikoku et al., 2008; Li et al., 2002; Suzuki et al., 2001; Wang et al., 2003).  In the lung, 
liver, and bladder, tissue-specific deletion of Pten led to tumors with increased latency 
(Horie et al., 2004; Tsuruta et al., 2006; Yanagi et al., 2007). On the other hand, tissue-
specific deletion in the β-cells of the pancreas or in the intestine did not lead to tumor 
formation, but led to polyps similar to those observed in PHTS (Marsh et al., 2008; Stiles 
et al., 2006). Notably, as previously mentioned, the combination of PTEN-loss with 
alteration of an additional oncogene or tumor suppressor can accelerate tumorigenesis.   
Somatic mutations and deletions in PTEN are frequent in a variety of cancers 
including endometrium, breast, brain, and prostate (Li et al., 1997; Steck et al., 1997). 
The Cancer Genome Atlas has cataloged over 1800 individual cancer-derived mutations 
in PTEN, and endometrial cancer has the highest frequency of PTEN mutation, present in 
over 60% of cases (Cerami et al., 2012; Gao et al., 2013). Loss of heterozygosity (LOH) 
of Chromosome 10q23 is common in cancer, and 70-80% of advanced prostate cancers 
and 30-40% of breast cancers exhibit mono-allelic loss of PTEN upon presentation, 
further supporting the concept of haploinsufficiency (Ali et al., 1999; Bose et al., 1998; 
Feilotter et al., 1999; Gray et al., 1998; Whang et al., 1998). Bi-allelic loss of PTEN is 
much less common upon presentation, but does occur in many advanced cancers.  
PTEN-loss is also involved in neurological disorders. Germline mutation of PTEN 
is associated with autism spectrum disorders (ASD) and accompanying microcephaly, 
where 17% of patients with these two phenotypes, and 1-5% of autism patients overall, 
	 34	
harbor germline PTEN mutations (Butler et al., 2005). Knockout of Pten in a subset of 
post-mitotic neurons of the cortex and hippocampus in mice caused microcephaly and 
behaviors reminiscent of ASD (Kwon et al., 2006). It is possible that PTEN-loss 
cooperates with other autism-related genes/pathways to modify or exacerbate the ASD 
phenotype, and this remains an active area of research. PTEN-loss is also involved in 
Alzheimer’s disease (AD), where PTEN influences long-term depression of neurons 
(Jurado et al., 2010). Inhibition of PTEN rescues normal synaptic function and cognition 
in cellular and animal models of AD (Knafo et al., 2016). In AD, the Ab protein recruits 
PTEN into the post-synaptic compartment though its PDZ binding domain. Interestingly, 
a knockin mutation in a mouse model of AD that deleted the PDZ binding domain of 
PTEN revealed that the synaptic toxicity and cognitive dysfunction associated with AD is 
dependent on the PDZ binding domain of PTEN (Knafo et al., 2016). These results 
suggest that PTEN is a mediator of AD phenotypes and may be a promising therapeutic 
target. Taken together, these data suggest that PTEN has profound effects on neuronal 
phenotypes. In addition to its roles in ASD and AD, PTEN-loss has also been implicated 
in other related neuronal defects including seizures, mental retardation, anxiety, and 
general learning deficits [reviewed in (Zhou and Parada, 2012)].   
The PTEN protein consists of a phosphatase domain (harboaring protein- and 
lipid phosphatase catalytic activity), a C2 domain, a C-terminal region and a PDZ-
binding domain (Figure 1.12) (Hollander et al., 2011). Cancer-derived mutations of 
Figure 1.12: The domain structure of the PTEN protein (Hollander et al., 2011) 
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PTEN occur across the entire length of the protein, and some of the cancer-related 
mutants of PTEN partially or fully retain phosphatase catalytic activity (Song et al., 
2012). As previously discussed, this suggests that the tumor suppressor activities of 
PTEN partially occur through phosphatase-independent mechanisms, and in some cases 
mechanisms that affect localization or binding partners that are independent of the PI3K-
AKT signaling axis (Song et al., 2012). As is the case with the p53 tumor suppressor, 
PTEN mediates tumor suppression through a complex mechanism that not only involves 
its negative regulation of PI3K signaling, but also a combination of its nuclear and PI3K-
independent functions.  
A secreted translational variant of PTEN, termed PTEN-long, was discovered 
recently that is able to enter cells to influence PI3K signaling, cell growth, and survival 
(Hopkins et al., 2013). An alternative translational start site upstream of PTEN allows for 
an additional 173 amino acid sequence to be translated on the N-terminus of PTEN; this 
sequence is evolutionarily conserved, and is mutated in cancer. The additional sequence 
allows for secretion and uptake of PTEN by other cells, and increases the contexts in 
which PTEN can influence signaling and act as a tumor suppressor. Recombinant PTEN-
long represents a promising therapeutic approach, especially in tumors that have lost 
PTEN expression through mutation or downregulation. Since the discovery of PTEN-
long, additional translational variants of PTEN have been discovered that could have 
important biological roles (Tzani et al., 2016).  
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THE NEED FOR A COMPREHENSIVE UNDERSTANDING OF TUMOR 
SUPPRESSOR REGULATION 
 Since the discoveries of Rb, p53, and PTEN, many more tumor suppressor genes 
have been identified using insights from genetically engineered animal models, inherited 
cancer predisposition syndromes, and somatic mutations in human cancer as well as 
experiments in vitro. The question that the scientific community strives to answer is how 
these tumor suppressor proteins interact either directly or indirectly to form broad 
network of tumor suppression in the cell and body. What are the normal functions and 
expression levels of these tumor suppressors in various tissues of the body? How are 
these tumor suppressors inactivated in cancer? What are the different mechanisms by 
which tumor suppressors can be regulated in cells? Are these mechanisms tissue- or 
context-specific? Are there common regulators of important tumor suppressors? Can the 
expression of tumor suppressors be restored when lost through pharmacological 
approaches? Would this be a viable therapeutic strategy for PTEN-deficient cancers? 
Scientists and physicians have begun to answer these questions, but an improved 
understanding of tumor suppressor networks in the body in normal and cancer cells 
would allow for the development more effective treatment for cancers or other diseases 















Chapter 2: Characterizing the transcriptional profile of 
PTEN and PTENP1 in normal mammary epithelium and 















BACKGROUND AND SIGNIFICANCE 
	
The mammary gland and the surrounding microenvironment contains different 
cell types with distinct gene expression signatures and cell surface markers [reviewed in 
(Visvader, 2009)]. The human mammary gland consists of a network of ducts, which end 
in clusters termed terminal ductal-lobular units (TDLUs) (Figure 2.1). During mammary 
gland development, mammary stem cells (MaSCs) give rise to the mature epithelium, and 
tissue homeostasis is maintained by MaSCs. The 
mature mammary epithelium in TLDUs consists of 
an inner layer of luminal epithelial cells and an outer 
layer of basal/myoepithelium (Figure 2.2). The 
mammary epithelium is encompassed by the 
basement membrane, which is surrounded by stromal 
(nonepithelial) tissue (Figure 2.2). The interactions 
between epithelial and stromal tissue can affect the 
maintenance and function of various cell types in the 
mammary epithelium, including MaSCs. The 
majority of breast tumors arise in TDLUs, and many tumors have gene expression 
signatures similar to particular subtypes of normal epithelium.	 Some subtypes of breast 
cancer have poor prognosis and poor response to therapy, such as the triple-negative 
group of breast cancers (mostly basal-like, negative for the estrogen receptor, 
progesterone receptor, and HER2 amplification/overexpression) (Sorlie et al., 2001).  
The PTEN tumor suppressor is expressed at high levels in the normal mammary 
epithelium, but PTEN monoallelic sporadic mutation occurs in a wide variety of cancer 
Figure 2.1: Schematic 
representation of the human 
mammary gland (Visvader, 
2009) 
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types, including 30-40% of breast cancers (Li et al., 1997; Steck et al., 1997). As 
mentioned in Chapter 1, PTEN is often downregulated in the absence of mutation in a 
large proportion of cancers, and downregulation of PTEN transcript and protein is 
associated with poor prognosis in breast cancer (Saal et al., 2007). PTEN transcript level 
is the key determinant for 
PTEN protein levels in breast 
cancers, which suggests that 
transcriptional regulation is 
critical in the expression of 
PTEN (Saal et al., 2007).  
In addition to 
transcription factors and other 
repressive complexes, multiple 
studies have discovered 
microRNAs (miRNAs) that can influence the expression of PTEN (discussed in Chapter 
1). A role for class II long noncoding RNAs (lncRNAs), originating from the sense or 
antisense strand, has been elucidated in guiding repressive complexes to target sites, such 
as the PRC2 complex (Guil et al., 2012; Khalil et al., 2009; van Leeuwen and Mikkers, 
2010; Zhao et al., 2010a). As was also discussed in Chapter 1, transcripts arising from the 
PTEN pseudogene PTENP1 can regulate PTEN by acting as decoys for PTEN-targeting 
miRNAs or by acting as a guide for the recruitment of the PRC2 complex to the PTEN 
locus (Johnsson et al., 2013; Poliseno et al., 2010b). 
Figure 2.2: Schematic representation of the duct 
(Visvader, 2009) 
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Downregulation of PTEN and abnormalities in the PI3K pathway are especially 
frequent in triple-negative breast cancer (TNBC) (Marty et al., 2008). Most TNBCs are 
basal-like, meaning that they have gene expression signatures similar to the basal 
mammary epithelium. Characterization of the cell subtype-specific expression profile of 
PTEN and PTENP1 in the normal mammary epithelium, and the changes that occur to 
this profile in cancer, will be a critical first step in elucidating the mechanisms of 
downregulation in breast and other types of cancer. These mechanisms may be confined 
to a particular cell subtype in the mammary epithelium. In this chapter, we briefly explore 
the expression patterns of PTEN in various normal and cancer samples, with a special 
emphasis on the transcriptional profile of the PTEN and PTENP1 loci as well as the poor-
prognosis gene expression signature associated with PTEN-loss (Saal et al., 2007).  
RESULTS 
PTEN expression is high in normal tissue, often decreased in cancer 
	
 Although it is well known that the expression of PTEN is often decreased in 
cancer, the expression profile of PTEN in normal mammary epithelium has not been well 
characterized. In order to study the progression from normal epithelium to cancer that can 
be driven by PTEN loss, it is crucial to define the PTEN expression profile not only in 
cancer cells and tissues, but also in the different cell subtypes present in the normal 
mammary epithelium. It is also important to determine the normal variation in this PTEN 
expression profile between people. We first decided to measure PTEN expression levels 
in a collection of five normal/tumor pairs from PTEN wild-type breast cancer cases. We 
found that 3/5 tumors (60%) were significantly downregulated for PTEN at the 
transcriptional level (Figure 2.3, A). PTEN transcript and protein levels in the normal 
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samples were highly variable between the five cases (Figure 2.3, A-B).   It was also 
apparent that all tumor samples had lower PTEN protein than the paired normal samples, 
suggesting that downregulation of PTEN could be required for tumor formation or 
progression (Figure 2.3, B).  
 
To begin to investigate the cell-type specific expression of PTEN in normal 
mammary epithelium, we performed immunohistochemistry for PTEN in a set of normal 
breast samples. Perhaps unsurprisingly, we found that the normal expression profile of 
PTEN was variable between patients, but we found recurring expression patterns. The 
vast majority of breast samples from normal, healthy patients had strong 
immunohistochemical staining for PTEN in the mammary epithelium, indicating high 
levels of PTEN protein (Figure 2.4, A-B). The H&E staining (hematoxalin and eosin 
staining, see Materials and Methods section for further detail) is used to visualize the 
general architecture of the tissues (Figure 2.4, A-B). The CK5 cell surface maker is used 
to identify basal epithelium, and the CK8/18 cell surface marker is used to identify the 
luminal epithelium (Figure 2.4, A-B).  In some normal cases, higher expression of PTEN 
Figure	2.3:	PTEN	expression	in	
wild-type	tumors 
Figure 2.3: PTEN expression in 
wild-type tumors. (A) PTEN 
transcript levels measured by qRT-
PCR. Error bars: mean ± s.d.  
Measurements made in triplicate. 
Significance: two-way Anova, 
Sidak's correction. (****P<0.0001) 
(B) PTEN protein levels measured 
by immunoblotting. B-actin is 
loading control. 
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was observed in the basal epithelium (Figure 2.4, A), but in other cases, the expression of 
PTEN was high in all cells of the mammary epithelium, both basal and luminal (Figure 
Figure	2.4:	PTEN	expression	in	normal	mammary	tissues 
Figure 2.4: PTEN expression in normal mammary tissues. IHC staining for PTEN in 
normal, healthy breast samples showing: (A) basal-heavy PTEN staining, and (B) PTEN 
staining in all subtypes of epithelium. H&E images are shown (left column), and CK8/18 
and CK5 were used to identify luminal and basal epithelium, respectively (right columns). 
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2.4, B). These results demonstrate variation in the pattern of PTEN staining across 
normal, healthy breast samples. This variation may be important for susceptibility to 
breast cancer or disease pathology, and could be a result of patient variables such as age, 
ethnic background, and history of pregnancy, among other factors.  
 Since the expression of PTEN transcript is the key determinant for PTEN protein 
levels, we wanted to investigate the PTEN transcript expression levels in a larger cohort 
of breast tumors and compare this to the transcript levels in a cohort of breast cancer cell 	
lines. We observed that a subset of breast tumors is indeed downregulated for PTEN 
transcript, and low PTEN transcript correlated very well with PTEN protein levels 
measured by IHC (Figure 2.5, A). We also observed that transcript levels for PTEN and 
its neighboring  gene ATAD1 were significantly correlated and often coordinately 
downregulated in cancer, which has been previously observed (Saal et al., 2007). It is 
possible that the two genes are controlled by a common regulatory mechanism that 




Figure 2.5: PTEN and ATAD1 transcript levels are coordinately downregulated 
in a subset of breast cancers. PTEN and ATAD1 transcript levels were measured by 
qRT-PCR in (A) tumors and (B) cell lines. Color key is indicated, immuno-
histochemistry (IHC), wild-type (WT), mutant (MUT). Measurements made in 
triplicate. Fold change: calculated from MCF10A cells.  r2 Pearson correlation 
coefficient is indicated. Significance calculated using two-tailed t-test. Normal breast 
and the HCC-1187 breast cancer cell line are circled in red (discussed in Chapter 4). 
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discussed in Chapters 3 and 4. When we measured PTEN and ATAD1 expression in 
breast cancer cell lines, although we still found that the transcript levels of these two 
genes are significantly correlated, we also observed that PTEN transcript levels are much 
lower relative to ATAD1 transcript levels in most cell lines (i.e. the slope of the line is 
different) (Figure 2.5, B). This further lowering of PTEN transcript levels could be an 
artifact of cell culture, as we don’t see it in primary tumors. One cell line that did show 
coordinate downregulation of both PTEN and ATAD1 
compared to normal breast is HCC-1187 (Figure 2.5, B 
indicated by red circle), and this cell line will be used 
for further experiments as a model of PTEN transcript 
downregulation that is more representative of the 
phenomenon observed in tumors.   
Notably, normal breast tissue has robust 
expression of both PTEN and ATAD1 transcript 
compared to most of the breast cancer cell lines and 
cultured normal cell lines (Figure 2.5, B green 
triangle). We decided to isolate normal mammary 
epithelial organoids from reduction mammoplasty 
(NM) and prophylactic mastectomy (PM) samples to 
measure whether cell culture alone can decrease PTEN 
levels (Figure 2.6). (Labarge et al., 2013). We measured PTEN and ATAD1 transcript 
levels in NM and PM samples before culture (indicated as passage 0, P0 in Figure 2.7) 




Figure 2.6: Flow chart of 
protocol for processing breast 
tissue (normal mammoplasty or 
prophylactic mastectomy). See 
Materials and Methods for 
further detail (Labarge et al., 
2013). ‘Purification’ is not part 
of published protocol.  
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these samples indeed decreased the transcript levels of PTEN and ATAD1 when 
comparing P0 samples to higher passages (Figure 2.7, A). We compared the NM and PM 
samples to the MCF10A cell line (immortalized nontumorigenic mammary epithelial 
cells) and primary human mammary epithelial cells (hMECs, 1 and 2 refer to two 
different donors), both of which are cultured cells. As expected, we found that the 
expression of PTEN and ATAD1 in the NM and PM samples that had been cultured 
resembled the levels of PTEN and ATAD1 transcript observed in the MCF10A and 
hMEC cell lines (Figure 2.7, A).  
When epithelial organoids are isolated from breast tissue, there are often stromal 
cells (adipose cells, endothelial cells, immune cells, etc.) that remain in the mixture. 
When these organoids are cultured in breast epithelial media (see MCF10A media from 
Materials and Methods), the media enriches for epithelial cells, and the stromal cells do 
not survive (Figure 
2.7, B). We wanted to 
determine whether the 
decrease in PTEN and 
ATAD1 transcript 
levels was due to the 
enrichment of 
epithelial cells, or 
from the cell culture 
and passage itself. To 




Figure 2.7: PTEN and ATAD1 transcript levels are high in 
uncultured normal cells. (A) Transcript levels were measured 
in normal samples by qRT-PCR. Error bars: mean ± s.d. 
Measurements made in triplicate. (B) H&E staining of 
enrichment of epithelial cells from uncultured (P0) normal 
mammoplasty (NM) samples using epithelial selection media.  
MCF10A and hMECs are non-tumorigenic mammary epithelial 
cell lines, ‘PM’ indicates prophylactic mastectomy, ‘-D’ 
indicates Dynabead-purified samples.  
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the EpCAM antibody (Dynabeads® Epithelial Enrich) to purify mammary epithelial cells 
from the NM P0 sample. We found that uncultured purified epithelial cells had similar 
levels of PTEN to the NM P0 sample, indicating that uncultured normal mammary 
epithelial cells have robust expression of PTEN (Figure 2.7, A ‘NM P0-D’). These results 
suggest that researchers should carefully consider the normal cells used in each 
experiment because passage in cell culture can drastically affect gene expression, as is the 
case with the PTEN tumor suppressor.  
Given our findings on the effect of cell culture and passage on the expression of 
PTEN in normal and cancer cells, we wanted to grow the HCC-1187 breast cancer cell 
line in a more physiologically relevant setting to determine if the coordinate 
downregulation of PTEN and ATAD1 is durable. We xenografted HCC-1187 cells into 
the mammary fat pad of athymic nude mice and allowed the tumors to grow for 12 
weeks. We measured the PTEN and ATAD1 transcript levels in these tumors and found 
that they remained drastically downregulated compared to the uncultured NM P0 sample 
Figure	2.8:	Xenografts	of	HCC-1187	cells	show	
sustained	downregulation	of	PTEN	and	ATAD1 
Figure 2.8: Xenografts of HCC-1187 cells show sustained downregulation of PTEN 
and ATAD1. (A) PTEN and ATAD1 transcript were measured by qRT-PCR in NM P0 
sample and four HCC-1187 mammary fat pad xenografts (1-4, different mice). Error 
bars: mean ± s.d. Measurements made in triplicate. (B) Representative xenograft was 
sectioned and stained for PTEN, epithelial markers CK5 and CK18, and stromal marker 
PDGFRa. H&E also shown. ‘S’ indicates stroma, ‘T’ indicates tumor. 
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(Figure 2.8, A). PTEN was also downregulated in the tumor by IHC staining, but 
remained high in the stroma (Figure 2.8, B). These results indicate that the coordinate 
downregulation of PTEN and ATAD1 observed in HCC-1187 is durable and is likely 
reminiscent of the tumor from which this cell line was derived.  It has been observed that 
PTEN is often downregulated in breast cancer among other cancer types, and our findings 
support this conclusion.   
Characterizing the PTEN/PTENP1 transcriptional profile in normal and tumor cells 
	
 To characterize the specific changes in transcriptional profile of the PTEN and 
PTENP1 genomic loci that occur in the progression from normal mammary epithelium to 
breast cancer, we combined the techniques of RNA-sequencing (RNA-seq) and 
NanoString nCounter to obtain a detailed catalog of transcripts arising from these 
complex loci. First, we used a directional (strand-specific) RNA-seq to catalog the 
transcripts present and their expression in PTEN wild-type cancer samples (four PTEN-
high and four PTEN-low cases determined by qRT-PCR) (Figure 2.9, step 1, Table S2.1-




Figure 2.9: RNA-seq and NanoString approach to define PTEN and PTENP1 
transcriptional profile. Strand-specific RNA-seq of rRNA-depleted samples was used 
to catalog all transcripts. This catalog was used to create a NanoString nCounter® 
probeset, where PTEN-loss signature genes (Saal et al., 2007) and PTEN 3’UTR probes 
were also included. This probeset was used to characterize the PTEN and PTENP1 
transcriptional profile in a set of normal and tumor samples.  
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RNA (rRNA) depletion method instead of polyA selection in order to preserve both 
polyA and non-polyA transcripts. Importantly, we only mapped unique reads for RNA-
seq to avoid misidentification of novel ncRNAs that actually arise from other 
homologous genomic loci. We made a NanoString probeset corresponding to the 
transcripts discovered (known and novel) through RNA-seq arising from unique regions 
Figure	2.10:	RNA-seq	and	NanoString	nCounter	data	at	PTEN	locus 
Figure 2.10: RNA-seq and NanoString nCounter data at PTEN locus. (A) RNA-seq 
on 8 PTEN wild-type breast tumors. Each case represented by separate bar. (B) 
NanoString nCounter data on 8 normal breast samples and 4 PTEN wild-type breast 
tumors. Negative and positive NanoString control probes are shown in gray and black. 
Horizontal gray dashed line indicates threshold for positivity. Each case represented by 
separate bar. Vertical gray dotted lines show alignment between data sets. (C) Map of 
PTEN locus with known genes and transcripts labeled. Strand of each transcript (+ or -) 
is indicated in red and blue, respectively.  
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of the PTEN and PTENP1 loci (Figure 2.9, step 2, Table S2.2-Appendix 2A). The 
NanoString nCounter system counts hundreds of transcripts simultaneously using a 
fluorescent barcode probe for each transcript. This method requires only very small 
amounts of RNA (>100ng) from each sample (Figure 2.9, step 3). We also included 
probes for genes in the previously published PTEN-loss signature (genes altered in 
PTEN-low poor-prognosis breast cancer) (Saal et al., 2007) and for the 3’UTR of the 
PTEN transcript, as the 3’UTR of PTEN has seed matches for several important miRNAs 
(discussed in Chapter 1). We also included several probes that were meant to increase the 
coverage of the PTEN locus, but did not necessarily have signal in RNA-seq (Table S2.1 
and S2.2-Appendix 2A, highlighted in blue). This approach was designed to give an 
unprecedented level of detail on the quantitative changes that occur to all transcripts in 
the PTEN and PTENP1 genomic loci when PTEN is downregulated in breast cancer.  
We used the NanoString nCounter probeset to quantify all cataloged transcripts 
(from RNA-seq) in additional normal mammary tissue and PTEN wild-type breast 
tumors in order to get a detailed view of the changes that occur when PTEN is 
downregulated in this poor-prognosis group. Overall, similar transcriptional patterns were 
observed between the RNA-seq and NanoString quantification methods at both the PTEN 
and PTENP1 genomic loci, indicating that the methods are likely reliable and 
comparable, and both loci were transcriptionally active on both strands of DNA (+ and –, 
referring to the forward and reverse strands of the reference Hg19 genome) (Figures 2.10 
and 2.11, respectively, A-B). At the PTEN locus (Figure 2.10, C), PTEN and ATAD1 
were the most highly expressed transcripts, though the expression between cases varied 
(Figure 2.10, A-B). Interestingly, exon 1 of PTEN was expressed at similar levels to the 
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other exons by RNA-seq (Figure 2.10, A), but exon 1 was not detected at comparable 
levels by NanoString (Figure 2.10, B). There were ncRNAs including CFL1P1 that were 
detected by RNA-seq (Figure 2.10, A and Table S2.1-Appendix 2A), but had low levels 
(near baseline) in most cases by NanoString (Figure 2.10, B). These discrepancies could 
depend on probe efficiency and sensitivity of the NanoString nCounter method. At the 
PTENP1 locus, PTENP1 and the nearby gene ANXA2P2 were expressed at very high 
levels in both the RNA-seq and NanoString data (Figure 2.11, A-B). Interestingly, the 
PTENP1-antisense (AS, relative to the PTENP1 gene) transcripts can repress PTEN 
through interaction with the PTENP1 transcript or by recruiting the PRC2 complex to the 
PTEN promoter depending on the isoform (Johnsson et al., 2013), and these transcripts 




Figure 2.11: RNA-seq and 
NanoString nCounter data at 
PTENP1 locus. (A) RNA-seq 
on 8 PTEN wild-type breast 
tumors. Each case represented 
by separate bar. (B) NanoString 
nCounter data on 8 normal 
breast samples and 4 PTEN 
wild-type breast tumors. 
Negative and positive 
NanoString control probes are 
shown in gray and black. 
Horizontal gray dashed line 
indicates threshold for 
positivity. Each case represented 
by separate bar. Vertical gray 
dotted lines show alignment 
between data sets. (C) Map of 
PTENP1 locus with known 
genes and transcripts labeled. 
Strand of each transcript (+ or -) 
is indicated in red and blue, 
respectively.  
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larger cohort of tumors to determine in what contexts these PTEN-AS transcripts are 
expressed.  
With the exception of exon 1, levels of PTEN as measured with probes from 
many of the other exons and introns show that levels of PTEN decrease in breast tumors 
compared to normal breast in most of the pairs measured by Nanostring (Figure 2.12). 
Notably, the 








2.12). This is 
interesting 
because the 
3’UTR of PTEN 
contains numerous seed matches for miRNAs that can downregulate PTEN (discussed in 
chapter 1), and loss of these seed matches would prevent these miRNAs from binding. 
Interestingly, the shortening of the 3’UTR of particular mRNAs is associated with poor-
prognosis in cancer (Lembo et al., 2012; Sandberg et al., 2008), and may affect the ability 
of competing endogenous RNAs (ceRNAs) to modulate the message levels of these genes 
Figure	2.12:	A	detailed	view	of	PTEN	transcript	
downregulation	in	breast	tumors 
Figure 2.12: A detailed view of PTEN transcript downregulation 
in breast tumors. NanoString nCounter probes from exons and 
introns of PTEN as well as the 3'UTR of PTEN were included. 8 
normal breast samples and 4 PTEN wild-type tumors were included. 
Paired samples indicated by gray line. Error bars: mean ± s.d. 
Significance: two-tailed t-test (P<.05).  
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(Li et al., 2014).  However, it may also be true that total levels of the PTEN transcript 
decreased in tumors, including the 3’UTR, which could occur through a variety of 
different mechanisms (also discussed in chapter 1). The sequence of the 3’UTR of PTEN 
is more unique (genome-wide) than the rest of the PTEN transcript; it is possible that the 
probes for the 3’UTR are favorable due to reduced background or nonspecific binding of 
the probes.  
The PTEN-loss signature genes were also significantly changed in tumors 
compared to normal samples, indicating that the decrease of PTEN expression observed 
in tumors is sufficient to affect downstream and PTEN-loss-associated signaling (Figure 
2.13). ATAD1 levels were significantly downregulated in tumors (Figure 2.13), which 
corroborates previous 
observations by our group 
that PTEN and ATAD1 
message levels are highly 
correlated, and 
coordinately 
downregulated in the 
poor-prognosis signature 
(Saal et al., 2007). In fact, 
many PTEN signature 
genes, both up and downregulated in the PTEN-loss signature, were significantly altered 
in the breast tumor samples compared to normal breast tissue (Figure 2.13). These results 
both validate the PTEN-loss signature, and confirm that both PTEN and PTEN-associated 
Figure	2.13:	Validation	of	poor	prognosis	
PTEN-loss	signature	in	breast	cancer 
Figure 2.13: Validation of poor prognosis PTEN-loss 
signature in breast cancer. NanoString nCounter probes 
for previously published PTEN-loss signature were used 
(Saal et al., 2007). 8 normal breast samples and 4 PTEN 
wild-type tumors were included. Paired samples indicated 
by gray line. Error bars: mean ± s.d. Significance: two-
tailed t-test (P<.05).   
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genes are significantly altered in tumor samples compared to normal tissue. From this 
data, we have also gained a detailed view of the changes in the transcriptional profiles of 
the PTEN and PTENP1 loci that occur in breast cancer; a crucial first step in 
understanding the specific mechanisms by which PTEN transcript is downregulated, and 
the contexts in which these mechanisms occur. 
DISCUSSION 
	
	 In this chapter, we gained an intricate understanding of the transcriptional changes 
that occur at the PTEN and PTENP1 loci in breast cancer. We started by characterizing 
the normal expression of PTEN in mammary epithelial cells. We measured PTEN 
expression in normal tissue adjacent to tumors, prophylactic mastectomy samples, normal 
mammoplasty tissue from healthy patients, uncultured epithelial cells isolated from the 
mammary tissue of these healthy patients, cultured mammary epithelial cells, and 
nontumorigenic immortalized mammary epithelial cell lines. We found that the 
expression of both PTEN and ATAD1 are quite high in normal mammary epithelial cells, 
and that this expression is reduced by passage of cells in culture. Notably, the expression 
of PTEN and ATAD1 are coordinately downregulated in breast tumor samples, but in 
most cultured cell lines, PTEN is downregulated to a greater extent than ATAD1. We 
found one breast cancer cell line, HCC-1187, that displays coordinate downregulation of 
PTEN and ATAD1 that is maintained when the cells form xenografted tumors in the 
mammary fat pad of athymic nude mice. This cell line may be a good model for the 
downregulation that occurs in tumors, and will be revisited in Chapter 4. We were also 
able to validate the previously published poor-prognosis gene signature of PTEN-loss 
(Saal et al., 2007) using NanoString in our normal and breast cancer tissue samples.  
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 Many of the previous studies on PTEN downregulation have focused on cancer 
samples, and the expression of PTEN in uncultured normal mammary epithelium has 
remained largely unexplored. Our study sought to elucidate the changes in PTEN 
transcriptional profile that occur in the progression from normal tissue to cancer, and was 
much enhanced by our extensive characterization of the PTEN transcriptional profile in 
normal mammary epithelium. It was not previously clear that passage of cells in culture 
had an impact on PTEN expression, and that these nontumorigenic mammary epithelial 
cell lines (both primary and immortalized) had lower-than-normal PTEN and ATAD1 
expression.  
In the future, it would be interesting to look at the transcriptional profile for the 
PTEN and PTENP1 loci in additional normal mammoplasty cases that we have available 
in the lab to see if this differs from the transcriptional profile observed in the normal 
breast tissue (adjacent to tumor) that we have already characterized. It would also be 
interesting to investigate the transcriptional profile in additional cancer samples and cell 
lines that are known to have PRC2 activity at the PTEN promoter and regulatory region, 
as we would expect to detect the previously identified PTENP1-AS transcript isoform 
(Johnsson et al., 2013) that guides these repressive complexes to their site of action at the 
PTEN locus (PRC2-mediated repression of PTEN is further discussed in Chapter 4). It 
would also be interesting to use microdissection to separate the different subtypes of 
normal mammary epithelium to determine if the transcriptional profile for 
PTEN/PTENP1 differs between cell subtypes, an experiment we have already started 
using the Leica Laser Microdissection (LMD) Microscope. 
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 Although it has been repeatedly reported that PTEN is downregulated in a large 
proportion of cancers in the absence of genetic mutation, broadly relevant mechanisms 
for this downregulation have not been identified. In addition, the transcriptional network 
of PTEN/PTENP1 is highly complex (discussed in Chapter 1) and this study represents 
the first that is capable of identifying specifically which transcript species corresponding 
to PTEN or PTENP1 (or any ncRNAs in the loci) are changing when PTEN is 
downregulated. Simple qRT-PCR experiments do not yield information about 
transcriptional changes at this level of detail.  This is an efficient and thorough approach 
to identify transcriptional changes at a defined locus that occur between normal and 
cancer cells, or in any other tissue of interest. The RNA-seq data should be used to 
catalog transcripts at additional loci for tumor suppressor genes, create NanoString 
probes, and further characterize the changes in transcriptional profile of other important 
tumor suppressor genes that occur in the progression from normal to cancer at a much 
greater level of detail than has been previously described. In order to establish a 
foundation for understanding the mechanisms by which genes become repressed, one 
must first understand the exact nature and context of the repression; a goal that this 
approach aims to accomplish. 
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Table S2.1: Catalog of transcripts arising from PTEN and PTENP1 genomic loci 
by stranded RNA-seq in breast tumors and normalized read counts in breast 
tumors. Reads from PTEN and PTENP1 genomic loci were obtained by RNA-seq of 
rRNA-depleted stranded libraries from eight PTEN wild-type breast tumors. Table 
contains hg19 genomic location (strand, chromosome, start, end) of corresponding 
Nanostring probe, transcript name, and normalized read counts for eight PTEN wild-
type tumors. Numbers are blockID numbers from the CUMC breast tumor bank, 
‘Low’ or ‘High’ refers PTEN status by qRT-PCR. Probes that were created to increase 






















Table S2.2: NanoString nCounter probeset designed for PTEN and PTENP1 loci 
and PTEN signature genes and counts from normal and breast cancer tissue. 
NanoString nCounter probeset including probes developed from stranded RNA-seq of 
PTEN and PTENP1 genomic loci (Table 2.1), 3’UTR of PTEN, PTEN signature 
genes, housekeeping genes, additional regions of the loci not covered by probes, and 
positive/negative nCounter controls. Table contains transcript name (same names as 
RNA-seq, where applicable), hg19 genomic location of nCounter probe (strand, 
chromosome, start, end), and normalized transcript counts for eight normal breast 
samples (N), and four PTEN wild-type breast tumors (T) (dataset contains four N/T 
pairs and four additional N samples).  Numbers are patient/blockID numbers from the 
CUMC breast tumor bank. Signature genes indicate ‘up’ or ‘down’ for the change in 
transcript level upon PTEN-loss in poor-prognosis breast tumors (Saal et al., 2007). 
For housekeeping genes, the geometric mean of the expression indicated by 
‘GeoMean’ is calculated for normalization.  Probes that were created to increase 
coverag of the PTEN locus that did not have signal in RNA-seq are highlighted in 
blue. 

































































BACKGROUND AND SIGNIFICANCE 
	
As discussed in Chapter 1, TP53 germline mutation is associated with Li-
Fraumeni cancer susceptibility syndrome, and its somatic mutation occurs in about half 
of all cancers (Olivier et al., 2010). p53-null or mutant mice develop spontaneous tumors 
in multiple organs (Donehower et al., 1992). p53 is a transcription factor that binds DNA 
in a sequence-specific manner (Farmer et al., 1992; Wafik S. El-Deiry, 1992), and the 
majority of missense mutations that inactivate p53 in cancer are clustered within the 
DNA binding domain (Olivier et al., 2010). p53 is well established to mediate acute 
stress response in the cell by activating known targets including CDKN1A(p21), 
GADD45a, BBC3(PUMA), and NOXA  among  many others (Figure 1.6) (Bieging et al., 
2014; Kawase et al., 2009). Interestingly, p53 stress response targets that regulate 
apoptosis, cell cycle arrest, and senescence are not required for p53-mediated tumor 
suppression in genetically engineered model systems (Brady et al., 2011; Li et al., 2012; 
Valente et al., 2013), discussed in Chapter 1.  
p53 is regulated by multiple posttranslational mechanisms that are involved in the 
regulation of target gene expression (Appella and Anderson, 2001). As described in 
Chapter 1, p53 is expressed at measureable levels in various tissues of the body in the 
absence of acute stress, where the levels depend on the tissue type and other contextual 
factors (Seim et al., 2016). Basally expressed p53, which has been attributed to various 
physiologic stresses (Loewer et al., 2010; Lu et al., 2012; Sablina et al., 2005), activates 
the constitutive expression of CDKN1A(p21) and miR-34a among other targets (Hamard 
et al., 2013; He et al., 2007; Tang et al., 1998b).  
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Tumor suppressor downregulation is a common event in many types of cancer, 
and is often due to defects in transcription (Kazanets et al., 2016). Inactivation both 
alleles of a tumor suppressor can be necessary for tumor development (Knudson, 1971); 
however, for tumor suppressors that are haploinsufficient, only loss of one allele is 
needed (Santarosa and Ashworth, 2004). Indeed, for some tumor suppressors, partial 
inactivation of just one allele is sufficient to cause tumor development alone or in 
cooperation with other gene mutations (further discussed in Chapter 1).  For instance, 
PTEN is a dosage-sensitive tumor suppressor often downregulated in cancer, and only a 
20% decrease in expression can lead to spontaneous tumor formation in mice (Alimonti 
et al., 2010; Trotman et al., 2003).    
	 It has been shown more recently that p53-bound enhancer elements are important 
for transactivation of particular target genes (Melo et al., 2013). p53 binding results in 
increased H3K27Ac at poised enhancers marked by H3K4me1, which shows that p53 
binding influences enhancer activity. Enhancers play an important role in the timing and 
tissue specificity of transcriptional regulation of genes. Patients with Li-Fraumeni 
syndrome harboring germline mutations in TP53 exhibit strong tissue specificity in 
cancer susceptibility, some of which may be attributable to p53-bound enhancer domains. 
The ability of p53 to regulate the expression of genes via enhancer binding represents a 
potentially important contribution to its tumor suppressive function. 
 Here, we show that basally expressed p53 acts as a transcriptional activator of 
approximately a dozen tumor suppressors, several of which are dose responsive in mice 
(Alimonti et al., 2010; Finnberg et al., 2008; Morton et al., 2010; Ohki et al., 2014); The 
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ability of p53 to maintain expression of these tumor suppressors could contribute to p53-
mediated tumor suppression.  
RESULTS 
	
Mutation of TP53 associates with downregulation of PTEN in breast tumors 
	
Breast cancers are known to harbor abnormalities in the tumor suppressors p53 
and PTEN (Phosphatase and Tensin homolog, deleted on chromosome 10), so we 
Figure	3.1:	Mutation	of	TP53	is	associated	with	reduced	PTEN	expression 
Figure 3.1: Mutation of TP53 is associated with reduced PTEN expression. (A) 
Primary breast tumors were measured and analyzed for several parameters (from top to 
bottom): PTEN mRNA by microarray (*p≤.05, n=95 by Mann Whitney test, expression 
lower in TP53-mutant group), PTEN signature (Saal et al., 2007), PTEN mutation, TP53 
mutation, PTEN IHC status (**p≤.01, n=107 by Chi-squared test, expression is lower in 
TP53-mutant group), Her2- ER- PR-status, and molecular subtype. Color key is indicated. 
(B) PTEN transcript measured by qRT-PCR in primary breast tumors (from the same 
cohort as above) that were either wild-type (WT, n=11) or mutant (MUT, n=18) for TP53. 
Numbers are fold change from MCF10A cells, normalized to GAPDH. Error bars: mean ± 
s.e.m. Measurements made in triplicate. Significance: Mann-Whitney test. (*p≤.05) 
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examined their relationship in primary breast tumors. We observed that mutation of TP53 
was associated with decreased PTEN transcript (P<.05) and protein levels (P<.01), and 
enrichment of the previously published PTEN-loss signature (Saal et al., 2007) (Figure 
3.1, A). This result was confirmed by qRT-PCR in tumors from the same cohort (P<.05, 
Figure 3.1, B). The idea that basally expressed p53 in breast tissues could regulate 
baseline expression of PTEN is interesting because PTEN is a dose-dependent tumor 
suppressor whereby only a 20% deficit in its expression can lead to tumor development in 
mice (Alimonti et al., 2010).  
 
p53 targets a group of tumor suppressor genes in the absence of acute stress 
	
Based on the relationship between p53 mutation and PTEN expression that we 
observed in breast cancer, we sought to explore the possibility that basal wild-type p53 
could have targets such as PTEN that are important for tumor suppression. In the absence 
of acute stress, we performed ChIP-seq for basal p53 in non-transformed human 
mammary epithelial MCF10A cells (wild-type for p53) and ranked the peaks by 
Figure	3.2:	Basally	expressed	p53	binds	to	multiple	important	tumor	suppressor	genes 
Figure 3.2: Basally expressed p53 binds to multiple important tumor suppressor 
genes. (A) Basal p53 ChIP-seq peaks ordered by significance in MCF10A (left) and U2OS 
cells (right). ρ is Spearman coefficient, and corresponding p-value is reported. (B) GSEA of 
basal MCF10A p53 ChIP-seq list (ordered by significance) for genes deleted in ≥0.5% of 
all cancers in TCGA. Enrichment score and p-value are indicated.  
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significance. Examination of the ranked list of peaks revealed that eleven of the first 200 
peaks (q<10-8) were within or adjacent to ten known tumor suppressor genes, including 
PTEN.  The number of tumor suppressor genes associated with peaks increased slightly 
to fourteen when the top 800 peaks (q<10-5) were queried (Figure 3.2, A left, processed 
data in Spreadsheet S3.1-Appendix 3B). These tumor suppressor genes were also among 
the top basal p53 peaks when ranked by sequence read pileup before processing for 
significance (Figure 3.3, A). The basal p53 binding sites at known tumor suppressors 
were STK11(LKB1), miR-34a, CDKN1A(p21) both 5’ and 3’ known sites (Resnick-
Silverman et al., 1998), PHLDA3, 
DLEU1, FAT1, KDM6A(UTX), 
TNFRSF10B, FOXO1, PTEN, 
WT1, SMARCA2, and BMPR1A 
(peaks shown in Figure S3.1-
Appendix 3A).  The tumor 
suppressor functions of these 
genes are highly validated using  
Figure	3.3:	Basally	expressed	p53	has	important	tumor	
suppressor	targets 
Figure 3.3: Basally expressed p53 has important 
tumor suppressor targets. (A) The top 1000 
MCF10A basal p53 ChIP-seq peaks were ranked 
based on MACS2 read pileup value at peak summit. 
The top 63 peaks were artifacts and were removed. 
Tumor suppressor targets of basal p53 are indicated. 
(B) Gene Ontology (GO) for biological processes was 
performed on the top 200 genes of the MCF10A basal 
p53 ChIP-seq list using the PANTHER 
Overrepresentation Test (release 20160715) with the 
Bonferroni correction. GO ID and p-values are 
indicated. 
	 67	
evidence from mouse models, inherited cancer predisposition syndromes, and somatic 
mutations in human cancer (Table S3.1- Appendix 3A). We also observed that basal p53 
binds near the other known basal p53 target gene MDM2, and to other targets that are not 
tumor suppressors, some of which are known 
p53 targets (peaks shown in Figure S3.1-
Appendix 3A). We performed Gene Ontology 
(GO) for biological processes on the top 200 
genes and discovered that only negative 
regulation of the G1/S phase transition of the 
cell cycle (GO: 2000134 and GO: 1902807) 
and signal transduction by p53 class mediator 
(GO: 0072331) were significantly enriched 
(Figure 3.3, B).  
We used basal p53 ChIP-seq data from 
the TP53 wild-type U2OS osteosarcoma cell 
line (Menendez et al., 2013a) to determine if targets of basal p53 in MCF10A cells were 
bound in another low-stress context. When comparing the two ranked lists, we found that 
Figure	3.4:	Exploring	the	DNA	
binding	targets	of	basal	p53 
Figure 3.4: Exploring the DNA binding 
targets of basal p53. (A) Plot of normalized 
significance of U2OS versus MCF10A basal 
p53 ChIP-seq peaks. ρ is Spearman correlation 










all of the tumor suppressor targets of basal p53 were present in both cell lines, except 
BMPR1A (Figure 3.2, A right, peaks shown in Figure S3.2-Appendix 3A, processed data 
in Spreadsheet S3.2-Appendix 3B), and a spearman correlation test was performed 
comparing the two lists, yielding a highly significant correlation (p-value < 10-36, Figure 
3.4, A). Furthermore, using the gene classifications in the Cancer Gene Census from 
COSMIC (Futreal et al., 2004) (Spreadsheet S3), we found that the ranked MCF10A 
basal p53 ChIP-seq list was enriched for tumor suppressor genes (TSGs) but not 
oncogenes (p-value for TSGs = 0.009, GSEA, Fig. 3.4, B). We also found significant 
enrichment of genes deleted across multiple cancers (frequency of 0.5% or greater in 




Figure 3.5 Validation of basal p53 binding sites. (A) ChIP-seq traces show fold 
enrichment over input for genes of interest in MCF10A (left) and U2OS (right) cells. 
Location of peak indicated by red triangle. Scales are indicated and start at zero. (B) 
ChIP-qPCR of p53 binding to PTEN (left) and 5’ CDKN1A(p21) (right) loci in MCF10A 
and U2OS cells transfected with control or p53-targeting siRNA. Relative DNA Binding 
is % input (normalized to IgG). Error bars: mean ± s.d. of representative experiment 
(performed twice), triplicate measurements. Significance: two-way ANOVA, Sidak’s 
correction. (C) ChIP-qPCR for basal p53 (left) and H3K27Ac (right) on the 
STK11(LKB1), PTEN, and 5’ CDKN1A (p21) loci in PBMCs from a healthy donor. Error 
bars: mean ± s.d., triplicate measurements. Significance (over IgG): paired t-test, two-
tailed. (****p≤.0001, ***p≤.001, **p≤.01, *p≤.05) 
	 69	
GSEA, Figure 3.2, B), independently suggesting that the p53-binding peak list is enriched 
for tumor suppressors. This enrichment was not present for frequently amplified genes 
(frequency of 0.5% or greater in TCGA, Figure 3.4, C). ChIP-seq peaks for select genes 
are shown (Figure 3.5, A, remainder in Figures S3.1 and S3.2-Appendix 3A). Using 
ChIP-qPCR in U2OS and MCF10A cells, we confirmed that p53 binds to the PTEN and 
5’ CDKN1A genomic loci identified by ChIP-seq, and found that this signal was 
diminished by p53 knockdown (Figure 3.5, B). In uncultured primary peripheral blood 
mononuclear cells (PBMCs) isolated from whole blood, basal p53 was bound to the 
STK11(LKB1), PTEN, and CDKN1A(p21) loci, all of which had the histone 3 lysine 27 
acetyl (H3K27Ac) mark of active enhancers and promoters (Figure 3.5, C).  
 
Mutations in TP53 are associated with loss of binding to the group of tumor 
suppressors 
	
p53 ChIP-seq studies have been published to investigate properties of wild type p53 after 
its induction or baseline mutant p53, but the baseline wild-type peaks were not analyzed.  
We examined published ChIP-seq data from four additional studies (in addition to our 
MCF10A datasest) in order to comprehensively characterize the binding activities of 
basally expressed p53. Firstly, we used a study that examined the effects of wild-type p53 
activation by Nutlin on the local chromatin environment in IMR90 lung fibroblasts 
(Sammons et al., 2015). We also used a study that investigated functions of wild-type p53 
and its interplay with p63 in response to genotoxic stress in human foreskin keratinocytes 
(HFKs) (McDade et al., 2014). Third, we used the study mentioned above from U2OS 
cells that investigated the binding activites of wild-type p53 in response to a diverse set 
of cell stressors (Menendez et al., 2013a); and lastly, a study of the gain-of-function 
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properties of mutant p53 that affect chromatin structure (Zhu et al., 2015).   In total, we 
examined basal p53 ChIP-seq data from three nontumorigenic normal cell lines 
containing wild-type p53 (MCF10A, IMR90, and HFKs), three cancer cell lines 
containing wild-type p53 (U2OS, MDA-MB-175-VII, and MCF7) and three cancer cell 
lines containing mutant p53 (BT-549, HCC-70, and MDA-MB-468) and found that both 
normal and cancer cell lines containing wild-type p53 have significantly more basal p53 
binding peaks near tumor suppressor genes than the p53-mutant group, and the p53-
mutant group does not have any basal p53 peaks near tumor suppressors (Table 3.1, 
*P<.05) (McDade et al., 2014; Sammons et al., 2015; Zhu et al., 2015). These datasets 
were presented as control datasets in manuscripts that did not focus on the activities of 
p53 expressed at baseline. We checked whether a transactivation-deficient hot spot 
mutation of TP53 (R273L, the most common TP53 hotspot mutation in the Catalogue of 
Table	3.1:	Basal p53 ChIP-seq peaks near tumor suppressor genes in published datasets 
Table 3.1: Basal p53 ChIP-seq peaks near tumor suppressor genes in published 
datasets. Table contains (left to right) Gene Name, Peak Location (Hg19 location 
from MCF10A basal p53 ChIP-seq dataset), and whether there is a basal p53 ChIP-seq 
peak in each location (yes or no, Y/N) datasets for the cell lines: MCF10A, IMR90 
lung fibroblasts (Sammons et al., 2015)1, human foreskin keratinocytes (HFKs) 
(McDade et al., 2014)2, U2OS (Menendez et al., 2013a)3, and the breast cancer cell 
lines MDA-MB-175-VII, MCF7, BT-549, HCC-70, and MDA-MB-468 (Zhu et al., 
2015)4. TP53 status (WT or specific p53 mutation) as well as normal or cancer status 
(N or C) is listed for each cell line. P-value: One-way ANOVA, Sidak’s correction. 
(*p≤.05, MUT-C group different than both WT-N and WT-C groups) 
	
	



























CDKN1A(p21) 5’ Chr6: 36644096-36644510 Y Y Y Y Y Y N N N 
DLEU1 Chr13: 51103523-51103774 Y Y Y Y Y Y N N N 
SMARCA2 Chr9: 1707411-1707559 Y N Y Y Y N N N N 
PTEN Chr10: 89602953-89603111 Y Y Y Y Y Y N N N 
KDM6A(UTX) ChrX: 44835018-44835187 Y Y Y Y N N N N N 
miR-34 Chr1: 9242010-9242446 Y Y Y Y Y N N N N 
TNFRSF10B Chr8: 22926070-22926238 Y Y Y Y Y N N N N 
STK11(LKB1) Chr19: 1210487-1210722 Y N Y Y N N N N N 
PHLDA3 Chr1: 201438170-201438422 Y Y Y Y Y N N N N 
WT1 Chr11: 32325276-32325457 Y N N Y N N N N N 
FOXO1 Chr13: 40907488-40907636 Y N Y Y N N N N N 
CDKN1A(p21) 3’ Chr6: 36644988-36645255 Y Y Y Y Y Y N N N 
FAT1 Chr4: 187841713-187841958 Y Y Y Y Y N N N N 
BMPR1A Chr10: 88566579-88566727 Y N N N N N N N N 
 Total TS Peaks 14/14 9/14 11/14 13/14 9/14 4/14 0/14 0/14 0/14 
 Group significance  *   *     
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Somatic Mutations in Cancer (Forbes et al., 2015)) would abrogate p53 binding. In the 
HCC38 breast cancer cell line harboring R273L, p53 did not bind to PTEN or 5’CDKN1A 
(Figure S3.3).  
Pan-cancer genomic analysis reveals an association between TP53 mutation and loss 
of expression of tumor suppressor targets 
	
We next explored the possibility that p53 mutation is associated with lower target gene 
expression in cancer. Using data from The Cancer Genome Atlas (TCGA) from 4899 
cases across 18 types of cancer, we found that TP53 mutation significantly increases the 
odds of transcriptional downregulation (by ≥ 1 standard deviation) of tumor suppressor 
targets of basal p53 (PHLDA3, TNFRSF10B, and PTEN) in cases with normal copy 
number (Figure 3.6). Although mRNA levels for PHLDA3 and TNFRSF10B had the best 
association with p53 status, most of the tumor suppressor targets showed this trend to 
some degree. This association was also detected in many cancer types when this analysis 




Figure 3.6: Large-scale genomic analysis reveals that TP53 mutation increases relative 
risk for basal p53 target downregulation. All cases included have normal copy number. 
Acronyms for TCGA cancer types expanded in Materials and Methods. Error bars: log2OR ± 
s.d. of dataset. Significance: Fisher’s exact test. (****p≤.0001, ***p≤.001, **p≤.01, *p≤.05) 
Downregulation: 
z-score >1 s.d. below mean 
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These data suggest that loss of p53 function could potentially lead to a lowering of 
mRNA for these tumor suppressor genes in tumors.  
p53 maintains expression of a group of tumor suppressor genes through consensus p53 
binding sites in enhancers and promoters 
	
Figure	3.7:	p53	regulates	baseline	expression	of	select	target	genes 
Figure 3.7: p53 regulates baseline expression of select target genes. MCF10A cells 
were transfected with control or p53-targeting siRNAs, transcript levels of (A) tumor 
suppressor targets, and (B) other select targets were measured by qRT-PCR. Error bars: 
mean ± s.d. of representative experiment (performed twice), triplicate measurements.  
Significance: two-way ANOVA, Sidak’s correction (****p≤.0001). Western blots 
measuring protein levels of select targets at 48h, 72h, and 96h post-transfection in (C) 
MCF10A cells and (D) U2OS cells. β-actin and Vinculin are loading controls. (E) 
Schlegel hMEC cells were transfected with control or p53-targeting siRNAs, qRT-PCR 
was used to measure transcript levels of select basal p53 targets identified by ChIP-seq 
in two tissue donors (Subjects 1 and 2). Error bars: mean ± s.d., triplicate 
measurements. Significance: two-way ANOVA, Sidak’s correction. (****p≤.0001, 
***p≤.001,*p≤.05, n.s. p>.05) 
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We sought to further characterize the binding and direct regulation of these genes by p53. 
We performed a siRNA knockdown of p53 in MCF10A cells and measured transcript 
levels of select targets using qRT-PCR. With the exception of DLEU1, WT1, and 
SMARCA2, all of the selected binding targets (TSGs and other targets) changed 
expression upon p53 knockdown, and all of the genes were activated by p53 except 
PLK2, which was repressed (Figure 3.7, A-B). Moreover, knockdown of p53 in MCF10A 
and U2OS cells decreased protein levels of the select tumor suppressor target genes 
measured. (Figure 3.7, C-D). We also performed knockdown of p53 in primary human	
human mammary epithelial cells (hMECs) (Liu et al., 2012), and observed decreased 
transcript levels for many of the tumor suppressor genes (Figure 3.7, E). Using JASPAR 
software, which predicts transcription factor DNA binding sites, we found that the basal 
p53 ChIP-seq peak for all of the tumor suppressors and a subset of the other targets 
contains a predicted p53 response 
element (Table 3.2, Table S3.2-
Appendix 3A for extended target 
list). These sites have no spacer 
DNA and obey the classic p53 
consensus site (Wafik S. El-Deiry, 
1992) (RRRCWWGYYY-
RRRCWWGYYY, where 
R=purine, Y=pyrimidine, W=adenine or thymine), suggesting that binding is mediated by 
the specific DNA sequence motif. Furthermore, we examined previously published Hi-C 




Table 3.2: Basal p53 binds to consensus binding 
sites that follow the classic sequence motif. 
Table contains (by column, left to right) gene, 
location of p53 peak, and p53 consensus binding 
site sequence. Deviations from the known p53 






(ENCODE, 2012) and determined that physical interaction exists between basal p53 
binding sites distal to tumor suppressor genes (20 kb or more from the transcriptional 
start site, TSS) and the gene promoter/TSS of the 
tumor suppressor genes (Figure S3.5-Appendix 
3A). Collectively, our results suggest that these 
tumor suppressors are direct targets of p53 in a 
basal, low-stress context.   
To examine the epigenetic landscape near 
the basal p53 binding sites, we used previously 
published ChIP-seq data from hMEC cells 
(ENCODE, 2012; Ram et al., 2011). Chromatin 
marks histone 3 lysine 4 monomethylation 
(H3K4me1) for poised enhancers, histone 3 lysine 
27 acetylation (H3K27Ac) for active enhancers, 
and histone 3 lysine 4 trimethylation (H3K4me3) 
for active promoters in combination with the 
distance from the TSS were used to classify each 
basal p53 binding region as a promoter or an 
enhancer (Table 3.3).  We found that 9/14 of the 
basal p53 binding sites near or within tumor 
suppressor genes were located in enhancers (7 
intergenic, 2 intragenic), 4/14 were located in 
promoters; CDKN1A(p21) had both promoter and 
Figure 3.8: p53-bound DNA near 
PTEN, STK11(LKB1), and 
KDM6A(UTX) has H3K27Ac and 
H3K4me1 enhancer marks. For 
each gene, top: basal p53 ChIP-seq 
in MCF10A cells (fold enrichment 
over input), and bottom (2 tracks): 
published data of enrichment of 
H3K4me1 and H3K27Ac ChIP-seq 
in hMEC cells (ENCODE, 2012; 
Ram et al., 2011). p53 peaks are 
indicated (red triangle). Sequence of 




enhancer peaks, and BMPR1A did not fit either category (Table 3.3). The intergenic 
enhancer elements were located between 2-450 kb from the TSS of tumor suppressor 
genes. This analysis supports the hypothesis that basal p53 binds to DNA elements that 
activate transcription of tumor suppressors. For example, the basal p53 binding sites near 
PTEN, STK11(LKB1), and KDM6A(UTX) are all located in enhancers (Figure 3.8).  
	
 
PTEN-eP53RE is a p53 response element upstream of PTEN 
	
To better understand the basal regulation of target tumor suppressors by p53, we 
chose to investigate PTEN in greater detail. The basal p53 binding site upstream of PTEN 
is representative because the predicted binding site has no spacer DNA, it was classified 
as an enhancer, and it is distal (~20 kb upstream) to the TSS of its target gene. In fact, 
	
Gene Name Peak Location  H3K27Ac H3K4me1 H3K4me3 ~bp to TSS Description 
CDKN1A(p21) 5’ Chr6: 36644096-36644510 Intergenic + + + 1.9 kb Enhancer 
CDKN1A(p21) 3’ Chr6: 36644988-36645355 near TSS + + + 1.1 kb Promoter 
DLEU1 Chr13: 51103523-51103774 Intergenic + + + 450 kb Enhancer 
SMARCA2 Chr9: 1707411-1707559 Intergenic + + - 300 kb Enhancer 
PTEN Chr10: 89602953-89603111 Intergenic + + - 20 kb Enhancer 
FAT1 Chr4: 187841713-187841958 Intergenic + + - 200 kb Enhancer 
KDM6A(UTX) ChrX: 44835018-44835187 Intronic + + - 100 kb Enhancer 
miR-34 Chr1: 9242010-9242446 near TSS + - + 0 bp Promoter 
TNFRSF10B Chr8: 22926070-22926238 near TSS + - + 462 bp Promoter 
STK11(LKB1) Chr19: 1210487-1210722 Intronic + + - 5kb Enhancer 
PHLDA3 Chr1: 201438170-201438422 near TSS + - + 0 bp Promoter 
WT1 Chr11: 32325276-32325457 Intergenic - + - 130 kb Enhancer 
FOXO1 Chr13: 40907488-40907636 Intergenic + + + 330 kb Enhancer 
BMPR1A Chr10: 88566579-88566727 Intronic - - - 50 kb Unknown 
Table 3.3: Chromatin properties of basal p53 binding sites near tumor suppressor 
genes. p53-bound DNA near tumor suppressor genes was analyzed for the presence of 
H3K27Ac, H3K4me1, and H3K4me3 marks, and for the distance from the transcriptional 
start site (bp from TSS) in hMEC cells.  We have indicated (columns left to right) the 
gene name, the genomic location of the peak, if the peak overlaps with H3K27Ac, 
H3K4me1, and/or H3K4me3 (Pos or Neg, +/-), distance from the TSS, and the 
classification of the element. Element was classified as ‘promoter’ if distance from TSS 
is <1.5kb and is ‘+’ for H3K4me3. Element was classified as ‘enhancer’ if distance from 
TSS is >1.5kb and is ‘+’ for H3K4me1 (active enhancers are also ‘+’ for H3K27Ac). 
Others are classified as ‘unknown’. Data is available from Broad/ENCODE (ENCODE, 
2012; Kent et al., 2002; Ram et al., 2011).  
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H3K27Ac and H3K4me1 peaks occur with this site across many cell lines (Figure 3.9). 
Since the p53 binding site on PTEN is in an active enhancer, we named this site PTEN-
eP53RE and a previously characterized p53 response element in the PTEN promoter 
Figure	3.9:	Enhancer	for	PTEN	is	present	in	multiple	cell	lines 
Figure 3.9: Enhancer for PTEN is present in multiple cell lines. PTEN-eP53RE is 
within a region of chromatin that interacts with H3K27Ac and H3K4me1 marks 
characteristic of enhancers as measured by ChIP-seq enrichment in publicly available 
data from Broad/ENCODE from multiple human cell types adapted from the UCSC 
genome browser (ENCODE, 2012; Kent et al., 2002; Ram et al., 2011). PTEN-eP53RE 
is indicated by a black line through all data sets. A549: lung adenocarcinoma cell line 
(black), HeLa: human cervical carcinoma cell line (light blue), HMEC: human 
mammary epithelial cells (purple), NH-A: normal human astrocytes (orange), NHDF: 
normal human dermal fibroblasts (red), NHEK: normal human epidermal keratinocytes 
(fuchsia), Osteobl: normal human osteoblasts (royal blue). 
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PTEN-pP53RE (Stambolic et al., 2001) (Figure 3.10, A). p53 is known to bind to PTEN-
pP53RE in response to stress, resulting in a subtle increase in PTEN levels in certain 
contexts (Feng et al., 2007; Stambolic et al., 2001). The PTEN gene locus is also in 	
proximity with the ATAD1, CFL1P1, and KLLN loci (3.10, A), and as shown in Figure 
S3.5, physical interaction occurs between the basal p53 binding site and these genes in 
lymphoblastoid cells. We found that p53 knockdown in MCF10A and U2OS cells led to 
Figure	3.10:	The	binding	and	regulation	of	the	PTEN	locus	by	basal	p53 
Figure 3.10: The binding and regulation of the PTEN locus by basal p53. (A) Map 
of the PTEN genomic locus adapted from the UCSC genome browser (Kent et al., 
2002) including genes upstream of PTEN that are near the basal p53 binding site. (B) 
MCF10A and U2OS cells were transfected with control or p53-targeting siRNAs, 
qRT-PCR was used to measure transcript levels of ATAD1, CFL1P1, and KLLN. 
Color key as indicated. Error bars: mean ± s.d. of representative experiment 
(performed twice for each cell line), triplicate measurements. Significance: two-way 
ANOVA, Sidak’s correction. (C) ChIP-qPCR in PBMCs from two healthy donors 
(Subjects 1 and 2) for basal p53 on PTEN-eP53RE and PTEN-pP53RE. Relative DNA 
Binding is % input (normalized to IgG). Error bars: mean ± s.d., triplicate 
measurements. Significance (over IgG): two-way ANOVA, Dunnett’s correction. 
(****p≤.0001, *p≤.05, n.s. p>.05)  
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decreased transcript levels of ATAD1 and KLLN, 
while CFL1P1, a pseudogene, was not expressed 
(Figure 3.10, B). Therefore, the p53-bound 
enhancer for PTEN also regulates other genes in 
the locus, as is typical for enhancers. In freshly 
isolated PBMCs, p53 is strongly bound to PTEN-
eP53RE but not PTEN-pP53RE (Figure 
3.10, C). Furthermore, PTEN-eP53RE is 
highly conserved in many mammals 
(Figure 3.11, A-B). Interestingly, p53 
knockdown led to a decreased H3K27Ac 
signal at PTEN-eP53RE in U2OS and 
MCF10A cells suggesting loss of p53-
dependent enhancer activity (Figure 3.12, 
A-B). To investigate whether the 




Figure 3.11: PTEN-eP53RE 
is a highly conserved p53 
response element. (A) p53 
consensus sites are typically 
two 10 base pair palindromic 
repeats separated by a 0-14bp 
spacer (Kern et al., 1991). (B) 
PTEN-eP53RE is highly 
conserved in mammals 
(Multiz alignment shown). 
Figure	3.12:	PTEN-eP53RE	is	within	a	
p53-dependent	enhancer 
Figure 3.12: PTEN-eP53RE is 
within a p53-dependent enhancer. 
ChIP-qPCR for H3K27Ac on PTEN-
eP53RE in cells transfected with 
control or p53-targeting siRNA in 
U2OS (A) and MCF10A (B) cells. 
Relative DNA binding is % input 
(normalized to IgG). Error bars: mean 
± s.d. of representative experiment 
(performed twice), triplicate 
measurements. Significance: two-way 
ANOVA, Sidak’s correction. 
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transcription, we performed a luciferase reporter assay in the p53-null cell line H1299. 
We overexpressed empty vector or p53 along with reporter plasmids containing 
5’CDKN1A-eP53RE (located in an intergenic enhancer), PTEN-eP53RE, or PTEN-
pP53RE. 5’CDKN1A-eP53RE and PTEN-eP53RE were able to strongly activate 
transcription, whereas PTEN-pP53RE activates transcription to a lesser extent (Figure 
3.13).  
We then investigated the dynamics of regulation of the basal p53 tumor 
suppressor targets using p53-inducing drugs, including Nutlin and doxorubicin (Figure 
4.14, A-B). In MCF10A cells following 6h, 10h, and 24h Nutlin-3 treatment, we 
measured PTEN, STK11(LKB1), and CDKN1A (p21) transcript levels, but only 
observed an increase in CDKN1A (p21) (Figure 3.14, C). In U2OS cells following 
treatment, PTEN, STK11(LKB1), KDM6A (UTX), PHLDA3 were unchanged, but 
CDKN1A(p21) increased (Figure 3.14, D).  Interestingly, in the MCF10A and U2OS cell 
lines, where robust binding of p53 to tumor suppressor targets occurs at baseline (Table 
3.1), PTEN expression does not increase following Nutlin-3 treatment. However, MCF7 
cells had low basal p53 binding to tumor suppressor targets (Table 3.1), but display  
Figure	3.13:	PTEN-eP53RE	is	capable	of	activating	transcription 
Figure 3.13: PTEN-eP53RE is capable of activating transcription. Luciferase 
reporter assay showing luciferase/renilla activity (fold change/empty vector) in H1299 
(p53-null) cells overexpressing p53 with a luciferase reporter vector containing 
5’CDKN1A-eP53RE, PTEN-eP53RE, or PTEN-pP53RE (constructs shown). Error 
bars: mean ± s.e.m.; n = 3 experiments. Significance: two-tailed Student’s t-test. 
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Figure	 3.14:	 	 Some	 basal	 p53	 tumor	 suppressor	 targets	 do	 not	
respond	to	p53	induction	by	p53	mimetics	
	
Figure 3.14: Some basal p53 tumor 
suppressor targets do not respond to p53 
induction by p53 mimetics. Structure and 
properties of (A) Nutlin-3, and (B) 
Doxorubicin.  (C) MCF10A cells treated with 
10 µM Nutlin-3 for 6, 10, and 24 hours. Error 
bars: mean ± s.d. (D) U2OS cells treated with 
Nutlin-3 for 24 hours. Error bars: mean ± 
s.e.m, n = 4 experiments. (E) MCF7 cells 
treated with Nutlin-3 for 24 hours. Error bars: 
mean ± s.d., repeated twice. Significance: two-
tailed t-test for each gene. (F) U2OS cells 
treated with 0.1 µg/mL Doxorubicin for 24 
hours. Transcripts measured by qRT-PCR, 
target genes are indicated. Error bars: mean ± 
s.d., triplicate measurements. Significance (for 
all others): two-way ANOVA, Dunnett’s 
correction. (****p≤.0001, n.s. p>.05). Western 
blots showing p53 stabilization for Nutlin-3 
treatment in (G) MCF10A cells, (H) U2OS 
cells, and (I) Doxorubicin treatment in U2OS 
cells. p-p53 (Ser15) also shown for 
Doxorubicin treatment. Treatments were 24 
hours. β-actin is loading control. 
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significantly increased expression of PTEN, KDM6A, PHLDA3, TNFRSF10B, and 
CDKN1A after Nutlin-3 treatment (Figure 4.14, E). Following doxorubicin treatment in 
U2OS cells, PTEN levels did not increase significantly, but CDKN1A(p21) and 
BBC3(PUMA) levels did (Figure 3.14, F). We also show that p53 protein is effectively 
Figure	3.15:	Deletion	of	endogenous	PTEN-eP53RE	by	CRISPR/Cas9 
Figure 3.15: Deletion of endogenous PTEN-eP53RE by CRISPR/Cas9. (A) There 
were 2 cases from TCGA harboring deletions in PTEN-eP53RE. Table contains (by 
column, left to right) the type of cancer, TCGA case number, the IGV-scaled copy 
number data for PTEN and PTEN-eP53RE, the TP53 status, the PTEN mRNA z-score by 
RNA-seq, and the approximate size (in kb) of the deletion. (B) The dual expression 
vector LentiCRISPRv2 containing CRISPR/Cas9 and sgRNA targeting PTEN-eP53RE 
was used to create modifications in the PTEN-eP53RE locus. (C) Sequences of clones 
generated using CRISPR/Cas9 in U2OS (top) and MCF10A (bottom) cells. Homozygous 
deletions in PTEN-eP53RE (PTEN-eP53RE-/-) are shown in red.  
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stabilized/induced using these doses and time points, including the phosphorylation at 
Ser15 of p53 after doxorubicin treatment. (Figure 3.14, G-I). These findings suggest that 
not all p53-dependent transcription can be induced with cell stress, which may be a 
feature of individual enhancers and promoters and is likely driven by binding affinity and 
binding partners. It is possible that in certain basal contexts, such as those observed in 
MCF10A and U2OS cells, the basal p53 binding sites near tumor suppressors are 
saturated at baseline, and thus do not respond to further induction of p53. Conversely, in 
the MCF7 line, these sites are likely not saturated at baseline, and thus can exhibit further 
activation upon Nutlin-3 treatment. Notably, MCF7 cells harbor a SNP in MDM2 that 
causes increased transcriptional activation, and reduced basal p53 levels (Bond et al., 
2004). 
A p53-dependent enhancer maintains expression of PTEN 
	
We discovered two cases from TCGA that harbor somatic focal deletions of the 
enhancer containing PTEN-eP53RE, both of which had downregulated PTEN transcript 
levels by RNA-seq (Figure 3.15, A). To test the enhancer function of the region 
containing PTEN-eP53RE, we transduced U2OS and MCF10A cells with a 
CRISPR/Cas9 lentiviral vector containing a sgRNA targeting PTEN-eP53RE (Figure 
3.15, B). After extensive screening, we found three clones containing homozygous 
deletions of all or part of PTEN-eP53RE (U2OS: Clone 1, MCF10A: Clones 5 and 6, 
labeled as PTEN-eP53RE-/-, Figure 3.15, C). We measured PTEN expression (Figure 
3.16, A-D) and discovered that the PTEN-eP53RE-/- clones had significantly lower 
expression of PTEN transcript and protein when compared to all other clones in both 
U2OS and MCF10A cells. In U2OS cells, we also observed increased pAKT (Thr308) in 
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Clone 1 (PTEN-eP53RE-/-) (Figure 3.16, C). In MCF10A cells, an increase in 
pAKT(Thr308) was only present in Clone 5 (PTEN- eP53RE-/-) (Figure 3.16, D). To 
confirm that the decrease in PTEN expression in the PTEN-eP53RE-/- clones is dependent 
Figure	3.17:	Loss	of	PTEN-eP53RE	results	in	downregulation	of	PTEN 
Figure 3.16: Loss of PTEN-eP53RE results in downregulation of PTEN. a-b, 
qRT-PCR of CRISPR/Cas9 clones in (A) U2OS and (B) MCF10A cells (PTEN-
eP53RE-/- clones in red). Error bars: mean ± s.d., triplicate measurements. 
Significance: one-way ANOVA, Sidak’s correction. Western blots of (C) U2OS 




Figure 3.17: Decrease in PTEN 
expression following p53 knockdown 
is dependent on PTEN-eP53RE. (A) 
U2OS Empty Vector or Clone 1 
(PTEN-eP53RE-/-) cells were 
transfected with control or p53-
targeting siRNA and qRT-PCR was 
used to measure PTEN transcript levels 
48h and 72h after transfection. Error 
bars: mean ± s.d., triplicate 
measurements. Significance: one-way 
ANOVA, Sidak’s correction. (B) 
Western blot for p53 showing that p53 
was effectively knocked down at 48h 
and 72h after transfection in both cell 
lines. β-actin was a loading control. 
(****p≤.0001, n.s. P>.05) 
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on PTEN-eP53RE, we performed a p53 knockdown in U2OS Empty Vector cells and 
Clone 1 (PTEN-eP53RE-/-) and discovered that a decrease in PTEN expression following 
knockdown only occurred when PTEN-eP53RE was present (Figure 3.17, A-B). In U2OS 
Clone 1 (PTEN-eP53RE-/-), because the deletion includes only half of PTEN-eP53RE, we 
used ChIP-qPCR to test whether this prevents p53 binding. As expected, p53 no longer 
binds at PTEN-eP53RE in Clone 1 even though half of the p53 binding site remains 
(Figure 3.19, A). Taken together, these results demonstrate that PTEN-eP53RE is part of 
a p53-bound enhancer for PTEN that drives baseline expression. 
 
Deletions in the p53-dependent enhancer for PTEN cause cell transformation 
phenotypes  
	
Given that the region of chromatin containing PTEN-eP53RE is an active 
enhancer for PTEN, we wanted to characterize its effect on tumorigenic properties of the 
cells. MCF10A clones showed no differences in proliferation under low serum conditions 
(Figure S3.6-Appendix 3A) but they do form acini in matrigel; hence, we grew MCF10A 
acini for 20 days in 3D matrigel culture. Compared to Empty vector, the acini from 
Clones 5 and 6 (both PTEN-eP53RE-/-) were overgrown and lacked normal morphology 
(Figure 3.18, A, acini size quantified in Figure 3.18, B). Furthermore, 
immunofluorescence staining for pAKT(S473), Ki67, and cleaved Caspase-3 revealed 
that pAKT (S473) and Ki67 levels were increased in acini from Clone 6  (Figure 3.18, C-
D), whereas cleaved Caspase-3 was decreased (Figure 3.18, E) compared to Empty 
Vector (quantified in Figure 3.18, F-H). These results are consistent with published data 
on acini from PTEN-/- MCF10A cells (Ghosh et al., 2013). We performed a proliferation 
assay in U2OS cells in low serum and found that Clone 1 (PTEN-eP53RE-/-) was able to 
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grow much faster than Empty Vector (Figure 3.19, B). Clone 1 was also able to form 
more colonies in soft agar when compared to both Empty Vector and Clone 3 (wild-type, 
Figure	3.18:	Deletion	of	PTEN-eP53RE	increases	
tumorigenic	phenotypes	in	MCF10A	cells 
Figure 3.18: Deletion of 
PTEN-eP53RE increases 
tumorigenic phenotypes 
in MCF10A cells. (A) 
MCF10A clones grown in 
3D culture for 20 days, 
representative photos of 
acini shown, average acini 
size quantified in (B). 
Representative 
immunofluorescence 
staining for Laminin V 
(red, all rows), (C) 
pAKT(Ser473), (D) Ki67, 
and (E) cleaved Caspase-3 
(green), DAPI (blue, all 
rows), merge (right, all 
rows). Quantified in (F-






expressing sgRNA) (Figure 3.19, C). Taken together, these data suggest that loss of 
PTEN-eP53RE leads to heightened transformation characterized by increased activation 
of the PI3K/AKT pathway, proliferation, and anchorage-independent growth, and 
decreased apoptosis.  
DISCUSSION: 
	
Here we show that p53 maintains expression of a diverse group of thirteen highly 
validated tumor suppressor genes. The tumor suppressors PTEN, STK11, KDM6A, and 





Figure 3.19: Deletion of PTEN-eP53RE 
increases tumorigenic phenotypes in U2OS 
cells. (A) ChIP-qPCR for p53 in U2OS clones on 
PTEN-eP53RE. Relative DNA Binding is % 
input (normalized to IgG). Error bars: mean ± 
s.d. of representative experiment (performed 
twice), triplicate measurements. Significance: 
two-way ANOVA, Sidak’s correction. (B) 
Proliferation assay of U2OS clones in low serum 
showing % confluence over time (days). 
Triplicate readings taken every 6 hours. Error 
bars: mean ± s.d. (C) Soft agar colony formation 
assay of U2OS clones showing colonies/well 
after 3 weeks (triplicate measurements). Error 
bars: mean ± s.d. of representative experiment 
(performed twice), significance: one-way 
ANOVA, Sidak’s correction. 
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analysis of 21 types of cancer (Lawrence et al., 2014). Germline mutations of the tumor 
suppressors PTEN, STK11(LKB1), WT1, and BMPR1A cause inherited cancer 
predisposition syndromes (Table S3.1-Appendix 3A). Furthermore, all of the members of 
this group of basal p53-regulated tumor suppressors, with the exception of FAT1, 
suppress development of tumors or other neoplasia in genetically engineered mouse 
models (Table S3.1-Appendix 3A).  
Lowering the expression of haploinsufficient tumor suppressors via 
downregulation or hypomorphic mutations is sufficient to stimulate cancer development. 
Importantly, among the group of tumor suppressors targeted by p53, PTEN, 
STK11(LKB1), PHLDA3, and TNFRSF10B are haploinsufficient and/or hypomorphic 
tumor suppressors in mice (Alimonti et al., 2010; Finnberg et al., 2008; Morton et al., 
2010; Ohki et al., 2014). Three of these tumor suppressors target the PI3K/AKT/mTOR 
signaling axis. PTEN directly antagonizes PI3K by dephosphorylating PIP3, 
STK11(LKB1) phosphorylates AMPK leading to inhibition of mTOR, and PHLDA3 
binds PIP3 to prevent the activation of AKT (Kawase et al., 2009; Maehama and Dixon, 
1998; Woods et al., 2003). TNFRSF10B is a cell death receptor that binds TRAIL and 
mediates apoptosis (Sheridan et al., 1997). In our pan-cancer genomic analysis, we found 
that TP53 mutation is significantly associated with PHLDA3, TNFRSF10B, and PTEN 
transcript downregulation, emphasizing the transcriptional changes that occur to these 
haploinsufficient tumor suppressors in the TP53-mutant setting. The statistical 
significance of the pan-cancer analysis was limited by the number of cases available, and 
these associations will likely become more significant when more cases are made 
available for analysis.  
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Our findings show that wild-type p53 binds enhancer and promoter elements that 
activate baseline expression of a team tumor suppressor genes. Thus, mutation of p53 
may contribute to cancer through the downregulation of tumor suppressors whose p53-
dependent regulation and tumor suppressive contribution could vary depending on the 
tissue and cell lineage, a feature that could contribute to the proclivity of p53 to suppress 
cancer development in some tissues more than others, and could explain the spectrum of 
tumors observed in Li-Fraumeni syndrome. In breast cancer, p53 mutations likely occur 
early in tumor development (Shah et al., 2012) where they coordinately downregulate 
p53 target tumor suppressors and could select for chromosome losses that would further 
the loss of expression of these genes. 
If p53 maintains expression of a team of tumor suppressors, one would predict 
that partial inactivation of two or more members of this team in the same tumor would 
cooperate to hasten tumor formation. Mice heterozygous for PTEN and hypomorphic for 
STK11(LKB1) develop tumors in multiple organs at a much shorter latency than PTEN 
heterozygous mice do (Huang et al., 2008), suggesting that loss of members of this group 
of tumor suppressors together can cooperate to drive tumor development.  
Most studies aimed to identify targets of p53 have been focused on stress 
response; thus, basal p53 has largely been overlooked. The group of tumor suppressor 
genes regulated by basal p53 comprises a distinct set of targets that only has some 
overlap with those genes robustly activated by p53 in response to stress (overlap includes 
CDKN1A(p21) (El-Deiry et al., 1993; El-Deiry et al., 1995), TNFRSF10B (Wu et al., 
1997), PHLDA3 (Kawase et al., 2009), and mIR-34a (Raver-Shapira et al., 2007). 
Notably, all of these genes have promoter p53 response elements, whereas tumor 
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suppressors not induced by stress tend to have basal p53 binding sites in enhancers but 
not promoters. Interestingly, in MCF10A and U2OS cells, when p53 transcriptional 
activity is induced with Nutlin-3 or doxorubicin, we do not see a significant increase in 
expression of PTEN, STK11(LKB1), KDM6A(UTX), or PHLDA3, but we do see an 
increase in CDKN1A(p21) and BBC3(PUMA) expression. However, in MCF7 cells, we 
do see a significant restoration in PTEN, KDM6A, PHLDA3, TNFRSF10B, and 
CDKN1A expression following Nutlin-3 treatment. This difference is likely due to the 
degree of saturation of these sites at baseline. Patients with low baseline levels of wild-
type p53 could potentially benefit from a p53-stabilizing therapeutic such as Nutlin.  This 
could be caused by overexpression or genetic amplification of the negative regulators of 
Figure	3.20:	Tumor suppressor targets 
of basal p53 may contribute to p53-
mediated tumor suppression 
Figure 3.20: Tumor suppressor targets of basal p53 may contribute to p53-
mediated tumor suppression. The low levels of p53 present under normal 
physiologic stress activate a set of basal targets. p53 is induced to much higher levels 
in response to enhanced or acute stress, and these elevated levels of p53 allow for 
binding to a large group of stress-response targets that activate pathways such as cell 
cycle arrest, DNA repair, apoptosis, and senescence (discussed in Chapter 1). Loss of 
stress response targets or the inability of p53 to activate stress response targets does 
not lead to spontaneous tumorigenesis alone in mice, perhaps due to the fact that many 
of these genes are not activated by p53 under normal conditions. Mutation of p53 in 
humans and mice causes spontaneous tumorigenesis, which may be due to the parallel 
downregulation of the basal targets of p53 in combination with the inability of p53 to 
appropriately activate stress-responsive targets. 
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p53 MDM2 and/or MDMX, which may be the case for MCF7 cells. We hypothesize that 
the difference between basal and induced activities of p53 not only depends on p53 
expression level and binding affinity to the site, but also depends on other factors that can 
mediate preferential binding to one site over another, such as the presence of repressor 
proteins or repressive chromatin states. Overall, our findings provide a model of p53-
mediated tumor suppression through activation of a team of tumor suppressor genes when 
the level of activated p53 is limited. Mutation of p53 may cause spontaneous 
tumorigenesis though the loss of expression of the tumor suppressor targets of basal p53 
in combination with the inability of p53 to activate stress-responsive targets (summarized 
in Figure 3.20).    
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Figure S3.1: Binding 
targets of basal p53 in 
MCF10A cells. ChIP-seq 
was performed for basal 
p53 in MCF10A cells, 
tracks show fold 
enrichment over input for 
genes of interest. Location 
of peak is indicated by red 
triangle. Tumor 
suppressor targets are 





Figure S3.2: Binding 
targets of basal p53 in 
U2OS cells. Published 
ChIP-seq data for basal 
p53 in U2OS cells 
(Menendez et al., 2013a), 
tracks show fold 
enrichment over input for 
genes of interest. Location 
of peak is indicated by red 
triangle. Tumor 
suppressor targets are 
shown in green, other 















Figure S3.4: Large-scale genomic analysis reveals that TP53 mutation increases 
relative risk for basal p53 target downregulation. (A) TCGA data shows that TP53 
mutation increases the relative risk for p53 target downregulation, without correcting 
for copy number changes of the targets. Error bars: log2OR ± s.d. of dataset. 
Acronyms for cancer types expanded in the Materials and Methods. Significance: 
Fisher’s exact test. Cancer types that increased at least one significance level (*) upon 
incorporation of deletions are written in red type. 
Downregulation: 





Figure S3.3: Mutation of p53 abrogates 
binding to tumor suppressor targets of basal 
p53. ChIP-qPCR in HCC38 cells (TP53 Mut: 
R273L) for IgG (negative control), p53, and 
H3 (positive control) on PTEN and 
5’CDKN1A. Error bars: mean ± s.d. of 
representative experiment (performed twice), 
triplicate measurements. Significance (over 
IgG): two-way ANOVA, Dunnett’s correction. 


































Figure S3.5: Long range chromatin interactions of enhancers with transcriptional 
start sites of basal p53 targets. Previously published Hi-C(Rao et al., 2014) and 
chromatin state (chromHMM) data(ENCODE, 2012) were adapted from the WashU 
genome browser(Zhou et al., 2013; Zhou et al., 2011) to investigate the physical 
interaction between select basal p53 binding sites (at least 20KB distal to the TSS) and the 
transcriptional start site (TSS) of putative target genes. Each target contains two chromatin 
state tracks (primary chromHMM from hMEC cells and GM12878 cells) and one 
normalized Hi-C track from GM12878 cells. See Materials and Methods for chromHMM 
color scheme. Resolution for Hi-C tracks is indicated for each target. Location of basal 
p53 peaks is denoted by the red triangle. Strength of Hi-C interaction is indicated by the 






Figure S3.6: Deletion of PTEN-
eP53RE in MCF10A cells does not 
affect proliferation in 2-
dimensional cell culture. 
Proliferation assay of U2OS clones in 
low serum showing % confluence 
over time (days). Triplicate readings 







	 Gene Name GEMM of TS? 
Inherited cancer 
syndrome? 
Somatic mut in 
cancer? 
Somatic mut Lawrence 
et al 
(Lawrence et al., 2014) 
CDKN1A(p21) Y 




(Furutani et al., 1997; 
Gao et al., 1995) 
Y 
DLEU1 Y 
(Klein et al., 2010; Lia et 
al., 2012) 
N Y 
(Yie Liu et al., 1997) 
N 
SMARCA2 Y 
(Shen et al., 2008) 
N Y 
(Endo et al., 2013; 
Gunduz et al., 2009; 
Oike et al., 2013) 
N 
PTEN Y 
(Cristofano et al., 1998; 
Podsypanina et al., 1999) 
Y 
(Liaw et al., 1997) 
Y 
(Li et al., 1997; Steck et 
al., 1997) 
Y 
FAT1 N N Y 
(Morris et al., 2013; 
Neumann et al., 2014) 
Y 
KDM6A(UTX) Y 
(Mann et al., 2012; 
Ntziachristos et al., 2014) 
N Y 
(Bailey et al., 2016; 
Jankowska et al., 2011; 
van Haaften et al., 2009) 
Y 
miR-34 Y 
(Cheng et al., 2014; 
Okada et al., 2014) 
N Y 
(Welch et al., 2007; Yin 
et al., 2013) 
N 
TNFRSF10B Y 
(Finnberg et al., 2008) 
N Y 
(Lee et al., 1999; Lee et 





(Miyoshi et al., 2002; 
Nakau et al., 2002) 
Y 
(Hemminki et al., 1998) 
Y 
(Avizienyte et al., 1999; 
Avizienyte et al., 1998; 




(Ohki et al., 2014) 
N Y 




(Hu et al., 2011) 
Y 
(Haber and Housman, 
1992) 
Y 
(Chen et al., 2012; 
Coppes et al., 1993) 
Y 
FOXO1 Y 
(Paik et al., 2007) 
N Y 
(Dong et al., 2006; 
Mercado and Barr, 2007; 
Trinh et al., 2013) 
N 
Table S3.1: Information on tumor suppressor genes identified as basal p53 targets. 
The list of genes contained within this table are well-validated tumor suppressors based 
on experimental evidence (columns from left to right) from genetically engineered 
mouse models (GEMM), inherited cancer predisposition syndromes driven by germline 
mutations, somatic mutations in human cancer, and somatic mutations in the pan-cancer 
(Lawrence et al., 2014) study. Each cell is labeled as yes or no (denoted ‘Y’ or ‘N’, 








Table S3.2: Predicted p53 response elements within basal p53 binding sites using 
JASPAR (extended list). Using the HOMER-annotated list of basal p53 peaks from 
MCF10A and U2OS cells, we used JASPAR software to scan the region of DNA 
containing the p53 peak for potential p53 response element sequences. This table 
contains (by column, left to right) the gene name, the location of the called peak, the 
predicted p53 response element sequence (the exact output of the program using the 
matrix model MA0106.3), the score of that binding site based on position-weight 
matrix (PWM), and the relative score. Note: The JASPAR program output for matrix 
model MA0106.3 is a sequence that lacks the outer two base pairs of the known 
consensus sequence(El-Deiry et al., 1993) (RRRCWWGYYY-RRRCWWGYYY, 
where R=purine, Y=pyrimidine, W=adenine or thymine).  
	
Gene Name Peak Location (MCF10A) JASPAR MA0106.3 sequence (+) Score (+) Rel. Score (+) 
PLAC8  Chr4: 84092183-84092485 RE1: 







TGFA Chr2: 70824017-70824382 AACATGCCCAGGCATGTC 26.586 0.988 
CDKN1A(p21) 5’ Chr6: 36644096-36644510 AACATGTCCCAACATGTT 21.840 0.944 
DLEU1 Chr13: 51103523-51103774 GGCTTGTCCGGGCATGTC 20.946 0.936 
SMARCA2 Chr9: 1707411-1707559 AACATGCCTGGGCTTGCC 20.450 0.932 
PTEN Chr10: 89602953-89603111 AACTTGTCTAGGCATGTC 20.235 0.930 
PLK2 Chr5: 57758019-57758216 GGCAAGTCCAGGCATGTT 20.085 0.928 
BRD1 Chr22: 501153990-50154296 GACATGCCTAAACATGCC 19.717 0.925 
JAG1 Chr20: 10713952-10714118 GGCTAGCCCGGGCATGTT 18.251 0.912 
KDM6A(UTX) ChrX: 44835018-44835187 GGCTTGCCTGGGCATGCC 17.648 0.906 
miR-34 Chr1: 9242010-9242446 AACAAGCCCAGGCAAGCC 17.471 0.904 
TNFRSF10B Chr8: 22926070-22926238 GTCTTGCCCGGACATGCC 17.301 0.903 
VAV2 Peak 2 Chr9: 136753460-136753626 GGCAGGCCCAGACATGTC 17.192 0.902 
STK11(LKB1) Chr19: 1210487-1210722 GGCATGTTCGGTCATGCC 14.493 0.877 
CCNG1 Chr5: 162864877-162865038 CACAAGCCCAGGCTAGTC 13.611 0.869 
TGFB2 Chr1: 218774483-218774664 GACAAGTCTGAACTTGCC 13.439 0.868 
PHLDA3 Chr1: 201438170-201438422 GATGTGCCCTTACATGTT 13.091 0.865 
NOTCH1 Chr9: 139444765-139445192 GAGTTGCCCGGGCAAGTC 11.830 0.853 
WT1 Chr11: 32325276-32325457 GGCATGTTAGCACATGCC 11.649 0.851 
PLK3 Chr1: 45265510-45265694 AACATGCCCGGGCAAAAG 11.134 0.847 
VAV2 Peak 1 Chr9: 136746439-136746521 AATGTGTCTGGACTTGCC 10.762 0.843 
FOXO1 Chr13: 40907488-40907636 GGCATGTCGGGGCATCAC 9.905 0.835 
CDKN1A(p21) 3’ Chr6: 36644988-36645255 AAGAAGACTGGGCATGTC 8.728 0.825 
MDM2 Chr12: 69202725-69202891 GTCAAGTTCAGACACGTT 8.524 0.823 
FAT1 Chr4: 187841713-187841958 GACATGCCCGGGCAAAGG 8.332 0.821 





Spreadsheet S3.1: Top 300 basal p53 ChIP-seq peaks in MCF10A cells (after raw 
data analysis described in Materials in Methods section) ordered by significance of the 
peak call. Spreadsheet includes (columns left to right) peak locus (Chromosome, start, 
end), MACS2 significance, closest relevant gene (genes discussed in paper in red 











Spreadsheet S3.2: Top 300 basal p53 ChIP-seq peaks in U2OS cells (after raw data 
analysis described in Materials in Methods section) ordered by significance of the 
peak call. Spreadsheet includes (columns left to right) peak locus (Chromosome, start, 
end), MACS2 significance, closest relevant gene (genes discussed in paper in red 


















Chapter 4: PRC2-mediated repression of PTEN driven 













BACKGROUND AND SIGNIFICANCE 
	
Transcriptional repression by the PRC2 complex in cancer 
	
 Oncogenes and tumor suppressors are often genetically altered in cancer, which 
has been extensively discussed in the previous chapters; however, gene expression in 
cancer can often be changed through mechanisms independent of mutations in the genetic 
code. The basic unit of chromatin is 
called the nucleosome; a structure 
made up of DNA wrapped around 
histone proteins (Figure 4.1) (Sha and 
Boyer, 2008).  The organization of 
nucleosomes into higher order 
structures can affect the function of 
the DNA, including gene expression. 
Nucleosomes can pack tightly to form 
condensed ‘heterochromatin’, which 
is not accessible to transcriptional 
machinery, and thus, is silenced. 
Nucleosomes can also form a more 
open conformation called 
‘euchromatin’ that allows access to transcriptional machinery (Figure 4.1) (Sha and 
Boyer, 2008). The epigenetic code dictates the accessibility of genes and other regulatory 
elements to transcriptional machinery. It consists of specific chromatin modifications, 




Figure 4.1: The basic organization of 
chromatin in the nucleus. Nucleosomes are 
made up of DNA wrapped around a core of 
histone proteins. Nucleosomes are organized 
into higher order structures, and the level of 
compaction influences gene regulation. 
Euchromatin is associated with an open 
chromatin conformation, allowing for 
transcription. Heterochromatin is compact and 
does not allow transcription factors to access the 
DNA. (Sha and Boyer, 2008). 
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Figure	4.2:	Modifications	of	the	tails	of	histone	proteins	(SABiosciences,	2008) 
covalent modification of DNA. These modifications affect the wrapping of DNA and 
chromatin condensation, and can have predictable effects on gene expression (Esteller, 
2007; Sha and Boyer, 2008). For example, acetylation of histone tails leads to a more 
open chromatin conformation and an increase in the transcription of genes in the 
neighborhood, but the effect of methylation of the histone tails on gene expression 
depends on the location of and the level of methylation of the specific lysine residue.  
DNA methylation can occur in genes, promoters, and other regulatory elements, and is 
generally associated with transcriptional silencing.  
Changes in the accessibility of chromatin through specific alterations in the 
epigenetic code often happen in cancer and can drive disease pathology. Polycomb group 
proteins (PcGs, first discovered in Drosophila) are known for their function in X-
chromosome inactivation, but are also involved in proliferation and neoplastic growth in 
humans and other organisms. The polycomb repressor complex 2 (PRC2) is a 
transcriptional repressor complex that silences genes through chromatin modification. 
The components of PRC2 include enhancer of zeste (EZH2), suppressor of zeste 12 
(SUZ12), and extra sex combs (ESC). PRC2 initiates gene repression where the 
catalytically active lysine methyltransferase (KMT) EZH2 tri-methylates histone 3 lysine 
Figure 4.2: Modifications of the tails of histone proteins. Diagram shows a 
nucleosome, with the possible histone modifications that can change gene expression by 
affecting the packing of the nucleosomes (SABiosciences, 2008). 
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27 (H3K27) and to a lesser extent, histone 3 lysine 9 (H3K9), and histone deacetylases 
(HDACs) which are transiently associated with the PRC2 complex deacetylate H3K27 
and H3K9 prior to methylation (Figures 4.2 and 4.3) [PRC complex components and 
human homologs are reviewed in (Sparmann and van Lohuizen, 2006)]. The EZH2 KMT 
enzyme also has the ability to directly control DNA methylation by recruiting DNA 
methyltransferases (DNMTs) to a subset of its targets, further silencing chromatin (Figure 
4.3) (Vire et al., 2006). The polycomb repressive complex 1 (PRC1) works in concert 
with PRC2, and consists of polycomb (PC), polyhomeotic (PH), posterior sex combs 
(PSC), and sex combs extra (SCE/RING). The PRC1 complex binds the H3K27 trimethyl 
mark made by PRC2 and both sterically hinders transcriptional machinery, and also 
facilitates the ubiquitination of H2AK119 leading to chromatin compaction (Figure 4.3).  
As discussed in 
Chapters 1 and 2, 
members of the PcG 
family of proteins 
including PRC2 bind 
to the PTEN promoter 
to repress PTEN 
transcription in certain 
cell types, and can be 
guided to the site of 
action at the PTEN 
locus by ncRNAs originating from the PTENP1 locus (Johnsson et al., 2013).  
Figure 4.3: Epigenetic gene silencing by PcG protein 
complexes (Sparmann and van Lohuizen, 2006). 
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 Changes in the epigenetic code that frequently occur in cancer have become 
promising targets for cancer therapy (Dawson and Kouzarides, 2012). The inhibition of 
DNMT enzymes is one of the few epigenetic therapeutic targeting approaches already 
used in the clinic. DNMT inhibitors such as azacitidine and decitabine cause 
hypomethylation and have shown mixed therapeutic benefit in solid tumors, but are 
consistently effective in myelodysplastic syndromes (MDS) that did not previously have 
effective treatment. HDAC proteins that remove acetyl groups from histone tails have 
also been successfully targeted in cancer therapy, and two pan-HDAC inhibitors called 
Vorinostat and Romidepsin have been clinically approved for use in cutaneous T-cell 
lymphoma. HDAC inhibitors have antitumor effects, can reverse gene expression 
changes observed in certain types of cancer, and can induce growth arrest, apoptosis and 
differentiation (Federico and Bagella, 2011; Johnstone and Licht, 2003).   
Two other promising epigenetic therapeutic targets in cancer are the 
bromodomain and Extra-Terminal motif (BET) family of proteins and KMT proteins.  
BET proteins including BRD2, BRD3, BRD4, and BRDT are essential for transcription 
and play a role in cell cycle progression. BET inhibitors are thought to act by interfering 
with the interaction of BET proteins with transcription factors and acetylated histones, 
thereby inhibiting transcription (Shi and Vakoc, 2014). More specifically, BET inhibitors 
interfere with the ability of BRD4 to activate transcription of MYC, which can be 
effective in inhibiting certain types of cancer characterized by MYC amplification or 
overexpression (Mertz et al., 2011).  The EZH2 KMT enzyme is overexpressed or 
aberrantly active in a wide variety of cancers including prostate and breast. However, the 
role of EZH2 in cancer is not consistent, and can behave as an oncogene or a tumor 
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suppressor depending on the context. EZH2 inhibitors have shown therapeutic benefits in 
specific malignancies including B-cell lymphoma and Kaposi’s sarcoma (Wagner and 
Jung, 2012). In breast cancer, EZH2 appears to be functioning exclusively as an 
oncogene [reviewed in (Yoo and Hennighausen, 2012)]. 
Transcriptional repression by NOTCH1/2 in cancer 
	
As discussed in Chapter 1, the transcriptional regulation of PTEN is very 
complex, and numerous groups have reported mechanisms of transcriptional repression 
that occur at the PTEN promoter in cancer. However, it remains unclear how broad these 
mechanisms are across cancer types, and whether or not these mechanisms are connected 
to or are part of a larger repressive network. As discussed in Chapter 1, PTEN is 
transcriptionally repressed by mutated NOTCH1 (named after the notched wing 
phenotype in Drosophila) through direct binding of the downstream hairy and enhancer 
of split-1 (HES-1, also discovered in Drosophila) transcription factor to the PTEN 
promoter in T-cell leukemia (Palomero et al., 2007). HES-1 binds and represses PTEN 
Figure 4.4: Cycle of nuclear NOTCH signaling through CSL (Bray, 2006) 
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though a similar NOTCH signaling mechanism at the ß-selection checkpoint during T-
cell development (Wong et al., 2012).  
NOTCH signaling is initiated by a receptor-ligand interaction between two 
neighboring cells. This interaction leads two successive proteolytic cleavage events, first 
by the ADAM-family metalloprotease ADAM10, then by γ-secratase, to release the 
intracellular cytoplasmic portion of NOTCH (NOTCH-IC) from the membrane. NOTCH-
IC is able to enter the nucleus, and competes with inhibitory proteins to bind the CSL 
(CBF1, Suppressor of Hairless, Lag-1) transcription factor. CSL rests at promoters of 
NOTCH target genes and forms complexes with co-activators and co-repressors that 
compete for binding in the CSL complex. The binding of NOTCH-IC to CSL induces 
binding to co-activators and transcriptional activation of target genes. The NOTCH-IC is 
eventually modified and targeted for proteosomal degradation, which allows for the 
binding of co-repressors of target genes, and more NOTCH-IC is required to re-initiate 
the cycle (Figure 4.4) [signaling reviewed in (Bray, 2006)].  
The NOTCH pathway is evolutionarily conserved from Drosophila to humans, 
functions in cell-cell communication, and can influence cell fate by regulating processes 
such as differentiation, proliferation, and apoptosis during development and in adult life 
[functions of NOTCH pathway are reviewed in (Aithal and Narayanappa, 2015; 
Andersson et al., 2011)]. Translocations and mutations of the NOTCH genes are frequent 
in cancer, and typically lead to a truncated gene product that resembles NOTCH-IC and 
is constitutively or abnormally activated. For example, in T-cell leukemia, the carboxy- 
terminus NOTCH1 is translocated to the TGF-β locus resulting in a truncated NOTCH1 
that behaves as NOTCH-IC (LW et al., 1991; Reynolds et al., 1987). Notably, the 
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maintenance of T-cell leukemia is dependent on NOTCH and represents an important 
signaling axis for targeted therapies (Weng et al., 2003). γ-secretase inhibitors restore 
PTEN expression in T-cell leukemia (Palomero et al., 2007). NOTCH signaling is also 
activated in a proportion of human breast cancers (Weijzen et al., 2002), and NOTCH1 
and NOTCH2 are often translocated to produce truncated forms of NOTCH in triple-
negative breast cancer (TNBC) (Robinson et al., 2011). Interestingly, PTEN is often 
downregulated in TNBC, and it is possible that PTEN is being transcriptionally repressed 
by similar NOTCH-driven mechanisms in this poor-prognosis subtype of breast cancer.  
RESULTS 
	
Repression of the transcriptional activity of PTEN occurs at distinct sites on the PTEN 
promoter 
	
 In Chapter 2, we discussed the changes that occur in the expression of PTEN 
when progressing from normal tissue to cancer. Transcriptional downregulation is 
frequent in breast cancer, and is part of a poor-prognosis gene expression signature (Saal 
et al., 2007). Understanding the mechanisms of transcriptional downregulation of PTEN 
continues to be important, as these studies may reveal important therapeutic approaches 
to treat PTEN-deficient malignancies. In Chapter 3, we discovered that the p53 tumor 
suppressor maintains baseline expression of thirteen tumor suppressor genes, including 
PTEN, through p53 consensus binding sites in enhancers and promoters. These tumor 
suppressors are downregulated in parallel when TP53 is mutated or p53 function is 
otherwise lost. Although this mechanism appears to be broadly relevant across multiple 
tissues, loss of activation by p53 through enhancer binding is likely not the only factor 
that contributes to loss of PTEN transcriptional activity. Several studies have indicated 
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additional repressive activity through transcription factors, repressor complexes, and 
chromatin remodeling at the PTEN promoter (reviewed in Chapter 1). Here, we begin to 
explore the complex mechanisms of transcriptional repression of PTEN that occur at or 
near the PTEN promoter.  
 We first wanted to determine which regions of the PTEN promoter are the most 
important for PTEN transcriptional repression in cancer. We chose four model cell lines, 
the non-tumorigenic mammary epithelial cell lines MCF10A and hMEC-hTERT, and two 
Figure	4.5:	Transcriptional	activity	of	the	PTEN	promoter 
Figure 4.5: Transcriptional activity of the PTEN promoter. (A) Map of luciferase 
constructs of the PTEN promoter and upstream regulatory region. Map includes 
restriction sites, distance from translational start site, Hg19 genomic loci on Chr10, and 
length in base pairs. (B) Luciferase activity normalized to Renilla for each luciferase 
construct, calculated as a fold change from Pgl3-1 construct. Error bars are mean ± s.d. 
(triplicate measurements). Important regions for transcriptional activity in HepG2 and 
HCC-1187 are indicated by purple and blue stars. 
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cancer cell lines that have low PTEN transcript levels, the HCC-1187 breast cancer cell 
line and the hepatocellular carcinoma cell line HepG2. We performed a luciferase 
reporter assay using various sections of the PTEN promoter and upstream regulatory 
region fused luciferase reporter gene (Figure 4.5, A). The luciferase activity corresponds 
to the transcriptional activity of that section of the PTEN promoter. We discovered that 
deletion of certain portions of the PTEN promoter/regulatory region caused a significant 
increase in transcriptional activity (Figure 4.5, B). Deletion of these regions did not result 
in an increase in PTEN transcriptional activity in the non-tumorigenic lines, indicating 
that these repressive regions are cancer-specific. We discovered two regions of the PTEN 
promoter that were most important for PTEN transcriptional activity (Figure 4.5, A-B). 
Interestingly, the regions that were most important for PTEN transcriptional activity were 
slightly different for the two cancer cell lines (Figure 4.5, B). Defining the regions of the 
PTEN promoter/regulatory region required for cancer-specific transcriptional repression 
is a helpful first step in identifying the molecular mechanisms of repression that are 
occurring at these sites.  
 




 We wanted to investigate at the chromatin properties of the regions of the PTEN 
promoter/regulatory region that are important for transcriptional repression in cancer. As 
discussed in Chapter 1 and earlier in this chapter, multiple groups have demonstrated the 
ability of the PRC2 complex to repress PTEN, often being guided to its site of action by	
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ncRNAs. We performed ChIP coupled with qRT-PCR for H3K27Me3 in the HCC-1187 
breast cancer cell line (coordinately downregulated for PTEN and ATAD1) at the PTEN 
promoter/regulatory region and found extensive interaction with the H3K27Me3 mark of 
PRC2-mediated transcriptional repression (Figure 4.6, A-B). Notably, the regions 
containing the highest interaction with H3K27Me3 were the same regions that were 
important for transcriptional repression in the luciferase reporter assay (Figure 4.6, B). 
We also found significant H3K27Me3 interactions closer to the transcriptional start site 
of PTEN (Figure 4.6, B).  
We did the same experiment for EZH2, which is the KMT member of the PRC2 
complex that trimethylates H3K27, and found binding of EZH2 to the PTEN 
promoter/regulatory region as well (Figure 4.6, C). The most significant EZH2 binding 
Figure	4.6:	PRC2	complex	activity	at	the	PTEN	promoter/regulatory	region 
Figure 4.6: PRC2 complex activity at the PTEN promoter/regulatory region. (A) 
Map of PTEN promoter containing priming regions for ChIP-qPCR. (B-C) ChIP-qPCR 
in HCC-1187 cells for (B) H3K27Me3 and (C) EZH2 at indicated regions of the PTEN 
promoter. Relative DNA binding is % input normalized to IgG. Error bars: mean ± 
s.e.m., n=3 experiments. Important regions for transcriptional activity in HepG2 and 
HCC-1187 indicated by purple and blue stars and by red brackets. 
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occured adjacent to the region most heavily interacting with H3K27Me3, which may 
indicate spreading of this repressive signal. Binding of the PRC2 complex to chromatin 
exerts a force that pulls other nucleosomes closer to the complex to facilitate repression 
of larger regions of chromatin, and these results would be consistent with that (Schwartz 
et al., 2006). Also, the signal for H3K27Me3 is typically quite broad (can be hundreds of 
kilobases), where the EZH2 signal is narrow, and this region could represent only a small 
portion of the H3K27Me3 signal at the PTEN/ATAD1 locus.  This result suggested that 
the PRC2 complex acts at the PTEN/ATAD1 locus, remains bound, and may contribute to 
the repression of PTEN observed in breast cancer.  
 
The PRC2 complex contributes to the transcriptional repression of PTEN and 
represents a therapeutic target 
	
 We had established that EZH2 is bound directly to the PTEN promoter, and that 
the PTEN promoter also interacts with H3K27Me3 marks of repression made by the 
EZH2 as part of the PRC2 complex in HCC-1187 PTEN-low breast cancer cells (Figure 
4.6). We sought to investigate a possible role for EZH2 in the repression of PTEN. We 
performed a stable knockdown of EZH2 in HCC-1187 cells and observed that PTEN 
transcript and protein levels were significantly restored following knockdown (Figure 
4.7, A-B). Interestingly, although EZH2 knockdown had a minor effect on ATAD1 
transcript levels in one of the hairpins, it seems to be more reliably targeting PTEN 
(Figure 4.7, A). It is possible that repression by the PRC2 complex at the PTEN promoter 
has a slight effect on ATAD1 by proximity. We also measured proliferation of HCC-
1187 cells following EZH2 knockdown and found that proliferation decreased markedly 
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(Figure 4.7, C). Taken together, these results suggest that EZH2 could control 
tumorigenic phenotypes in these cells through repression of PTEN expression. 
Given the role of the PRC2 complex in the expression of PTEN and in the 
proliferation of HCC-1187 cells, we asked whether inhibitors of EZH2 would have the 
same effect on PTEN expression. EZH2 inhibitors have been developed that show 
anticancer activity, and many of these inhibitors are SAM-competitive, meaning that they 
inhibit EZH2 through binding to the SET domain of EZH2 to prevent the transfer of a 
methyl group from the cofactor S-adenosyl-methionine (SAM) to the histone. We treated 
the cells with two SAM-competitive inhibitors: (1) UNC1999, which is a specific 
inhibitor of EZH1 and EZH2 (Figure 4.8, A), and (2) 3-deazaneplanocin A (DZNep), 
which is not selective for EZH2, and can target other methyltransferases to globally 
inhibit histone methylation (Figure 4.8, B).  
Figure	4.7:	Knockdown	of	EZH2	restores	PTEN	expression	and	reduces	proliferation 
Figure 4.7: Knockdown of EZH2 
restores PTEN expression and 
reduces proliferation. Expression 
of (A) transcript and (B) protein 
for indicated target genes. β-actin 
was a loading control. (C) 
Proliferation in HCC-1187 cells 
after stable knockdown of EZH2. 
Error bars are mean ± s.d. 
(triplicate measurements). 
Significance from Ctrl: 2-way 
ANOVA, Dunnett’s correction. 
(***P<0.001, *P<0.5) 
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Both drugs were able to restore PTEN expression, and both drugs increased 
PTEN transcript levels about 1.5 fold, but DZNep worked to restore PTEN slightly better 
than UNC1999 and had dose-dependent effects on PTEN expression (Figure 4.8, C-D).  
This could be explained by the fact that DZNep also inhibits other methyltransferases, 
which may have an effect on PTEN expression independently of the inhibition of EZH2. 
Both drugs also had a slight effect on ATAD1 expression, which suggest that these 
chromatin-based repressive mechanisms target PTEN and may affect ATAD1 by 
proximity (Figure 4.8, C-D). These results suggest that EZH2 can repress expression of 
PTEN and drive proliferation, and may contribute to other tumorigenic phenotypes in 
cancers where PTEN is often downregulated, such as TNBC. Furthermore, these results 
suggest that inhibition of EZH2 could be a promising therapeutic approach in PTEN-
deficient cancers. Although the effect size of these inhibitors on PTEN expression is 
Figure	4.8:	EZH2	inhibition	restores	PTEN	expression 
Figure 4.8: EZH2 inhibition restores PTEN expression. Basic properties and 
chemical structures of (A) UNC1999, and (B) 3-deazaneplanocin A (DZNep).  PTEN 
transcript was measured by qRT-PCR following (C) UNC1999 and (D) DZNep 
treatment for indicated times and concentrations. Error bars are mean ± s.d. (triplicate 
measurements). Significance: 2-way ANOVA, Dunnett's correction. (****P<0.0001, 
***P<0.001, *P<0.05) 
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relatively small, PTEN is a haploinsufficient dose-responsive tumor suppressor, so these 
changes in expression are likely significant in terms of biological impact. Also, these 
experiments represent preliminary results and it is likely that a greater effect size couold 
be achieved if doses and time points were optimized.  
Mutation of NOTCH1 and NOTCH2 associates with downregulation of PTEN  
	
 We identified a role for the PRC2 complex in the repression of PTEN, but we 
wanted to investigate the upstream signaling changes that cause increased PRC2 activity 
at the PTEN promoter. As previously discussed, increased NOTCH signaling can lead to 
repression of PTEN through the HES-1 transcription factor (Palomero et al., 2007; Wong 
et al., 2012), and several NOTCH1 and NOTCH2 translocations have been identified in 
TNBC that create a truncated form of NOTCH resembling the NOTCH-IC (Robinson et 
al., 2011). In fact, the HCC-1187 cell line is derived from a TNBC case and harbors a 
Figure	4.9:	Mutations	in	NOTCH1	and	NOTCH2	in	triple-negative	breast	cancer 
Figure 4.9: Mutations in NOTCH1 and NOTCH2 in triple-negative breast cancer. 
(A) Previously identified translocation SEC22B-NOTCH2 in HCC-1187 TNBC cell 
line (Robinson et al., 2011). Whole-genome sequencing, RNA-seq, and whole exome 
capture were employed to identify (B) point mutations and (C) translocations in 
NOTCH1 and NOTCH2 in 27 TNBC cases. Hotspot mutations are in pink boxes. 
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SEC22B-NOTCH2 translocation that constitutively produces the NOTCH2-IC (Figure 
4.9, A). In a cohort of 27 TNBC cases, we identified 5/27 cases (19%) harboring point 
mutations (Figure 4.9, B) as well as 2/27 cases (7%) harboring translocations (Figure 4.9, 
C) in NOTCH1 and NOTCH2. One case had two distinct point mutations in NOTCH1 
(Figure 4.9, B TNBC 207). Genetic alterations in NOTCH1 and NOTCH2 are frequent in 
TNBC, and may have direct roles in driving this aggressive, poor-prognosis form of 
breast cancer. However, it is important to note that we have not investigated the specific 
functional consequences of each of these mutations individually, though it is known for 
the hotspot mutations (Figure 4.9, B).  
 Given that such a large proportion of these TNBC cases harbor genetic alterations 
in NOTCH1 and NOTCH2, we asked whether these mutations correlate with reduced 
expression of PTEN, also a common event in TNBC. We performed IHC staining for 
PTEN on the same cohort of TNBC cases and found that that cases harboring mutations 
in NOTCH1 and NOTCH2 had lower expression of PTEN (Figure 4.10, A-B), although 
this did not reach statistical significance due to the small number of cases studied.  We 
then examined publically available reverse-phase protein array (RPPA) data from TCGA 
and found significant associations between NOTCH1 or NOTCH2 mutations and PTEN 
protein downregulation in a variety of cancer types including invasive breast cancer, 
glioblastoma, prostate adenocarcinoma, thyroid carcinoma, and clear cell renal cell 
carcinoma (Figure 4.10, C). These results suggest an important relationship between 
NOTCH mutation and PTEN expression in not only the poor-prognosis triple-negative 





















Figure 4.10: NOTCH mutations associate with reduced PTEN expression in 
TNBC cases. (A) Representative examples of NOTCH1 and NOTCH2 mutant cases 
showing reduced PTEN IHC staining in tumor compared to paired normal. (B) 
Quantification of all cases. ∆TN is the difference in IHC score between normal and 
tumor, negative = reduced in tumor. Mutations in NOTCH1 and NOTCH2 were 
included. Error bars are mean ± s.e.m. Significance: student’s t-test, one-tailed. (C) 
Boxplots of PTEN RPPA data from TCGA from various cancer types in NOTCH1 or 
NOTCH2 wild-type (WT) or mutant (MUT) groups. Significance: student’s t-test, 
two-tailed.   
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Knockdown of NOTCH2 in NOTCH2-mutant breast cancer cells leads to 
downregulation of EZH2 and restoration of PTEN expression   
	
	 We concluded in this chapter that the HCC-1187 TNBC cell line has reduced 
expression of PTEN mediated by the PRC2 complex. This cell line also harbors a 
transforming SEC22-NOTCH2 translocation (Robinson et al., 2011).   We performed a 
stable knockdown of NOTCH2 in this cell line and observed a restoration of PTEN 
transcript and protein levels (Figure 4.11, A-B). Concomitant with the stable restoration 
of PTEN expression, we observed a decrease in the NOTCH target gene HES-1 transcript 
Figure	4.11:	Knockdown	of	NOTCH2	leads	to	restoration	of	PTEN	expression 
Figure 4.11: Knockdown of NOTCH2 leads to restoration of PTEN expression. (A) 
Transcript levels measured by qRT-PCR and (B) protein levels measured by 
immunoblotting of indicated genes following stable knockdown of NOTCH2. P5, P6 
indicate passage number after infection. β-actin was a loading control. (C) ChIP-qPCR 
binding of indicated proteins to the PTEN promoter (Site B, near R3P1, Figure 4.6, A) 
following stable knockdown of NOTCH2. Relative DNA Binding is % input (normalized 
to IgG). Error bars are mean ± s.d. (triplicate measurements). Significance from Ctrl: 2-
way ANOVA, Dunnett’s correction. (****P<0.0001, ***P<0.001, **P<0.01, *P<0.5) 
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and protein levels and a decrease in EZH2 transcript and protein levels (Figure 4.11, A-
B). We did not see a significant change in ATAD1 transcript levels (Figure 4.11, A). 
Furthermore, we observed co-localization of both HES1 and EZH2 at the PTEN 
promoter, and these signals were diminished by NOTCH2 knockdown (Figure 4.11, C). 
These results suggest that NOTCH2 translocation could be the initiating event that drives 
increased PRC2 complex activity at the PTEN promoter in these TNBC cells. It is 
possible that the HES-1 transcription factor could recruit the PRC2 complex to the PTEN 
promoter, or that the two proteins interact in some way to mediate repression.  
Chromatin modifying enzymes are promising therapeutic targets for PTEN-deficient 
breast cancer 
	
It has been reported that HES-1 can recruit chromatin-modifying complexes to 
sites of target gene repression. HES-1 can recruit both types of histone deacetylases, 
HDACs and sirtuins, using different binding domains to repress of target genes [reviewed 
in (Fischer and Gessler, 2007)]. It is possible that HES-1 interacts with members of the 
PRC2 complex to mediate repression, and it is well-known that PRC2 also interacts with 
other chromatin modifying enzymes such as HDACs and DNMTs. Interestingly, 
treatment of cell lines with the HDAC inhibitor Trichostatin A (TSA) (Figure 4.12, A) or 
the DNA hypomethylating agent 5-AZA-2’-deoxycytidine (AZA) (Figure 4.12, B) led to 
robust restoration of PTEN expression (Figure 4.12, C-D).  Treatment with TSA led to a 
3-fold increase in PTEN transcript levels at the highest 1 µM dose in HCC-1187 cells 
(Figure 4.12, C).  TSA restored PTEN levels at the lower dose in two other TNBC cell 
lines (BT-20 and MDA-MB-157) as well as in a hepatocellular carcinoma cell line 
(HepG2), all of which have downregulated PTEN transcript levels (Figure 4.12, C). 
Notably, treatment of two nontumorigenic mammary epithelial cell lines (MCF10A and 
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hMEC) with TSA also led to a restoration of PTEN expression (Figure 4.12, C), 
indicating that this repression is not necessarily cancer-specific. However, most cell lines 
are abnormal to some degree in 2-dimensional culture, and these lines may have 
repression of PTEN that mimics the cancer-specific context. Treatment of HCC-1187 
cells with AZA had a dose-dependent effect on PTEN expression, showing more than a 
2-fold increase in PTEN expression at the highest 9 µM dose (Figure 4.12, D). 
Interestingly, while the BT20 and HepG2 cell lines also showed restoration of PTEN 
transcript levels following treatment with this drug, the MDA-MB-157 line did not 
(Figure 4.12, D). MCF10A and hMEC cells did not exhibit restoration of PTEN 
Figure	4.12:	Inhibition	of	chromatin	modifying	enzymes	restores	PTEN	expression 
Figure 4.12: Inhibition of chromatin modifying enzymes restores PTEN 
expression. Basic properties and chemical structures of (A) Trichostatin A (TSA), 
and (B) 5-Aza-2’-deoxycytidine (AZA). PTEN transcript was measured by qRT-
PCR following (C) TSA treatment, and (D) AZA treatment at indicated times/doses 
in cell lines. Error bars are mean ± s.d. (triplicate measurements). Significance: 2-
way ANOVA, Dunnett’s correction. (****P<0.0001, ***P<0.001, **P<0.01, 
*P<0.05) 
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expression following AZA treatment (Figure 4.12, B), suggesting that DNA methylation 
might be a more cancer-specific phenotype. 
These results indicate that histone deacetylases and DNA methylation play 
important roles in the repression of PTEN, though the importance of each may vary 
between cell lines. Also, HDAC inhibitors may have indirect effects on expression 
because class 1 and 2 HDACs can influence the expression of a broad set of genes. This 
can help to explain why the effect of TSA on PTEN expression is not as large at the 
highest dose for three of the cell lines. The PRC2 complex could mediate a portion of 
these effects, because PRC2 possesses HDAC and DNMT activity. However, the effect 
size for restoration of PTEN expression was much larger compared to the EZH2 
inhibitors, suggesting that HDACs and DNMTs may also act independently from the 
PRC2 complex to mediate repression of PTEN. As was the case for the KMT inhibitors, 
it will be important to optimize the dosing and time points in order to maximize the 
effects of these drugs. Importantly, HDACs and DNMTs may be important potential 
therapeutic targets in treating PTEN-deficient cancers, and many of the drugs in these 
classes are clinically approved.   
DISCUSSION 
	
In this chapter, we have uncovered an additional layer in the transcriptional repression of 
PTEN in breast cancer and other types of cancers. In the HCC-1187 cell line model of 
TNBC characterized by transcriptional downregulation of PTEN, we found that the 
PTEN promoter and upstream regulatory region have defined loci important for 
repression, and that these loci overlap with PRC2 activity on the PTEN promoter (both 
the binding of EZH2 and the interaction with H3K27Me3). In fact, loss of EZH2 function 
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by knockdown or inhibition led to a restoration of PTEN expression, and knockdown of 
EZH2 also caused a decrease in proliferation. We then asked, what is the upstream signal 
that causes the PRC2 complex to repress PTEN in particular contexts? We found that 
NOTCH1 and NOTCH2 also play a role in the repression of PTEN, and when NOTCH2 
is knocked down in HCC-1187 cells harboring an oncogenic SEC22B-NOTCH2 
translocation, we observe a dramatic restoration of PTEN expression, but also a decrease 
in HES-1 and EZH2 expression. These results suggest that these oncogenic mutations in 
NOTCH1 and NOTCH2 may (directly or indirectly) drive the increased PRC2 activity at 
the PTEN promoter and upstream regulatory region (summarized in Figure 4.13).  The 
HES-1 transcription factor, which is also bound to the PTEN promoter with EZH2, may 
be responsible for recruiting the PRC2 complex (Figure 4.13).  As previously discussed, a 
ncRNA originating from the antisense strand of the PTENP1 locus (PTENP1-AS, ⍺-
isoform) has the ability to recruit the PRC2 complex to the site of repression on the PTEN 
promoter, but we were unable to detect this PTENP1-AS transcript in the HCC-1187 cell 
Figure	4.13:	Model	of	transcriptional	repression	of	PTEN	by	the	PRC2	complex 
Figure 4.13: Model of transcriptional repression of PTEN by the PRC2 complex. 
Mutation or translocation of NOTCH1 and NOTCH2 leads to upregulation of HES-1 and 
PRC2/EZH2. The PRC2 complex may be recruited to the PTEN promoter by HES-1. 
PRC2 adds the H3K27Me3 mark of transcriptional repression, allowing for condensation 
of chromatin, and the subsequent repression of PTEN. 
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line or in any of the normal or tumor tissue samples we analyzed by RNA-seq. Our 
results suggest that this ncRNA is not required for transcriptional repression by the PRC2 
complex at the PTEN promoter. 
 A large body of research has demonstrated that PTEN is a haploinsufficient dose-
responsive tumor suppressor, and that a decrease in expression as small as 20% can lead 
to tumorigenesis in mice. Thus, the strong transcriptional downregulation of PTEN 
observed in many types of cancer including TNBC, is more than likely contributing to 
tumorigenic phenotypes in many cases. EZH2 is a promising therapeutic target for many 
different types of cancer, and our results show that EZH2 inhibitors have the potential to 
restore PTEN expression, which may inhibit tumorigenesis or tumor progression. 
However, it is important to note that the role of EZH2 is context-dependent, so it is 
important to establish whether EZH2 is acting as an oncogene or a tumor suppressor in 
each cancer type. The drugs we used in our study, UNC1999 and DZNep, lack 
specificity, and even UNC1999 has some activity towards EZH1. There are more 
selective inhibitors available today that are currently in clinical trials that could exhibit a 
more potent effect on PTEN expression and tumorigenic phenotypes. Since the PRC2 
complex also interacts with HDACs and DNMTs in certain contexts, we tried using an 
HDAC inhibitor (TSA) and a DNA hypomethylating agent (AZA) to restore PTEN 
expression, which was even more efficacious than the EZH2 inhibitors. This greater 
effect size was likely due to other repressive events occurring at the PTEN promoter that 
are independent of PRC2 activity.  
For example, in Chapter 3, we discuss a p53-depednent enhancer upstream of 
PTEN (PTEN-eP53RE) that is characterized by the H3K27Ac mark of active enhancers. 
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HDAC inhibitors could work to prevent the deacetylation of this enhancer, thereby 
helping to maintain its activity, and thus, the expression of PTEN. As mentioned in 
Chapter 1, the PTEN promoter is frequently methylated in a variety of different cancer 
types, and this methylation can occur independently of the PRC2 complex. 
Hypomethylating agents such as AZA could have a larger impact on PTEN expression 
due to the many sources of methylation of the PTEN regulatory region. Several drugs of 
these classes are clinically approved and could also help alone or in combination with 
EZH2 inhibitors to treat PTEN-deficient cancers. 
In addition, this study suggests that NOTCH1 and NOTCH2 can influence PTEN 
expression in TNBC through the binding of NOTCH target gene HES-1, and may also be 
important regulators of PRC2 complex expression and activity at the PTEN promoter. It 
would be interesting to test whether there is a physical interaction between HES-1 and 
any PRC2 complex members. Also, given the decrease in EZH2 expression upon 
NOTCH2 knockdown, it would be worthwhile to investigate the mechanism behind this 
association. One could conceivably use γ-secratase inhibitors to prevent the cleavage and 
activation of NOTCH-IC for certain NOTCH-mutant cancers to restore PTEN levels, as 
was previously done in T-ALL (Palomero et al., 2007). As was previously mentioned, it 
is important to acknowledge that the inhibitor studies presented here are preliminary, and 
would require testing of many additional time points and doses to achieve the maximum 
effect for each drug. It is likely that we could dramatically increase the effect of these 
drugs under optimized conditions, and one should only use these studies as proof of 
concept that these drugs can restore PTEN expression.  It would be interesting to 
combine therapies that target NOTCH, EZH2, HDACs, and/or DNA methylation to 
	 125	
develop an even more effective combination therapy for restoring PTEN levels. 
Importantly, even though loss of PTEN expression is sufficient to cause tumorigenesis in 
multiple organisms, therapies that aim to restore this downregulation are not clinically 
available and could be an interesting approach to boost tumor suppressor signaling. 
Importantly, therapies that inhibit PI3K activity are distinct from therapies that aim to 
restore PTEN expression due to the PI3K-independent effects of PTEN that may also be 
playing a role in cancer following PTEN mutation or downregulation.  
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Genetic loss or downregulation of tumor suppressor genes represents a key 
hallmark in the initiation and/or progression of many different types of cancer. Since the 
discovery of the two-hit model of carcinogenesis proposed by Knudsen in 1971, a wide 
diversity of tumor suppressor genes has been discovered and characterized, some of 
which follow the two-hit paradigm, and others that follow alternative models such as 
haploinsufficiency or dominant negativity, among others (described in Chapter 1). 
Importantly, even though loss of tumor suppressor function is so common in various 
types of malignancy, most therapeutic approaches focus on the inhibition of oncogenes or 
oncogenic signaling pathways, rather than the restoration of tumor suppressor expression. 
This could represent an important and underrepresented niche for therapy in cancers that 
are driven by loss of tumor suppressor expression.  
Characterizing the transcriptional profile of PTEN and PTENP1 in normal mammary 
epithelium and breast cancer 
	
In Chapter 2, we explored the commonly observed phenomenon of PTEN 
downregulation in breast cancer and evaluated the ability of various systems to model 
this downregulation. We found that PTEN expression is high in normal mammary 
epithelium, and that culture of this normal tissue can dramatically decrease PTEN 
expression through artefactual mechanisms related to the culture conditions.  This 
becomes important when choosing model systems that represent that normal expression 
of PTEN. We employed a combined RNA-seq and Nanostring nCounter approach to 
determine the detailed transcriptional profile of the PTEN and PTENP1 genomic loci, as 
well as to measure the expression of the poor-prognosis signature of PTEN 
downregulation in a variety of samples. We reproduced the finding that PTEN is often 
downregulated in a large proportion of breast cancers, and this downregulation correlates 
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with the previously discovered poor-prognosis signature associated with PTEN 
downregulation (Saal et al., 2007). Importantly, PTEN is a haploinsuffiicient, dose-
dependent tumor suppressor, and the level of downregulation we observed has biological 
consequences, including spontaneous tumorigenesis. Surprisingly, we did not observe 
any antisense PTENP1 transcripts (PTENP1-AS) in the PTEN-downregulated samples, 
even though these transcripts can aid in the repression of PTEN in specific contexts either 
by destabilizing the PTENP1 transcript or by recruiting the PRC2 complex to the site of 
repression in the PTEN locus (Johnsson et al., 2013).   
The approach designed in Chapter 2 to investigate the transcriptional profile of 
the PTEN and PTENP1 loci is extremely thorough, gives strand-specific information 
about any transcriptional species arising from these loci, and gives expression data for the 
associated PTEN-loss gene signature. In the future, this approach should be applied to a 
larger set of normal and tumor samples to better characterize the full catalog of 
transcripts arising from these loci, and how their expression levels differ between 
samples with various molecular or clinical characteristics. It would be interesting to use 
laser microdissection to separate the different types of mammary epithelium and stroma 
in normal and tumor samples to determine if the transcriptional profile of PTEN and 
PTENP1 would differ between the different cell types.  This is important because if we 
could identify a specific type of cell that is downregulating PTEN, this might help to 
suggest a cell type of origin for particular cancers characterized by PTEN 
downregulation. Since we did not observe any of the PTENP1-AS transcripts in the 
samples we analyzed, it would be worthwhile to determine which samples or cell types 
express these transcripts.  
	 130	
 Much of the previous research on tumor suppressor genes is focused on their 
genetic mutation, as opposed to their loss of expression. This approach should be applied 
to other tumor suppressor genes, such as those mentioned in Table S3.1, in order to 
obtain detailed information about their transcriptional profiles in different tissue and 
cancer types. It would also be interesting to investigate the transcriptional profiles of 
PTEN and PTENP1 in other tissues and cancer types. In terms of other tumor suppressor 
genes, it would be wise to focus on the haploinsufficient tumor suppressors, as subtle 
downregulation would likely be sufficient for phenotypic changes. Detailed information 
about tumor suppressor expression in a wide variety of tissue and cell types would be 
incredibly useful in determining the proportion of cases of different types of cancer that 
are characterized by tumor suppressor downregulation, and would suggest which cancer 
types would benefit from therapies aimed to restore tumor suppressor expression.  
 
p53 maintains expression of multiple tumor suppressor genes  
	
 In Chapter 3, we found that the low level of p53 expressed in the normal, low-
stress setting maintains baseline expression of thirteen tumor suppressors, as well as a 
wide array of other genes. These tumor suppressors are well-validated in genetically 
engineered mouse models, many of them are associated with inherited cancer 
predisposition syndromes, and are somatically mutated in cancer (Table S3.1). The 
classic view of p53-mediated tumor suppression is that p53 suppresses tumors by acting 
as the ‘guardian of the genome’, where p53 responds to acute stress by activating the 
appropriate protective, reparative, senescence, and/or cell death pathways (summarized in 
Figure 1.6 and 1.7). However, recent research has suggested that loss of these stress 
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response targets, or mutation of p53 so that it can no longer activate these pathways, does 
not cause spontaneous tumorigenesis in mice (Brady et al., 2011; Metallo et al., 2012; 
Valente et al., 2013). From the perspective of our study, the reason for this seems 
apparent, and that is because the stress response targets are largely not activated at 
baseline, and thus, their loss does not lead to spontaneous tumorigenesis. Rather, these 
mice likely have a decreased ability to respond to enhanced stress, which can lead to 
susceptibility to tumorigenesis under specific stress conditions such as intense irradiation.  
 The low levels of p53 expressed at baseline have been shown to be a result of 
physiologic stress, such as that encountered during DNA replication, or oxidative stress 
due to normal cell processes (Loewer et al., 2010; Lu et al., 2012; Sablina et al., 2005). 
The basal expression level of p53 also depends on tissue type and other contextual factors 
(Seim et al., 2016). We would like to perform ChIP-seq for basal p53 in human tissues 
and additional uncultured human cells to determine which tumor suppressor targets are 
bound in these contexts. Interestingly, these functions of basally expressed p53 could also 
be the mechanism by which p53 functions as a tumor suppressor, which is strongly 
corroborated by the findings of our study. If the p53 expressed under normal physiologic 
conditions maintains the expression of thirteen well-validated tumor suppressor genes as 
well as other growth inhibitory targets, then mutation of TP53, which is the most 
common genetic event in cancer, would result in the parallel downregulation of all of 
these targets and would be a potent loss of tumor suppressor activity. This loss of tumor 
suppressor activity could be exacerbated by the oncogenic gain-of-function of some point 
mutations in TP53. We believe that the basal regulation of this group of genes is highly 
important for the function of p53 as a tumor suppressor.  
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 Our results suggest that the role of basal p53 in maintaining expression of tumor 
suppressor targets is important for tumor suppression, but we still lack the in vivo 
evidence to support this claim. In the future, it will be important to develop animal 
models to explore the role of the baseline targets of p53 in tumor suppression. For 
example, it would be interesting to knock out the basal p53 binding sites for p53 in 
enhancers and promoters alone or in combination in mice, and examine the effect on 
tumorigenesis. For example, we know that in in vitro cell culture experiments, 
homozygous deletion of PTEN-eP53RE leads to at least a 50% reduction in PTEN 
expression. From an extensive body of prior work, we know that PTEN is a dose-
dependent tumor suppressor as little as a 20% reduction of PTEN expression can lead to 
spontaneous tumorigenesis in mice (Alimonti et al., 2010; Trotman et al., 2003; 
Vasudevan et al., 2007). Based on this research, it is likely that homozygous deletion of 
PTEN-eP53RE in mice would yield spontaneous tumorigenesis.  
Additionally, it would be informative to take the PTEN-eP53RE-/- mice and 
perform homozygous deletion of additional p53 binding sites near the tumor suppressor 
targets of p53 to determine if these combined deletions accelerate tumorigenesis. For 
example, mice heterozygous for PTEN and hypomorphic for STK11(LKB1) develop 
tumors in multiple organs at a much shorter latency than PTEN heterozygous mice 
(Huang et al., 2008), suggesting that these two tumor suppressors cooperate in 
tumorigenesis. We would suspect that homozygous deletion of the basal p53 binding site 
on STK11(LKB1) would accelerate tumorigenesis compared to PTEN-eP53RE alone. 
Homozygous deletion of basal p53 binding sites near haploinsufficient tumor suppressor 
genes would be more likely to accelerate tumorigenesis to a greater degree because only 
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partial loss of expression is required. However, it would be worthwhile to investigate the 
other tumor suppressor targets of basal p53 as well to determine their contribution to p53-
mediated tumor suppression.  
 We would also like to explore the different factors that dictate p53 binding to 
certain targets over others. We know that under normal conditions, p53 is expressed at 
low levels, and binds to a subset of targets, where many of the stress response targets are 
not bound. We suspect that this is related to binding affinity, as many of the basal p53 
targets have few to no mismatches from the consensus site, and no spacer, but also may 
depend on binding partners that can influence binding. It will be important to test a wide 
variety of stressors and a longer list of p53 targets to determine if the binding profile 
differs depending on the stress being applied. Also, the basal expression of p53 differs 
depending on the cell type and various contextual factors that can cause physiologic 
stress. The level of p53 expressed at baseline obviously would affect which targets are 
bound, and also would affect which targets are saturated at baseline. Importantly, if a 
target is saturated at baseline, it will not be activated by p53 mimetics such as Nutlin-3, 
or any cell stressor that induces p53 to express at higher levels.  In the MCF7 breast 
cancer cell line, only 4/13 tumor suppressor targets were bound at baseline and we 
observed a robust restoration of PTEN expression following treatment with Nutlin-3, 
which corroborates this hypothesis.  
A better understanding of the dynamics of p53 binding to its various targets 
would be extremely informative, and would help us to exploit these mechanisms of p53-
mediated tumor suppression for therapeutic benefit. For example, tumors that harbor 
MDM2 amplification or overexpression have lower levels of basally expressed p53, and 
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thus, may benefit from treatment with a p53 mimetic such as Nutlin-3 to help restore 
tumor suppressor activity in the tumor. Although Nutlins have not been successful in the 
clinic thus far, this may be due to a poor selection of biomarkers to identify those tumors 
that would benefit from Nutlin therapy. In the case of a p53 mutation, it may be effective 
to use therapeutic approaches to restore key tumor suppressors that contribute to tumor 
suppression in that specific tumor type. We hope to be able to build on the knowledge 
gained in this study to better understand p53-mediated tumor suppression and to use this 
understanding for therapeutic approaches.    
PRC2-mediated repression of PTEN driven by mutations in NOTCH1 and NOTCH2 
	
 In Chapter 4, we uncovered yet another molecular mechanism of transcriptional 
repression of PTEN, further demonstrating the complexity of PTEN regulation. In this 
study, we identified key regions of the PTEN promoter and upstream regulatory region 
that are important for transcriptional repression. We then examined chromatin marks of 
repression in the same region of DNA and found that the H3K27Me3 mark of PRC2-
mediated repression was present in the same regions of chromatin important for 
transcriptional repression. We also found robust binding of EZH2, the KMT enzyme that 
trimethylates H3K27, to the PTEN promoter and regulatory region. We showed that 
EZH2 regulates PTEN and stable knockdown of EZH2 leads to restoration of PTEN 
transcript and protein, as well as a decrease in proliferation. We found that 
pharmacological inhibition of EZH2 also led to a restoration of PTEN transcript levels. 
We would like to examine the effect of these EZH2 inhibitors on proliferation, and would 
expect the effect to be similar to EZH2 knockdown. Taken together, these results 
confirmed a role for the PRC2 complex in the repression of PTEN in breast cancer.  
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 We next wanted to investigate the upstream events that cause increased PRC2 
activity in the PTEN promoter and regulatory region. We investigated sequencing data 
from 27 TNBC cases and found that 7/27 cases harbor point mutations or translocations 
in NOTCH1 and/or NOTCH2, and that NOTCH1/2 mutations correlate with decreased 
expression of PTEN by IHC in these cases. In fact, mutations in NOTCH1 and NOTCH2 
associate with decreased expression of PTEN in many different types of cancer. The 
HCC-1187 TNBC cell line harbors an SEC22B-NOTCH2 translocation, and we 
confirmed that knockdown of NOTCH2 led to dramatic restoration of PTEN transcript 
and protein expression in that cell line, as well as a decrease in the expression of the 
NOTCH target HES-1. Surprisingly, we also observed that NOTCH2 knockdown 
decreased expression of EZH2. These results suggested that oncogenic NOTCH can 
either directly or indirectly affect the expression of EZH2. Furthermore, we found that 
HES-1 and EZH2 are co-localized on the PTEN promoter, which also suggests 
cooperation between the two signaling axis.  
 Notably, HES-1 can recruit HDACs, sirtuins, and other repressive complexes to 
the site of repression, so it is fathomable that HES-1 could also recruit the PRC2 complex 
to the site of repression on the PTEN promoter. In the future, we would like to look at 
more sites on the PTEN promoter to determine which regions have the strongest co-
localization of HES-1 and EZH2.  We would also like to determine whether there is a 
physical interaction between HES-1 and EZH2. Since NOTCH2 knockdown led to 
restoration of PTEN expression, we would expect that NOTCH2 knockdown would also 
decrease proliferation in HCC-1187 cells, as was observed following EZH2 knockdown. 
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Taken together, these experiments would help to solidify this transcriptional regulatory 
mechanism for PTEN.  
 The PRC2 complex also associates with DNMT and HDAC enzymes, which aid 
in repression. In this study, we measured the effect of TSA (Class I and II HDAC 
inhibitor), and AZA (DNA hypomethylating agent) on PTEN expression, and these drugs 
were able to robustly restore transcript levels for PTEN. These drugs had a greater ability 
to restore PTEN expression than the EZH2 inhibitors, which suggests that there may be 
other mechanisms PTEN repression involving HDACs and DNA methylation that are 
independent of the PRC2 complex. For example, the activity of the p53-bound enhancer 
for PTEN (PTEN-eP53RE) discussed in Chapter 3 could potentially be repressed by 
HDACs, and may gain activity in response to an HDAC inhibitor. It is also possible that 
this enhancer could be repressed in certain contexts by the PRC2 complex. Furthermore, 
the promoter of PTEN is methylated in many different types of cancer, which could have 
contributed to the effect of AZA (Alvarez-Nunez et al., 2006; Garcia et al., 2004; Wang 
et al., 2007). Since certain members of these classes of drugs are approved for the clinic, 
this could be a convenient therapeutic avenue to treat PTEN-deficient tumors. It also may 
be worthwhile to try combination therapy of EZH2 inhibitors, HDAC inhibitors, and 
DNA hypomethylating agents, because these combinations may have additive or 
synergistic effects. γ-secretase inhibitors may be worth testing in NOTCH1 and 
NOTCH2-mutated lines alone or in combination with other drugs because they can 
restore PTEN expression in NOTCH1-mutated AML (Palomero et al., 2007). We would 
like measure the effect of these drugs on the proliferation of a larger panel of cancer cell 
lines harboring repressed PTEN, and compare it to those with higher levels of PTEN. It 
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will also be important to determine if any other key tumor suppressors are repressed 
through similar mechanisms. 
 We would also like to test some of the concepts of this study in animal models. 
We could start with xenograft studies, where the HCC-1187 cell line is injected into the 
mammary fat pad of nude mice, and we could test the efficacy of these drugs alone and in 
combination to both restore PTEN expression and inhibit tumor growth in an in vivo 
setting. I would expand this experiment to include a panel of cancer cell lines, including 
TNBC lines as well as others characterized by PTEN downregulation, and determine how 
the response correlates with PTEN expression status. It is possible that PTEN expression 
status is a good biomarker for response to these types of epigenetic therapy. We could 
measure the level of H3K27Me3, EZH2, and HES-1 at the PTEN promoter and upstream 
regulatory region before and after therapy, to determine if these drugs truly affect these 
regulatory axes. The combined knowledge gained in Chapters 2, 3, and 4 will hopefully 
lead to an effective therapy for PTEN-deficient, poor-prognosis patients to restore tumor 
suppressor expression and inhibit tumor growth. Importantly, therapies that inhibit PI3K 
activity are distinct from therapies that aim to restore PTEN expression due to the PI3K-
independent effects of PTEN that may also be playing a role in cancer following PTEN 
mutation or downregulation. PTEN-restorative therapies may be more effective for a 
more broad set of cancers for this reason.  
 Decades of research have suggested that tumor suppressor inactivation represents 
an important hallmark of cancer, yet the current therapeutic approaches rarely aim to 
restore tumor suppressor expression, but more often inhibit oncogenes and downstream 
signaling. Tumor suppressor genes are often downregulated but remain intact genetically, 
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and this represents a reversible change that could potentially be targeted through 
pharmacological approaches. Furthermore, tumor suppressor downregulation is often 
sufficient to cause spontaneous tumorigenesis in animal models. Taken together, the 
studies outlined in this thesis suggest a potential avenue for treatment that could have 
major promise for cancers that have yet to be successfully treated through targeted 
therapy. In the future, additional focus should be placed on restoring tumor suppressor 
expression and signaling in patients either prophylactically, or as a therapeutic approach 
in cancer. 
 






































Cell Culture:  
MCF10A, hMEC-hTERT,  HCC38, and HCC-1187 cell lines were purchased from 
ATCC. Primary hMECs were purchased from Lonza (CC-2551). The U2OS cell line was 
a gift from Dr. James Manfredi. Cell lines were regularly tested in the lab for 
mycoplasma. All cells were cultured at 37°C and 5% CO2. MCF10A cells were cultured 
in 50/50 DMEM/Ham’s F-12 media with 5% horse serum (Gibco 16050-122), 1X 
Penicillin/Streptomycin (Corning 30-002-Cl), 20 ng/ml of EGF (Peprotech AF-100-15), 
10 µg/ml insulin (Sigma I9278), 0.5 mg/ml hydrocortisone (Sigma H0888), and 100 
ng/ml cholera toxin (Sigma c8052). U2OS cells were cultured in 1X DMEM with 10% 
fetal bovine serum (Atlanta Biologicals S11150) and 1X Penicillin/Streptomycin. hMEC-
hTERT cells were cultured in MEGM Complete Growth Medium (Lonza  CC-3051A and 
CC-4009). HCC38 and HCC-1187 cells were cultured in 1X RPMI with 10% fetal bovine 
serum and 1X Penicillin/Streptomycin. Cells were split using 0.05% or 0.25% trypsin 
(Corning 25-051-Cl or 25-053-Cl, respectively) before they reached full confluence and 
media was changed every 3-4 days. Corning Cellgro Media product information is as 
follows, DMEM: 10-013-CV, RPMI: 10-040-CV, 50/50 DMEM/ Ham’s F-12: 10-090-
CV.  Human mammary epithelial cells were derived using the Schlegel method as 
described(Liu et al., 2012). Instead of using conditioned media + cells, only conditioned 






Drug Treatments:  
Nutlin: Nutlin-3 (Sigma Aldrich, N6287-5MG) was dissolved in DMSO and was used at 
a concentration of 10 µM in media for 24h.  Control is treatment with equal volume of 
DMSO.  
Doxorubicin: Doxorubicin hydrochloride (Sigma 44583-1MG) was dissolved in DMSO 
and was used at a concentration of 0.1 µg/mL in media for 24h.  Control is treatment with 
equal volume of DMSO. 
Trichostatin A: (Sigma T1952) was dissolved in DMSO and was used at indicated 
concentration in media for 24h. Control is treatment with equal volume of DMSO. 
5-aza-2’-deoxycytidine: (Sigma A3656) was dissolved in PBS and was used at indicated 
concentration in media for 48h. Control is treatment with equal volume of PBS. 
DZNep: (Sigma SML0305) was used at indicated concentration for 48h. Control is 
treatment with equal volume of DMSO. 
UNC1999:  (Cayman 1431612-23-5) was used at indicated concentration for 24h. Control 
is treatment with equal volume of DMSO. 
 
Human Tissue Samples:  
De-identified breast cancer tissue samples were distributed by the Tumor Bank in the 
Herbert Irving Comprehensive Cancer Center Molecular Pathology Shared Resource. De-
identified peripheral blood mononuclear cells (PBMCs) from healthy donors were 





Purification of epithelial organoids from breast tissue:  
The protocol followed for purification of organoids from breast tissue has been 
previously published (Allinen et al., 2004). Further purification of epithelial cells from 
organoid preparations was performed using CELLection™ Epithelial Enrich 
Dynabeads®(Thermo 16203, manufacturer’s protocol).   
 
Mammary fat pad breast cancer xenografts: 
HCC-1187: 5 million cells were suspended in media (50 µL media per 1 million cells), 
and were then diluted 1:1 in Matrigel (BD Biosciences 356231). Cell/Matrigel mixture 
was injected directly into the mammary fat pad of 8-week old athymic nude female mice. 
Tumors were allowed to grow for 12 weeks before being harvested and processed. 
Tumors were either sectioned for IHC, or homogenized in RIPA buffer (25 mM Tris pH 
7-8, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40, protease 
inhibitors) . Homogenized tumors were either diluted with 2X sample buffer (see 
Immunoblotting protocol), or buffer RLT, provided with Qiagen RNeasy Kit (74104).  
 
Histology and Immunohistochemistry (IHC): 
All histology and IHC were performed by the Molecular Pathology Shared Resource at 
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center. 
Dr. Hanina Hibshoosh (pathologist) and Dr. Tao Su (manager) procured all patient 
samples used. When scored, the 0-3 clinical scoring system was used (0 = none, 1 = 
weak, 2 = intermediate, 3 = strong). ΔTN was calculated by taking the change between 
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the tumor and normal tissue from the same case. A negative number indicates that the 
staining was weaker in the tumor.  
Antibodies: PTEN (138G6, CST 9559), CK5 (PRB-160P), CK18 (AB 668), PDGFRα 
(CST 3164) 
H&E: The blue hematoxylin stains nuclei and the pink eosin stains extracellular and 
intracellular protein. See original protocol for details (Wu, 1940).  
 
Transient Knockdown of p53:  
Cells were transfected using the Lipofectamine 2000 reagent (Thermo 11668019) in 
Opti-MEM media (Invitrogen 11058021). SMARTpool: ON-TARGET plus Human 
TP53 siRNA (L-003329-00-0020) was used to transiently knock down p53 and the 
MISSION siRNA Universal Negative Control (Sigma SIC001) was used as a negative 
control. The lipofectamine, Opti-MEM, and siRNA were mixed together and incubated at 
room temperature for 30 minutes. The mixture was added dropwise to cells already 
containing an equal volume of the fully supplemented media for that cell line without 
antibiotics. This media was left on the cells for 5-16 hours and was subsequently changed 
to fully supplemented media with antibiotics. The cells were harvested 48-96 hours post-
transfection, as indicated.  
 
Stable knockdowns: 
Prepackaged viral particles containing shRNA (Sigma-Aldrich MISSIONÒ lentiviral 
transduction particles, SHCLNV):  
EZH2 shRNA#1: TRCN0000286227 
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EZH2 shRNA#2: TRCN0000286290 
NOTCH2 shRNA#1: TRCN0000262587 
NOTCH2 shRNA#2: TRCN0000282338 
Negative Control (pKLO.1-puro non-target): SHC016V 
*All shRNAs were expressed in the pKLO.1 vector backbone.  
 
T25 flasks of HCC-1187 cells (~30% confluent) were infected with indicated viral 
particles in in the presence of 12µg/mL polybrene, and 2 µg/mL of puromycin (Sigma 
P8833) was used to select for infected cells. Used an MOI of 1 viral particle per cell.  
 
Luciferase Reporter Assay:  
Cells were seeded at 2x105 cells/well of Falcon 6-well dishes.  The transfections were 
carried out the following day using Lipofectamine (18324-020) and Plus (11514-015) 
reagents according to the manufacturer’s instructions.  The cells were harvested 24h later 
using reagents supplied by the Dual-LuciferaseÒ Reporter Assay System (Promega 
E1910).  For the Chapter 3 assay, the total protein concentration was determined using 
the Bio-Rad Protein Assay reagent (Bio-Rad), and luciferase expression was normalized 
to protein and expressed as Luciferase units/µg protein. For Chapter 4 assay, luciferase 
expression is normalized to Renilla activity, and was calculated as a fold change from the 
Pgl3-1 plasmid. The luciferase assays were performed as specified by the manufacturer’s 




Plasmids for Luciferase Reporter Assay (Chapter 3): 
p53 Expression Plasmid:  
The pC53-pSN3 plasmid (previously published(Baker et al., 1990), gift from Dr. Bert 
Vogelstein) was used to overexpress p53 where WT p53 cDNA was cloned into the 
unique Bam H1 site in the expression vector pCMV-Neo (empty vector) to produce 
pC53-SN3. 
Luciferase Plasmid:  
The pGL3 basic reporter vector is commercially available (ProMega). The construction 
of pGL3-EibTATA (a pGL3 based luciferase reporter under the control of the minimal 
adenovirus E1b promoter) and pGL3-E1bTATA-p21 5’ have been previously described 
(Resnick-Silverman et al., 1998).   The plasmids, pGL3-TATA-Hu PTEN-eP53RE 
(GAACTTGTCTAGGCATGTCT), pGL3-TATA-Hu PTEN-pP53RE 
(GAGCAAGCCCCAGGCAGCTACACTGGGCATGCTC) were constructed by 
synthesizing and cloning oligonucleotides with Xho1 and Nhe1 ends into the polylinker 
of pGL3-E1bTATA. 
 
Plasmids for Luciferase Reporter Assay (Chapter 4): 
Luciferase Plasmid: The pGL3 basic reporter vector was used (as described above). See 
below for the sections of the PTEN promoter that were cloned into the pGL3 vector, 
including the restriction sites that flank each section.  These constructs were made by 





Multiz alignment was run from the UCSC genome browser for selected organisms as 
previously described(Blanchette et al., 2004). 
 
CRISPR of Hu PTEN-eP53RE: 
Cloning of the custom CRISPR guides targeting Hu PTEN-eP53RE was performed 
according to the LentiCRISPRv2 vector cloning protocol in the Lentiviral CRISPR 
toolbox from the Zhang lab that uses single guide RNAs(Sanjana et al., 2014; Shalem et 
al., 2014). The custom targeting oligos used are shown below. The LentiCRISPRv2 
(Addgene #52961) plasmid backbone with the custom guide targeting Hu PTEN-eP53RE 
was named p53-PTEN-LentiCRISPRv2.  




Lentivirus was produced in HEK-293T cells as previously described(Lois et al., 2002) by 
transfecting 0.3 µg of VSV-G, 3 µg of pCMV-DR8.9, and 3.6 µg of p53-PTEN-
LentiCRISPRv2 or empty LentiCRISPRv2 into a 10cm plate of cells and collecting 
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viral particles from media 24 and 48 hours post-transfection. The viral media was filtered 
through a .45 micron syringe filter (Fisher 194-2545) and stored at -80°C. Viral media 
was used to infect mammalian cells in the presence of 12µg/mL polybrene and 2 µg/mL 
of puromycin (Sigma P8833) was used to select for infected cells. Limiting dilution was 
used to isolate single colonies, which were amplified and sequenced by Genewiz using 
the following primers:  







If the CRISPR deletion was too large to use the sequencing primers, then the PCR 
product was purified and the PCR primers were used for sequencing. Selected clones 
were used for further experiments.  
 
RT-qPCR:  
RNA was prepared using the QiaShredder (79654) followed by the Qiagen RNeasy Kit 
(74104). cDNA was synthesized using the SuperScript Reverse Transcriptase II kit 
(Thermo 18064-014). The Applied Biosystems 7500 Fast Quantitative Realtime PCR 
System was used according to manufacturers’ protocol using Fast SYBR Green Master 
Mix (Thermo 4385612).  All qRT-PCR values were normalized to GAPDH.  
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The temperature program was as follows:  
Initial Denaturation: 95°C 20sec 
40 cycles: 95°C 3sec, 60°C 30sec 
Chapter 2 qRT-PCR primers: 
 








Chapter 3 qRT-PCR primers: 
 

























































Chapter 4 qRT-PCR primers: 
 


















Chapter 2: RNA was prepared using the QiaShredder (79654) followed by the Qiagen 
RNeasy Kit (74104). The ribosomal RNA (rRNA) removal was performed using the 
Illumina RiboZero Gold kit (MRZG 126) following manufacturers protocol. The RNA-
seq libraries were then prepared using the Illumina ScriptSeq™ v2 kit (SSV 21106) 
following manufacturers protocol. Libraries were sequenced by the Icahn School of 
Medicine Genomics Core Facility. 
Data Analysis: RNA-seq data was analyzed by Dr. Ravi Sachidanandam (MSSM). The 
reads from the sequencing data were mapped to the genome and a coverage (per base) 
was calculated for each exon. The numbers were normalized to the total number of reads 
(after removing ribosomal RNA reads).   
Chapter 4: RNA was obtained for 27 TNBC samples from the Tumor Bank in the Herbert 
Irving Comprehensive Cancer Center Molecular Pathology Shared Resource at CUMC. 
For 6 of the samples, the rRNA removal was performed using the Illumina RiboZero 
Gold kit (MRZG 126) following manufacturers protocol. These samples were then 
submitted to the Genome Center in the Department of Systems Biology at CUMC for 
library preparation and sequencing. For the other 21 samples, the rRNA-depletion, library 
preparation and sequencing was performed by the Genomics Core Facility at Icahn 
School of Medicine at Mount Sinai.  
Data Analysis: Collaboration with the laboratory of Dr. Raul Rabadan to perform the 
analysis of calling expressed fusion transcripts.  
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NanoString nCounter: Nanostring probesets were designed from a catalog of transcirpts 
obtained by RNA-seq (see above, Table 2.2) with the aid of NanoString company 
technicians. Only probes containing <90% sequence homology to other regions of the 
genome were used. NanoString experiments were performed by the NanoString core at 
Icahn School of Medicine at Mount Sinai. Total counts for each probe were obtained, and 
were normalized to the housekeeping genes (geometric mean of probe counts for all 
housekeeping genes) for each sample. See Table 2.2 for NanoString probeset.  
 
Whole-genome sequencing (WGS): 100-nucleotide paired-end sequencing was 
performed by Illumina on 6 N/T matched triple-negative breast cancer (TNBC) DNA 
samples. Coverage was 50X for normal samples and 80X for tumor samples.  
Data Analysis: Collaboration with the laboratory of Dr. Raul Rabadan to perform the 
analysis of calling somatic point mutations and indels.   
 
Whole exome sequencing (WES): Whole-exome capture and 100-nt paired-end 
sequencing was performed by Centrillion Biosciences on 21 TNBC DNA samples. 
Average coverage was 227X.  
Data Analysis: Collaboration with the laboratory of Dr. Raul Rabadan to perform the 
analysis of calling somatic point mutations and indels.   
 
Immunoblotting:  
Cells were lysed in 2x sample buffer (125 mM Tris-HCl at pH 6.8, 10% βME, 2% SDS, 
20% glycerol, 0.05% Bromophenol Blue, 8 M urea). Protein lysates were loaded into 4-
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20% TRIS-glycine gels and resolved by electrophoresis. Samples were then blotted on 
PVDF membrane (Millipore IPVH00010) using the wet transfer technique (Invitrogen). 
Membranes were blocked in 5% milk-TBST for 1 hour, washed in TBST for 10 minutes, 
and incubated in primary antibody in 5% milk-TBST or 5% BSA-TBST at 4°C for 16 
hours. Membranes were rinsed (3 x 6 min) in TBST and incubated in horseradish 
peroxidase-conjugated secondary antibodies in 5% milk-TBST for 1 hour and rinsed 
again in TBST (3 x 6 min). Membranes were visualized using the chemiluminescence 
system (Thermo 34080, 37075) on autoradiography film (Denville E3018).  
Primary Antibodies: Vinculin (Sigma V9131), β-actin (Sigma A5316), PTEN (138G6, 
CST 9559), pAKT (Thr308 CST 9275, Ser473 CST 9721), total AKT (CST 9272), p53 
(DO-1, SC-126), p21 (C-19, SC-397), LKB1 (CST 3050), KDM6A/UTX (CST 33510), 
EZH2 (Active Motif 39901), HES1 (H-140, SC-25392), ATAD1 (not commercial). 
Secondary Antibodies: Mouse (Thermo 31432), Rabbit (Thermo 31460). 
 
 
Chromatin Immunoprecipitation (ChIP-qPCR and ChIP-sequencing):  
ChIP assays were performed as previously described (Niu et al., 2003). Cells were cross-
linked in 1% formaldehyde (J.T. Baker 2106-01) for 5 minutes on ice. After quenching 
with glycine, the cells were harvested in 1X PBS containing 1X protease inhibitor 
cocktail (Sigma P8340) and pelleted. For ChIP-qPCR, cells were sonicated for 20 
minutes (30s on, 30s off) on the Diagenode Bioruptor Twin (UCD-400) sonicator at 4°C. 
For ChIP-seq, cells were sonicated similarly for 40 minutes. Lysates were precleared for 
1 hour with the appropriate beads (For Chip-qPCR: Protein A Agarose/Salmon Sperm 
DNA beads Emdmillipore 16-157, and for ChIP-seq: Magna ChIP™ Protein A+G 
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Magnetic Beads Emdmillipore 16-663). Precleared lysates were then incubated with 7µg 
of antibody overnight at 4°C. Samples were then incubated with appropriate beads (same 
as preclear) for at least 2 hours at 4°C and beads were repeatedly washed. The Protein-
DNA complexes were eluted, crosslinks were reversed, and DNA was purified using 
phenol/chloroform extraction followed by sodium acetate/ethanol precipitation. For 
ChIP-seq, DNA was purified again using the Qiaquick PCR purification kit (Qiagen 
28104). Purified DNA was then subject to qPCR (ChIP-qPCR) or high throughput 
sequencing (ChIP-seq).  For ChIP-qPCR, % input was calculated and normalized as a 
fold change from IgG.  
Antibodies: p53 (DO1-X, sc-126X), H3K27Ac (Millipore 07-360), H3 (ab 1791), IgG 
(sc-2025), EZH2 (Active Motif 39901), H3K27Me3 (Millipore 07-449).  
Chapter 3 ChIP-qPCR Primers: 
PTEN-eP53RE-For: CACATAAAGGCTGCATTCACA 
PTEN-eP53RE-Rev: TTCCTAGCAGACTCCTCCCA  
PTEN-eP53RE-Rev (Alt): CTCCCTAAGGTTTCCAGTATTCTG (for U2OS CRISPR 
Clone 3) 
PTEN-pP53RE-For: CAAAAGCCGCAGCAAGTG 







Chapter 4 ChIP-qPCR primers:  
Name Sequence Hg19 Loc. (Chr10) 
R1P1-For AGGACCGGTAACAGTGCTTG 89616383 
R1P1-Rev GTTTGAAAATGGCGGAAATG 89616468 
R1P2-For CCCCATGGTATCAGTTCAGG 89617236 
R1P2-Rev GACATGTGGGAAGCCATCTT 89617325 
R1P3-For GGCCAGAAGGATGTTTTGAA 89618222 
R1P3-Rev GGACATTGAGAAGGAGCCAA 89618295 
R1P4-For GAGAGATTTGGGACATGGGA 89618828 
R1P4-Rev GCGCTACTGTGGGTCATACA 89618913 
R1P5-For CAAGCTTCTACTTCTCCCTATGGT 89619440 
R1P5-Rev CCCGGCCATACTTAGTTCTTT 89619509 
R1P6-For GCACCCTTGTTTCATTTGCT 89620304 
R1P6-Rev CCCTGGAGCCTACCCTAAGT 89620393 
R2P1-For CGGAGTTAGGTAATGGCCTG 89620937 
R2P1-Rev GCAGGCAACCTCTGAAGACT 89621008 
R2P2-For GCTCAGGGGTAGTGACTGGA 89621491 
R2P2-Rev TTGAGGGTATCTCCTGCTGC 89621567 
R2P3-For AACCCTCCTAGGTCTCCTCG 89622108 
R2P3-Rev TTACCGGGTTGAGTGGAAAG 89622188 
R2P4-For AGGGGGAATCTCTAGGCAAA 89622658 
R2P4-Rev TGCATTCGCTCTTTCCTTTT 89622746 
R3P1-For ATGTGGCGGGACTCTTTATG 89623316 
R3P1-Rev CAGCTTCCGAGAGGAGAGAA 89623402 
R3P2-For AACGTGGGAGTAGACGGATG 89624355 
R3P2-Rev GCAACCTGACCAGGGTTAAA 89624426 
R3P3-For CGGGCTTCAAAAGTTAGTGG 89625500 
R3P3-Rev CCCCATCCCTAATCAAAACC 89625583 
R4P1-For TTCCAACGTACTTGGTTTGC 89626712 
R4P1-Rev TTTTAATGCCTTCCCACTCC 89626781 
R4P2-For AAATTTGCCTCCATTTGCTG 89627788 
R4P2-Rev AAGTGATTACTTCAGAAGCGGC 89627873 
R4P3-For ACCTCCACATAGTGTGAAAAAGAA 89629345 
R4P3-Rev CACTGTTCATATTTGAAGTGGTGAG 89629445 
R4P4-For GGTATTCCTTTAGGAAGTCTGGGTA 89630063 
R4P4-Rev TTAGCAGAGATTTATTTCCCATTTG 89630142 
A-For AGGTCTCAGTCCTTTGGCTTGC  89621703 
A-Rev TGGTTACACAAGCACCCACATC 89621851 
B-For GTGATGTGGCGGGACTCTTTAT  89623313 





Analysis of ChIP-seq data:  
ChIP-seq reads were aligned to the genome using Bowtie (Version 2.2.3).  Hg19 was 
used as the reference genome for all alignments. For p53 alignments, all default 
parameters were used. MACS2 Version 2.1.0 was used to call significant peaks, and the 
narrow peak option was used with the following parameters: p53 peaks: -B --SPMR --
nomodel --extsize 150 --keep-dup 2. All other parameters were run in the default setting. 
Initial output of MACS2 is a pileup value. MACS2 determines peak significance using a 
binomial test to determine p-value at each genomic location followed by the Benjamini-
Hochberg procedure to control for FDR (q-value). MACS2 was also used to calculate 
fold enrichment scores (IP sample over input across genome) using the bdgcmp FE 
function. Plots to visualize the data were generated by the UCSC genome browser and 
adapted in Illustrator. Nearest genes to peaks were called using HOMER software(Heinz 
et al., 2010). MCF10A cells and DMSO-treated U2OS cells were used as starting 
material for the two basal p53 ChIP-seq data sets. The U2OS (DMSO- treated) p53 ChIP-
seq data set was previously published(Menendez et al., 2013a) and can be accessed from 
the Gene Expression Omnibus (GEO) using the accession number GSE46641. We chose 
to analyze the U2OS DMSO-treated dataset over the ’no treatment’ (NT) dataset from the 
same study because the NT dataset did not contain peaks for CDKN1A (p21) or mIR-34a, 
two genes that are known to be regulated by basal p53; suggesting that the U2OS NT data 





Sample Sequenced Reads Aligned Reads 
MCF10A input 57,840,295 55,854,243 
MCF10A p53 27,482,537 25,976,864 
U2OS DMSO input 34,268,308 32,009,064 
U2OS DMSO p53 39,717,260 36,629,383 
 
Broad/ENCODE ChIP-seq data:  
Data for various histone modifications (H3K27Ac, H3K4me1, H3K4me3) in various cell 
lines were adapted from the UCSC Genome Browser under the ‘Encode Histone 
Modifications’ track set(ENCODE, 2012; Kent et al., 2002; Ram et al., 2011). GEO 
accession numbers can be accessed for each cell line and histone mark via the UCSC 












Chromatin State Segmentation (ChromHMM) and Hi-C:  
Chromatin state tracks were produced by the ENCODE project(ENCODE, 2012), see 
original publication for description of classification strategy(Ernst and Kellis, 2010; Kent 
et al., 2002). Hi-C data was also previously published(Rao et al., 2014), and can be 
accessed through the GEO accession GSE63525. Both ChromHMM and Hi-C data were 
adapted from the WashU genome browser(Zhou et al., 2013; Zhou et al., 2011). The 
color key for ChromHMM data is as follows:  
 
p53 response element prediction:  
We used a program called JASPAR that uses position-weight matrix (PWM) to identify 
and assign a score to potential p53 response elements, as has been previously 
described(Wasserman and Sandelin, 2004). The matrix model MA0106.3 was used to 




Proliferation assay:  
Chapter 3: U2OS cells (Empty Vector and Clone 1) were plated at 2000 cells/well in 96-
well tissue culture plates (Corning 3595) media containing 1% FBS (low serum). Cells 
were allowed to grow for the indicated number of days. The Essen BioScience 
IncuCyte® ZOOM Live-Cell Analysis System took phase-contrast images in triplicate 
wells every 6 hours. The IncuCyte® software package was used to estimate confluence at 
each time point.  
Chapter 4:  HCC-1187 cells (Empty Vector and EZH2 shRNA#1 and EZH2 shRNA#2) 
were plated at 8000 cells/well in 96-well tissue culture plates (Corning 3595) full media. 
Cells were allowed to grow for the indicated number of days. The Essen BioScience 
IncuCyte® ZOOM Live-Cell Analysis System took phase-contrast images in triplicate 
wells every 6 hours. The IncuCyte® software package was used to estimate confluence at 
each time point.  
 
Three-dimensional cell culture assay: 
Three-dimensional culture assays were performed as previously described (PMID: 
12798140) in the 8-well chamber slides (BD Falcon 08-774).  Assay medium 
(DMEM/F12 supplemented with 2% horse serum, 10 µg/mL insulin, 1 ng/mL cholera 
toxin, 100 µg/mL hydrocortisone, 50 units/mL penicillin, and 50 µg/mL streptomycin) 
containing 5 ng/mL epidermal growth factor and 2% growth factor-reduced Matrigel (BD 
Biosciences 356231) was replaced every 4 days.  Cells were collected using Cell 
Recovery Solution (BD BioSciences 354253) to remove Matrigel.  
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Immunofluorescence on 3D cultures: 
Cultures were fixed with 4% paraformaldehyde/PBS, permeabilized with 0.5% Triton X-
100/PBS, and washed 3 times with PBS buffer (137 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na2HPO4, 1.47 mM KH2PO4, Adjust to a final pH of 7.4).  Primary antibodies were 
suspended in IF buffer (3% bovine serum albumin, 0.1% NP-40 in PBS) and incubated 
overnight. The cultures were washed with 0.1% NP-40/PBS for 6 times, and incubated 
with Alexa fluorophore conjugated rabbit or mouse secondary antibodies (Life 
Technologies) in IF buffer. The slides were washed with 0.1% NP-40/PBS for 6 times 
and counterstained with 4', 6-diamidino-2-phenylindole (DAPI) and mounted with 
antifade solution (Life Technologies).  Confocal microscopy was done using Zeiss LSM 
780 laser scanning confocal microscope (Carl Zeiss AG). p-AKT(S473) (4060) and 
cleaved Caspase-3 (9664) antibodies were from Cell Signaling Technology. Rabbit 
polyclonal antibody against Ki67 (ab833) was from Abcam and Mouse anti-laminin-5 
(MAB1947) was from EMD Millipore. Alexa Fluor 488 anti-rabbit (A11008) and Alexa 
Fluor 594 anti-mouse (A21201) secondary antibodies and ProLong® Gold antifade 
reagent with DAPI (P36931) were obtained from Life Technologies. 
 
Soft agar assay: 
U2OS empty vector cells and subclones were trypsinized and resuspended in 2X DMEM 
media. The bottom layer consisted of 1 ml/well of 0.7 % agar noble (Difco 214220) for 
24-well plate. The cell suspensions were cultured in a 0.3 % agar noble (1ml/well) and 
layered on top. The cells were maintained in an incubator for 21 days. The colonies were 
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stained with 0.005% Crystal Violet, photos were taken, and colonies were counted with 
ImageJ. The experiments were independently performed at least twice, each in triplicate. 
 
Abbreviations for Cancer Types in The Cancer Genome Atlas:  
SKCM: skin cutaneous melanoma, LGG: brain lower-grade glioma, BRCA: breast 
invasive carcinoma, LAML: acute myeloid leukemia, PRAD: prostate adenocarcinoma, 
GBM: glioblastoma mutliforme, KIRP: kidney renal cell papillary carcinoma, THCA: 
thyroid carcinoma, KIRC: kidney renal clear cell carcinoma, STAD: stomach 
adenocarcinoma, CESC: cervical squamous cell carcinoma and endocervical 
adenocarcinoma, BLCA: bladder urothelial carcinoma, LIHC: liver hepatocellular 
carcinoma, OV: ovarian serous cystadenocarcinoma, LUSC: lung squamous cell 
carcinoma, LUAD: lung adenocarcinoma, HNSC: head and neck squamous cell 
carcinoma, PAAD: pancreatic adenocarcinoma. 
 
Gene Set Enrichment Analysis of MCF10A basal p53 ChIP-seq dataset:  
Tumor suppressor genes (TSGs) and oncogenes were classified in the Cancer Gene 
Census from COSMIC (Futreal et al., 2004) (as of January 4th, 2017). Frequencies of 
somatic copy-loss and copy-gain by gene were retrieved from the cBio portal, averaged 
across 18 cancer types, and thresholded at 0.5% mean frequency to yield gene sets of the 
most recurrently deleted and amplified genes in TCGA. Enrichment of the list of 
MCF10A ChIP-seq peaks (ranked by significance) for these gene sets of TSGs and 
oncogenes, or recurrent deletions and amplifications was quantified using the Gene Set 
Enrichment Analysis package (Subramanian et al., 2005).  
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Analysis of odds of basal p53 target downregulation in cases with TP53 mutation: 
We restricted our analysis to the TCGA cases for which exome sequencing, SNP array, 
and RNA sequencing data were all available, and queried the mutational status of TP53 
along with the expression levels of its target tumor suppressors. Contingency tables were 
constructed between TP53 mutation status and target gene expression z-scores, 
thresholded at -1 standard deviation. Associations were quantified via Fisher’s exact test. 
Cancer types that were included in this analysis had sufficient data available from enough 
cases. 
 
Statistical Analysis:  
No statistical methods were used to determine sample size, and experiments were not 
randomized. The experimenters were not blinded. Aside from traditional Mann-Whitney 
(non-parametric), Spearman correlation test (non-parametric), student t-tests (parametric) 
to compare two data sets, and Chi-squared test (non-parametric), parametric statistical 
methods were used in order to make appropriate multiple comparisons of repeated 
measures of data (following 1-way or 2-way ANOVA as indicated in figure legends). 
Graphpad Prism was used to make these simple predetermined statistical comparisons.  
Tukey’s Multiple Comparisons Correction: Used for making all possible pairwise 
comparisons in a data set. 
Dunnett’s Multiple Comparisons Correction: Used for comparing all samples to a control 
sample, but not for comparing the non-control samples to one another.  
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Sidak’s Multiple Comparisons Correction: Used when specific multiple comparisons are 
pre-selected.   
We also used another statistical test to analyze the Odds Ratio data from TCGA cases (as 
mentioned above).  Fischer’s Exact Test: Used to analyze items in a contingency table. 
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